• Adamax is described as a synthetic Semax-family neuropeptide analog with chemical modifications intended to improve stability.
• Direct Adamax-specific human evidence is limited.
• The claims here are extrapolated from Semax/derivative literature and anecdotal reports unless a direct Adamax source is named.
• Adamax is a Semax-family derivative, not a clinically established nootropic.

• Proposed mechanisms include neurotrophin signaling, melanocortin-system effects, and improved resistance to enzymatic degradation.
• Terms such as “massive BDNF release” or “strongest version” are not used here as established clinical findings; They are marketing or anecdotal language unless directly supported.
• The useful mechanism frame is neuropeptide-modulation plus possible melanocortin/BDNF-neurotrophin signaling overlap, but direct Adamax-specific human mechanism data are thin. The mechanism here is a plausibility map, not proof of a clinical outcome.

• Evidence is limited.
• Standard Semax has preclinical and regional clinical literature; Adamax-specific claims about 12-14 hour cognitive effects, motor learning, or mood regulation require direct citation.
• At most, Adamax is a possible nootropic/neuroprotective analog, not a validated human therapy.
• Most confidence comes from Semax-family and preclinical analog literature. Direct Adamax evidence is early and exploratory, with community reports kept apart from controlled human outcomes. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.

Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions.

• Protocol 1: Beginner Protocol [Community/Biohacker/Anecdotal]; Route: Intranasal spray; Dose: 100 mcg (one spray total); Frequency: Once daily (Morning); Timing: Upon waking; Duration: 2 to 4 weeks; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 2: Advanced Protocol [Community/Biohacker/Anecdotal]; Route: Intranasal spray; Dose: 200 mcg – 400 mcg; Frequency: 1 to 2 times daily; Timing: Morning and Early Afternoon; Duration: 4 to 8 weeks; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Community use is usually intranasal or occasionally injectable, and the dosing here is reported protocol context, not validated treatment dosing. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.

• Time until steady state: not calculable from current human data.
• Half-life basis: No verified Adamax-specific human elimination half-life. Reliable Adamax-specific human PK was not verified. Duration claims are pharmacodynamic/anecdotal rather than true steady-state concentration.
• Beginner translation: This is a deliberately conservative read. A missing steady-state number does not mean the compound has no effect; It means the available human PK data are not strong enough to justify a precise accumulation estimate for common use patterns.
• Practical interpretation: Reliable Adamax-specific human pharmacokinetic data were not verified. Any stated half-life or duration is anecdotal or extrapolated from related analogs.
• The reason Adamax is discussed is proposed improved stability or duration compared with Semax, but public human PK is not robust. Half-life calculators do not imply a known steady-state profile. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.

• Stacks with Selank, NAD+, or other neuroactive agents are anecdotal, not evidence-based treatment protocols.
• Adamax is usually stacked conceptually with focus, mood, or neuro-recovery compounds. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.

• Potential issues include overstimulation, insomnia, irritability, anxiety, headache, and theoretical mood destabilization.
• Rare claims such as hair thinning are not clinically verified.
• Main practical cautions are insomnia, agitation, headache, blood-pressure sensitivity, and unknown long-term CNS effects. Limited human exposure data means absence of reports is not evidence of low risk. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.

• Track sleep, irritability, anxiety, mood elevation, and cognitive function if use occurs under research or clinician oversight.
• Track sleep latency, anxiety/irritability, headache, resting blood pressure if sensitive, and objective cognition or work-output measures rather than only subjective focus. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.

• Not FDA-approved.
• Not verified as an approved medicine in the sources reviewed.
• WADA/USADA: Adamax was not verified as a named prohibited substance, but athletes should treat non-approved neuroactive substances as high-risk under S0 and check Global DRO/USADA before use.
• Adamax is not an FDA-approved drug. Its presence in research or community markets is distinct from approval, clinical validation, or pharmacy-compounding acceptance. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.

1. [D] Radchenko et al. (2025). The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer’s Disease. Acta Naturae. 17(4):110-120. PMID:41479572; PMCID:PMC12755871; DOI:10.32607/actanaturae.27808

2. [D] Dolotov et al. (2003). The heptapeptide Semax stimulates BDNF expression in different areas of the rat brain in vivo. Doklady Biological Sciences. PMID:14556513; DOI:10.1023/a:1025177812262

3. [D] Medvedeva et al. (2014). The peptide Semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis. BMC Genomics, 15, 228. PMID:24661604; PMCID:PMC3987924; DOI:10.1186/1471-2164-15-228.

4. [D] Dmitrieva et al. (2010). Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia. Cellular and Molecular Neurobiology, 30(1), 71-79. PMID:19633950; DOI:10.1007/s10571-009-9432-0.

5. [C] Gusev et al. (2018). The efficacy of Semax in treatment of patients at different stages of ischemic stroke. Zhurnal Nevrologii i Psikhiatrii. PMID:29798983

6. [D] Barnhart et al. (2011). A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Science Translational Medicine. PMID:22072637

7. [D] Kolonin et al. (2004). Reversal of obesity by targeted ablation of adipose tissue. Nature Medicine. PMID:15133506

8. [F] Bordet & Lodish. (2012). A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Science Translational Medicine / PubMed commentary. PMID:22539771

9. [RouteEvidence] Lebedeva et al. Effects of Semax on the default mode network of the brain. Bull Exp Biol Med. 2018.

• Adipotide, also called FTPP, prohibitin-TP01, or TP01, is a synthetic chimeric pro-apoptotic peptidomimetic, not an endogenous signaling peptide and not a GLP-1, stimulant, lipolytic, or appetite suppressant.
• The core research identity is a fat-homing CKGGRAKDC motif joined by a GG linker to a pro-apoptotic KLAKLAK repeat payload; The monkey-paper sequence is commonly written CKGGRAKDC-GG-D(KLAKLAK)2.
• The scientific concept is targeted injury to white-adipose-tissue vasculature. This makes it qualitatively different from metabolic peptides that reversibly activate a receptor.
• Human development reached an initiated/dosed Phase 1 oncology/obesity safety study, but no peer-reviewed human obesity-efficacy or routine-safety results were identified. Do not summarize it as having established human fat-loss efficacy.
• Adipotide is a pro-apoptotic peptidomimetic aimed at adipose vasculature, not a metabolic hormone, GLP-1 alternative, or ordinary fat-loss peptide.

• The CKGGRAKDC homing sequence was selected for white-fat vasculature and is associated with prohibitin biology in adipose endothelial tissue.
• After binding/internalization, the KLAKLAK payload is intended to disrupt mitochondrial integrity and induce apoptosis in targeted vascular cells.
• The downstream result in animal models is loss or rarefaction of adipose blood supply, followed by reduction/resorption of the supported white fat depot.
• Prohibitin is a multifunctional protein and the PHB/ANXA2/CD36 system participates in fatty-acid transport. Do not overstate the target as universally fat-exclusive or human-validated for safe selectivity.
• The central idea is targeting prohibitin-associated markers in white-adipose vasculature and delivering a pro-apoptotic KLAKLAK payload after internalization. The mechanism here is a plausibility map, not proof of a clinical outcome.

• Foundational rodent work used targeted ablation of adipose vasculature to reduce white fat in obesity models.
• The main nonhuman-primate study used 0.43 mg/kg subcutaneous adipotide daily for 28 days in obese rhesus monkeys; Reported body-weight loss was in the approximate 7-15% range, often summarized as about 11% over four weeks.
• MRI/DEXA and anthropometric measures supported reduced white adipose tissue, not merely scale-weight change, and insulin-resistance measures improved in the primate study.
• Renal proximal-tubule changes were a central safety signal. The animal study described them as predictable, dose-dependent, and reversible under study conditions; That does not establish safety under unsupervised, chronic, repeated, or human use.
• A published comment questioned whether reduced food intake could explain part of the weight-loss effect. The original authors responded, but the uncertainty stands, and the mechanism is not completely settled.
• The strongest efficacy signal is animal work, especially obese primate data, plus early development history. Human trial initiation does not equal established human obesity efficacy, and it implies no routine human safety profile. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.

Educational reference only. FDA-label, clinical, preclinical, and community rows are separated when available; These are not medical instructions.

• Protocol 1: Rhesus-Monkey Fixed-Dose Research Protocol [Animal/Preclinical - not a human protocol]; Route: Subcutaneous (SC); Dose: 0.43 mg/kg; Frequency: Daily; Duration: 28 days; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 2: Community/Anecdotal Research-Market Low-Dose Pattern - Not Equivalent to Primate Protocol [Community/Anecdotal - unvalidated]; Route: Subcutaneous (SC); Dose: 250 mcg – 500 mcg (Total daily); Frequency: Once daily; Duration: 21 to 28 days; Titration/loading: Community reports sometimes describe very low test exposures, but an initial low exposure does not rule out renal risk or validate escalation.; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Only SC administration has meaningful published/clinical-development context. Oral, nasal, topical, and transdermal adipotide routes lack route-efficacy support.
• The 0.43 mg/kg daily x 28 days rhesus-monkey protocol is an animal research dose, not a human dose recommendation.
• The initiated Phase 1 human trial was not a general obesity trial; It involved patients with metastatic castration-resistant prostate cancer and obesity/no standard options, with a single 28-day SC cycle, dose escalation, MTD, PK, weight, and disease-progression endpoints.
• Community microgram protocols, where listed, are community/anecdotal research-market patterns, not equivalents to the primate dose and not clinically validated safer regimens.
• Do not infer that a low “test dose” proves kidney safety; Renal injury risk is not ruled out by tolerance of an initial small exposure.
• Animal protocols and community microdose reports are not equivalent. Any dosing discussion needs to state species, route, mg/kg basis, cycle duration, and renal-stop criteria; Otherwise the numbers are misleading. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.

• Human PK is not publicly established well enough for a calculator preset, accumulation estimate, or steady-state model.
• The Phase 1 trial planned PK assessment, but public peer-reviewed PK results were not identified.
• Do not say systemic persistence is limited unless a specific PK dataset is available. A short plasma exposure, if later shown, would not necessarily mean a short biological effect because apoptosis/vascular remodeling can outlast circulating peptide.
• Steady-state, loading-dose, missed-dose, and half-life calculators do not apply to adipotide and return “not applicable/insufficient human PK.”
• Public human PK is insufficient for steady-state or missed-dose calculators. For this compound, pharmacodynamic toxicity and organ exposure matter more than a simple plasma half-life estimate. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.

• Adipotide is not a normal stacking peptide. Its mechanism is pro-apoptotic vascular injury, so “repair,” “hydration,” or antioxidant stacks do not neutralize the central risks.
• There are no validated human data showing safe coadministration with GLP-1/GIP agents, stimulants, diuretics, dehydration protocols, NSAID-heavy use, nephrotoxic drugs, or aggressive calorie restriction.
• If a website stack checker says no obvious conflict, that does not mean same-cycle safety. The limiting issue is not only receptor overlap; It is kidney/perfusion/exposure risk and tissue-injury biology.
• The practical default is “standalone high-risk research compound; No evidence-based stack.”
• Adipotide should not be casually stacked with GLP-1s, diuretics, nephrotoxic agents, stimulants, or dehydration-prone protocols. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.

• Primary known safety concern: renal proximal-tubule toxicity in nonhuman primates. Reversibility in the animal study does not establish a human safety margin.
• Higher concern contexts include reduced eGFR, kidney disease history, proteinuria/albuminuria, dehydration, uncontrolled blood pressure, diabetes with kidney involvement, concurrent nephrotoxic exposure, pregnancy, breastfeeding, active systemic illness, or inability to obtain lab monitoring.
• Cancer is not a simple absolute contraindication here, because the registered human trial was in metastatic prostate cancer. Correct wording: active cancer or cancer history requires physician/clinical-trial oversight and is not a community-use indication.
• Other possible concerns include injection reactions, malaise/fatigue, hypotension or volume issues, nausea/food-intake effects, unexpected tissue injury, and unknown immunogenicity/impurity risks from research-market material.
• Because the active mechanism is injury-based, absence of immediate symptoms is not proof of safety.
• The kidney signal is the gating safety issue. Nausea, dehydration, renal tubular injury, and unintended tissue effects are more relevant than ordinary injection-site concerns. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.

• Monitoring cannot make adipotide clinically validated, but if it were studied, kidney monitoring would be central rather than optional.
• Baseline and follow-up renal markers should include serum creatinine, eGFR, BUN, cystatin C if available, urinalysis, urine albumin-to-creatinine ratio or protein-to-creatinine ratio, electrolytes, hydration status, and blood pressure.
• Metabolic tracking may include body weight, waist circumference, fasting glucose/insulin, A1c when relevant, lipids, and liver enzymes, but these are secondary to renal safety.
• Stop/escalation boundaries in a formal protocol should be based on changes from baseline, not generic “normal ranges.” Any worsening renal marker, new protein/albumin in urine, hematuria, dehydration/hypotension, or systemic illness would be a red-flag event.
• Home scale weight is not enough. The primate efficacy interpretation relied partly on imaging/DEXA/MRI and metabolic measures.
• Monitoring should prioritize renal function, hydration, urine findings, electrolytes, and blood pressure before body-composition enthusiasm. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.

• Adipotide/prohibitin-TP01 is not FDA-approved for obesity or any other indication.
• FDA IND clearance and first-patient dosing were reported in 2012 for a Phase 1 trial, but this is not approval and does not establish clinical efficacy.
• The trial context was metastatic castration-resistant prostate cancer with obesity/no standard options, not ordinary weight-loss care.
• No peer-reviewed human obesity-efficacy results or routine safety dataset were identified. Marketing claims of “human-proven fat loss” are unsupported unless they cite actual published clinical results.
• Do not confuse Adipotide/prohibitin-TP01 with newer “Adipo” programs such as ADPO-002NP; Those involve different mechanisms/products.
• Adipotide is not FDA-approved for obesity or wellness use. Trial-development history is investigational, not validation for the research-market product category. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.

1. [C] Kolonin MG, Saha PK, Chan L, Pasqualini R, Arap W. Reversal of obesity by targeted ablation of adipose tissue. Nature Medicine. 2004;10(6):625-632. PMID:15133506. Use: Foundational in-vivo phage-display study identifying the CKGGRAKDC prohibitin-homing motif and showing fat-ablation weight loss in obese mice.

2. [C] Barnhart KF, Christianson DR, Hanley PW, et al. A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Science Translational Medicine. 2011;3(108):108ra112. PMID:22072637. Use: Rhesus-monkey study showing ~10.6% body-weight loss over 28 days plus reversible, dose-dependent renal tubular toxicity, basis for the entry’s high safety concern.

3. [B] National Cancer Institute Drug Dictionary. Prohibitin-targeting peptide 1. Use: identity, structure, mechanism, oncology context.

4. [C] Barnhart KF et al. A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Science Translational Medicine. 2011;3(108):108ra112. PMID: 22072637. Use: main nonhuman-primate efficacy/safety evidence.

5. [C] Criscione L. Comment on the adipotide monkey paper. Science Translational Medicine. 2012. PMID: 22539771. Use: mechanism/food-intake uncertainty.

6. [C] Salameh A et al. Prohibitin/annexin 2 interaction regulates fatty acid transport in adipose tissue. JCI Insight. 2016;1(10):e86351. Use: PHB/ANXA2/CD36 mechanistic context.

7. [D] Arrowhead Pharmaceuticals. FDA clearance and first-patient dosing press releases for Adipotide Phase 1. Use: clinical-trial initiation context; company source, not outcome evidence.

• AHK-Cu is L-alanyl-L-histidyl-L-lysine complexed with copper.
• It is usually grouped as a signal peptide and copper-delivery complex.
• In practical use it appears mostly in topical scalp serums, cosmetic formulations, and some provider-supervised mesotherapy contexts.
• AHK-Cu is best framed as a copper-binding tripeptide cosmetic/hair-research compound. It is close in theme to GHK-Cu but is not interchangeable with it, because sequence, target tissue, formulation, and evidence base differ.

• Proposed mechanisms include support of dermal-papilla cell activity, wound-healing signaling, angiogenic signaling around follicles, and extracellular-matrix remodeling.
• Because copper complexation is central to the molecule, formulation pH and oxidation state matter.
• The practical mechanism is local copper-peptide signaling around follicle and skin biology, not systemic endocrine action. The relevant claims center on extracellular-matrix remodeling, follicle-support hypotheses, and local tissue signaling. The mechanism here is a plausibility map, not proof of a clinical outcome.

• The most useful evidence concerns local skin/scalp biology: hair-cycle support, dermal fibroblast signaling, and cosmetic formulation behavior.
• There is no proof that AHK-Cu has systemic anti-aging effects, and blue copper-peptide products do not all share equivalent activity.
• Evidence is mainly in vitro, cosmetic, scalp/hair-oriented, or extrapolated from copper peptide biology. Human hair-growth claims need careful wording because robust, large controlled trials are not the foundation here. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.

Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions for you.

• Protocol 1: Topical Scalp Serum [Topical/Cosmetic]; Route: Topical scalp; Frequency: Once or twice daily; Duration: 3 to 6 months (Minimum); Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 2: Cosmetic Formulation [Topical/Cosmetic]; Route: Topical cosmetic; Frequency: Once daily (Nightly); Duration: Indefinite; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 3: Typical topical use-case concentrations [Topical/Cosmetic]; Route: Topical serum/scalp tonic/microneedling adjuvant; Frequency: Once or twice daily; Duration: 12-week cycles with rest periods to assess effect; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Topical and mesotherapy-style community use are separate categories. Concentration, vehicle, scalp penetration, irritation, and frequency matter more than simply naming milligrams. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.

• Time until steady state: not calculable.
• Half-life basis: reliable human systemic PK for topical or mesotherapy AHK-Cu is not established. Local tissue exposure depends on formulation, pH, vehicle, barrier status, and application method.
• Beginner translation: If you're new, this means there is no honest blood-level steady-state number. Hair and skin effects, if present, are tissue-remodeling outcomes measured over weeks to months.
• Practical interpretation: Track standardized scalp photos, hair density, irritation, and product tolerance rather than trying to model systemic accumulation.
• Systemic PK is not the right lens for topical AHK-Cu. Local delivery, skin barrier penetration, copper binding, and formulation stability drive practical interpretation. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.

• Microneedling, minoxidil, niacinamide, and GHK-Cu are common pairing discussions, but compatibility depends on timing and formulation.
• Do not combine copper peptides in the same application with strong acids such as low-pH L-ascorbic acid or aggressive AHA/BHA products unless the formulation is designed for that use.
• Comparison note: AHK-Cu is generally framed as more hair/scalp-targeted, while GHK-Cu is more broadly discussed for skin remodeling and wound-healing biology.
• That comparison is practical, not proof that one is universally superior.
• Common pairings are minoxidil, microneedling, GHK-Cu, caffeine serums, or anti-inflammatory scalp routines. Do not imply same-vial compatibility with copper peptides unless exact formulation testing exists. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.

• Topical irritation, redness, dryness, or itching may occur, especially with high concentrations, harsh vehicles, or recent microneedling.
• Avoid use on infected or broken skin unless supervised.
• Known copper allergy or Wilson disease requires clinician review.
• Topical irritation, dermatitis, copper sensitivity, staining, and overuse are the realistic concerns. Injectable or systemic AHK-Cu claims need a much higher safety burden. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.

• Track standardized photos, hair-shed counts, trichoscopy if available, scalp irritation, and changes in hair caliber over 8 to 12 weeks or longer.
• For systemic copper-peptide use, copper and ceruloplasmin may be relevant only under clinician supervision.
• For scalp use, track shedding, photos, irritation, dandruff/seborrhea flare, and adherence over months. Hair-cycle timing makes week-to-week conclusions unreliable. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.

• AHK-Cu is commonly sold as a cosmetic or research raw material. It is not an FDA-approved drug for hair loss.
• Athletes should still verify any injectable or compounded product against current anti-doping rules and product ingredients.
• AHK-Cu is generally encountered as cosmetic/RUO material rather than an approved drug. Cosmetic availability is not proof of therapeutic efficacy. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.

1. [E] Pyo et al. (2007). The effect of tripeptide-copper complex on human hair growth in vitro. Archives of Pharmacal Research. PMID:17703734

2. [F] Fan et al. (2026). Overview of Short Peptides for Hair Loss. Biomedicines. 14(4):864. PMCID:PMC13113319; DOI:10.3390/biomedicines14040864

3. [F] Pickart & Margolina. (2018). Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of New Gene Data. International Journal of Molecular Sciences. PMID:29986520

4. [RouteEvidence] Pickart et al. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. 2015 review.

5. [RouteEvidence] Dou et al. The potential of GHK as an anti-aging peptide. 2020 review.

6. [RouteEvidence] Skin barrier / transdermal drug-delivery review.

• AOD-9604 is a synthetic peptide derived from the C-terminal region of human growth hormone.
• It was developed to investigate lipolytic signaling while avoiding the broader growth-promoting activity of full hGH.
• AOD-9604 is a modified hGH-fragment-derived compound, but it is not a growth hormone replacement or a GLP-1-like obesity drug. Its identity is tied to the lipolytic region of hGH, not to broad anabolic GH activity.

• Proposed mechanisms include lipolysis and reduced lipogenesis in experimental systems.
• It is not equivalent to full hGH, a GLP-1 drug, or a validated obesity treatment.
• The proposed mechanism is fat-metabolism modulation with reduced growth-promoting activity compared with full hGH. That mechanistic selectivity is the rationale, but it does not prove clinically meaningful fat loss. The mechanism here is a plausibility map, not proof of a clinical outcome.

• The most defensible claims are that AOD-9604 was studied for metabolic effects and appears to have a relatively favorable early safety profile.
• Larger human obesity-efficacy claims are weaker and remain unproven.
• Cartilage and joint claims hold only when tied to specific preclinical or clinical sources.
• Oral human trial history exists, but efficacy was inconsistent and did not establish a strong anti-obesity drug profile. Positive community claims are anecdotal unless matched to a specific trial-grade formulation. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.

Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions for you.

• Protocol 1: Fat Loss Protocol [Research/Experimental]; Route: Subcutaneous (SC); Dose: 300 mcg – 500 mcg; Frequency: Once daily (Morning); Timing: 30–60 mins before cardio; Duration: 12 to 20 weeks; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 2: Joint/Cartilage Protocol [Research/Experimental]; Route: Subcutaneous or Intra-articular; Dose: 500 mcg – 1 mg; Frequency: Once daily or localized; Timing: Any time; Duration: 4 to 8 weeks; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Oral, subcutaneous, and topical/cosmetic claims are separate. Do not use a fixed oral-to-SC conversion; Route and formulation determine exposure. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.

• Time until steady state: if a short 4 to 10 minute half-life is assumed, about 20 to 50 minutes; Otherwise not formally calculable.
• Half-life basis: rapid degradation is reported in metabolism work, but robust route-specific human injectable PK is limited.
• Beginner translation: A very short plasma half-life does not prove fat loss. It only says the circulating molecule would clear quickly if that half-life applies.
• Practical interpretation: Measure outcomes such as body composition, waist circumference, glucose, and lipids. Do not infer efficacy from half-life alone. The key distinction is plasma exposure versus downstream effect. Even if AOD clears rapidly, any metabolic claim still requires outcome evidence in humans.
• Public PK is not strong enough for precision calculator use across routes. Absorption and degradation are especially important because the compound is small enough to be modified but still peptide-like. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.

• AOD-9604 and HGH Fragment 176-191 overlap conceptually; Stacking them is generally redundant.
• Pairing with GLP-1/GIP drugs, GH secretagogues, or fasting protocols is community practice rather than controlled clinical evidence.
• AOD is often paired with diet, GLP-1 drugs, carnitine/lipolysis stacks, or GH secretagogues. Stacking can make it impossible to know whether any body-composition change came from AOD itself. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.

• Reported issues may include injection-site reactions, headache, nausea, or unexpected metabolic effects.
• Pregnancy and breastfeeding lack adequate safety data.
• People with active cancer, uncontrolled endocrine disease, or complex metabolic disease need clinician review.
• The main caution is false confidence: weak efficacy does not mean zero risk. Product quality, route, immune response, injection-site reactions, and metabolic overinterpretation remain concerns. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.

• Relevant monitoring includes body composition, waist circumference, fasting glucose, HbA1c, lipids, blood pressure, and adverse effects.
• These markers help evaluate change but do not by themselves prove AOD efficacy.
• Track waist, weight trend, nutrition, training, glucose/lipids if metabolically relevant, and adverse reactions. Without consistent lifestyle tracking, AOD effects cannot be interpreted. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.

• AOD-9604 is not FDA-approved as a drug.
• Any "Generally Recognized as Safe" or food-related status is not approval for injection.
• Compounding and anti-doping status must be checked against current rules; Athletes should treat non-approved metabolic peptides as high-risk.
• AOD-9604 is not FDA-approved as an obesity drug. Some jurisdictions and supplement markets have handled it differently, so region and product type matter when discussing status. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.

1. [D] Heffernan et al. (2001). The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism. Endocrinology. PMID:11713213

2. [D] Ng et al. (2000). Metabolic studies of a synthetic lipolytic domain of human growth hormone. Hormone Research. PMID:11146367

3. [D] Heffernan et al. (2001). Increase of fat oxidation and weight loss in obese mice caused by a synthetic fragment of human growth hormone. International Journal of Obesity. PMID:11673763

4. [C] Moré et al. (2014). Safety and metabolism of AOD9604, a novel nutraceutical ingredient. Journal of Endocrinology and Metabolism.

5. [E] Cox et al. (2015). Detection and in vitro metabolism of AOD9604. Drug Testing and Analysis. PMID:25208511

6. [RouteEvidence] AOD-9604 safety/metabolism review and clinical-trial summary.

• ARA-290 is a synthetic 11-amino acid peptide derived from the structure of Erythropoietin (EPO).
• However, it is specifically designed to be “non-erythropoietic,” meaning it does not stimulate red blood cell production.
• Instead, it is a selective agonist for the Innate Repair Receptor (IRR).
• It is classified as a powerful anti-inflammatory and neuroprotective agent.
• ARA-290, also called cibinetide in development contexts, is an EPO-derived peptide designed to activate tissue-protective signaling without classical erythropoietic stimulation.

ARA-290 targets the body’s primary “distress” signaling system to shut down chronic inflammation and initiate repair:

• Selective IRR Binding: In the presence of tissue injury or metabolic stress, the body expresses the Innate Repair Receptor (a complex of the EPO receptor and the beta-common receptor). ARA-290 binds to this specific heteromer.
• Inflammation Suppression: Once bound, it inhibits the production of pro-inflammatory cytokines (like TNF-alpha and IL-6) and prevents the activation of the “inflammasome.” Small-fiber neuropathy research: ARA-290/cibinetide has been studied in sarcoidosis-associated small-fiber neuropathy and painful diabetic neuropathy, including corneal and skin small-fiber endpoints. This supports an investigational nerve-repair rationale, not a guaranteed or unique ability to repair small-fiber neuropathy.
• Apoptosis Prevention: It protects cells from “programmed cell death” triggered by ischemia (lack of oxygen) or oxidative stress.
• The key mechanism frame is innate repair receptor/tissue-protective signaling, including anti-inflammatory and neuroprotective pathways. It is not a general nerve-regeneration guarantee. The mechanism here is a plausibility map, not proof of a clinical outcome.

• ARA-290/cibinetide has selected clinical research in sarcoidosis-associated small-fiber neuropathy and painful diabetic neuropathy.
• Diabetes/metabolic findings are small-study exploratory signals, not established metabolic treatment.
• The 2026 lupus brain-fog report involves EG501, not ARA-290/cibinetide.
• Wound-healing claims remain preclinical/adjacent unless a specific human wound-healing study is cited.

Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions.

• Protocol 1: Clinical/SFN Protocol [Clinical/Human Trial]; Route: Subcutaneous (SC); Dose: 4 mg – 10 mg; Frequency: Once daily; Duration: 28 to 30 days; Titration/loading: The "Clinical Loading": successful neuropathy trials used higher doses (10 mg daily) for 4 weeks.; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 2: General Repair Protocol [Community/Biohacker/Anecdotal]; Route: Subcutaneous (SC); Dose: 1 mg – 4 mg; Frequency: Once daily; Duration: 14 to 28 days; Titration/loading: After an initial cycle, some users move to a maintenance dose of 2 mg twice weekly.; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Trial-style SC dosing and research-market extrapolations are different things. Dosing decisions are usually tied to neuropathic-symptom endpoints, not acute performance or cosmetic goals. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.

• Time until steady state: about 10-100 minutes by the 5-half-life rule.
• Half-life basis: Few minutes to about 20 minutes depending route and source. The repair signal may outlast plasma exposure, so this estimate applies to plasma concentration, not duration of biological effect.
• Beginner translation: This estimate uses the standard four-to-five-half-life convention. It describes when plasma exposure would be expected to approach a plateau during repeated dosing, not when the desired outcome is complete.
• Half-life: Very short systemically (estimated <2 minutes).
• Biological Duration: Despite leaving the blood rapidly, the “switch” it flips on the Innate Repair Receptor triggers a cellular signaling cascade that lasts for 24 hours or longer.
• Stability: The lyophilized powder is relatively stable but should be refrigerated once reconstituted with Bacteriostatic Water.
• ARA-290 has a short plasma half-life, yet effects may be assessed through downstream symptom or tissue-protection markers. Short exposure does not automatically mean frequent redosing is beneficial. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.

• BPC-157: Often stacked for systemic “healing” protocols, as BPC-157 focuses on growth factors while ARA-290 focuses on the inflammatory “off-switch.” Cerebrolysin: Combined in 2026 protocols for neurodegenerative recovery to address both nerve growth (Cere) and nerve inflammation (ARA).
• NAD+: To provide the energy required for the nerve regeneration processes stimulated by ARA-290.
• It is commonly discussed with mitochondrial, anti-inflammatory, or neuropathy-support stacks. Avoid combining many anti-inflammatory agents if the research goal is to understand a single signal. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.

• Side Effects: Generally well tolerated in the small clinical trials to date, though long-term safety is not established. In human trials, side effects were nearly identical to the placebo group. Occasionally, users report a mild “flushing” sensation or injection site redness.
• No Polycythemia Risk: Unlike EPO, ARA-290 does not increase red blood cell counts or thicken the blood, which removes EPO’s blood-thickening risk; This is not the same as proven cardiovascular safety, which has not been established for this investigational peptide.
• Contraindications: Pregnancy and breastfeeding (due to lack of data).
• Major practical concerns are injection-site effects, immune reactions, uncertain long-term outcomes, and disease-context mismatch. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.

• Pain Scales: Tracking levels of neuropathic pain (burning, tingling, numbness).
• Skin Biopsy: In clinical settings, “Skin Nerve Fiber Density” tests are the gold standard for measuring success.
• Inflammatory Markers: Monitoring hs-CRP and ESR to track the systemic reduction in inflammation.
• Useful monitoring includes neuropathic pain scores, small-fiber/autonomic markers when available, glucose control if diabetic neuropathy is involved, CBC, inflammatory markers, and adverse-event diary. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.

• FDA: Currently has Orphan Drug Designation for the treatment of Sarcoidosis-associated neuropathy but is not yet approved for general use.
• WADA: Not currently on the prohibited list (since it does not increase red blood cell production), though it is often scrutinized due to its relation to EPO.
• Availability: Widely available as a “research chemical.”
• ARA-290/cibinetide is investigational and not a general FDA-approved peptide therapy. Trial references are separate from research-market product claims. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.

1. [C] Heij et al. (2012). Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy. Molecular Medicine. PMID:23168581

2. [C] Dahan et al. (2013). ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density. Molecular Medicine. PMID:24136731

3. [F] van Velzen et al. (2014). ARA 290 for treatment of small fiber neuropathy in sarcoidosis. Expert Opinion on Orphan Drugs. PMID:24555851

4. [C] Brines et al. (2015). ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Molecular Medicine. PMID:25387363

5. [C] Culver et al. (2017). Cibinetide improves corneal nerve fiber abundance in patients with sarcoidosisassociated small nerve fiber loss. Investigative Ophthalmology & Visual Science. PMID:28475703

6. [B] Lois et al. (2020). A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema. Journal of Clinical Medicine, 9(7), 2225. PMID:32674280; PMCID:PMC7408632; DOI:10.3390/jcm9072225.

• BPC-157 is a synthetic 15-amino-acid pentadecapeptide derived from a sequence associated with a larger gastric-protein complex.
• It is usually described as a cytoprotective or tissue-repair peptide because early work emphasized stomach-ulcer protection, mucosal healing, and resistance to degradation in gastric conditions.
• The forms most often discussed are BPC-157 free base and BPC-157 acetate.
• Those names matter for sourcing and regulation because salt form, counterion content, purity, endotoxin burden, and peptide identity can differ between products.
• BPC-157 is not an FDA-approved drug, and research-use-only vials are not pharmaceutical equivalents.
• BPC-157 is a synthetic fragment related to a gastric body-protection compound concept.

BPC-157 is best framed as a multi-pathway repair-signal candidate rather than as a single-receptor drug. Its proposed mechanisms are not yet unified into one confirmed human pathway. Core proposed pathways:

• Vascular and nitric-oxide signaling: Animal and cell studies suggest effects on nitric-oxide balance, endothelial function, and vascular tone. This may help explain why the peptide is repeatedly studied in ischemia, ulcer, and wound models.
• Angiogenesis and perfusion: BPC-157 is often linked to VEGF-related signaling, VEGFR2/Akt/eNOS pathways, and improved blood-vessel organization in damaged tissue. This is a potential repair advantage but also the reason active cancer is a serious theoretical concern.
• Fibroblast migration and tendon matrix repair: Tendon and ligament models point toward fibroblast migration, FAK-paxillin signaling, collagen organization, and possible growth-hormone receptor effects in tendon fibroblasts.
• Gastrointestinal cytoprotection: The original research base includes gastric ulcer, NSAID injury, inflammatory bowel, and gut-barrier models. These findings do not automatically prove efficacy in human IBD, leaky gut, or reflux, but they explain why oral BPC-157 remains a major community use case.
• Nervous-system and organ-protection models: Some preclinical studies report effects in traumatic brain injury, nerve injury, liver injury, and kidney/ischemia models. These are hypothesis-generating, not validated indications.
• The common mechanism story includes angiogenesis, nitric-oxide modulation, tendon/ligament healing models, gut protection, and inflammatory modulation. The mechanism here is a plausibility map, not proof of a clinical outcome.

• Musculoskeletal evidence: Systematic and narrative reviews describe consistent positive effects in animal models of tendon, ligament, muscle, bone, and osteotendinous injury. This supports the rationale for further clinical trials, but the evidence grade remains low for real-world human injury recovery because most studies are animal, cell, or uncontrolled reports.
• Human evidence: The 2025 IV pilot study in two healthy adults reported that infusions up to 20 mg were tolerated without measurable acute changes in cardiac, hepatic, renal, thyroid, glucose, or magnesium markers. This is useful safety signal generation, not evidence that BPC-157 treats injuries or gut disease.
• Gut and mucosal evidence: BPC-157 has a stronger mechanistic rationale for gastrointestinal use than many peptides because it was developed from gastric-protection research and shows stability in gastric conditions. However, gastric stability is not the same as quantified human oral bioavailability or proven disease modification.
• Data-integrity and translation caution: A large share of the mechanistic literature comes from a limited research network. If you're new, don't interpret repeated animal-study positivity as equivalent to independent multi-center human evidence.
• The literature is heavy in animal and mechanistic studies with limited controlled human data. The most defensible educational point is that BPC-157 has an unusually broad preclinical repair literature, not that it has established human efficacy. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.

Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions for you.

• Protocol 1: Clinical/Trial Protocols [Animal/Preclinical]; Dose: Starting Dose: 0.01 mg/kg (in rat studies); Frequency: Once daily or single treatment; Duration: Variable (often 10–20 days); Max: 10 mg (single IV/Intra-articular); Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 2: Common Biohacker Protocols [Community/Biohacker/Anecdotal]; Route: Subcutaneous (SC) or oral; Dose: 0.25 mg – 0.5 mg (250–500 mcg); Frequency: Twice daily (morning/night); Duration: 4 to 12 weeks; Max: 2 mg commonly reported qd or BID; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Community protocols often use oral capsules for GI goals and SC/local injection for injury claims. Those are community patterns, and oral and injectable use are not interchangeable. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.

• Time until steady state: not calculable from validated human PK for common oral, subcutaneous, or intramuscular use. Some reviews and secondary sources cite metabolism with a half-life under 30 minutes and renal clearance, but that is not enough to define a human therapeutic steady-state target.
• Half-life basis: No robust, route-specific human elimination half-life has been established for the common community routes.
• Estimated time until steady state: Not calculable. If the often-cited less-than-30-minute estimate is used only as a teaching example, the 4-5 half-life rule gives less than about 2-2.5 hours. That number is not a dosing target.
• Why this matters: BPC-157 claims usually involve tissue repair, vascular signaling, and inflammatory modulation. Those pharmacodynamic effects may outlast measurable blood exposure, so plasma half-life does not tell the whole story.
• Route notes: oral, subcutaneous, intramuscular, intra-articular, and IV exposure are not interchangeable. Route changes can change peak exposure, local tolerability, infection risk, and uncertainty.
• Oral gastric stability is part of the rationale, but systemic bioavailability and tissue exposure remain uncertain. Plasma half-life is a weak proxy for wound-healing claims. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.

BPC-157 + TB-500 (“Wolverine stack”): This is the most common repair-oriented stack in online discussion. The usual rationale is that BPC-157 is framed as the inflammation/angiogenesis/fibroblast-recruitment component, while TB-500 is framed as the actin/cell-migration component. This is mechanistically plausible but not proven as a superior human protocol.

• GLOW stack: In current market language, GLOW usually means BPC-157 + TB-500 + GHK-Cu. The logic is repair signaling plus cell migration plus copper-peptide support for skin, collagen, and tissue remodeling. It is a popular marketing and community term, not a standardized clinical product.
• KLOW stack: KLOW commonly refers to GHK-Cu + BPC-157 + TB-500 + KPV. The added KPV is usually described as the anti-inflammatory or gut/skin-calming component. This can be a useful explanatory category, but it is a community/market stack rather than an evidence-based regimen.
• Stacking cautions: Stacks increase interpretive noise. If you use four peptides at once, it becomes hard to identify which peptide caused benefit, irritation, insomnia, nausea, allergic reaction, or abnormal lab changes. Premixed vials also create analytical concerns because COA identity, purity, mass spec, endotoxin, sterility, and content should ideally be verified for each component and for the final blend.
• BPC-157 is often stacked with TB-500/Tβ4-family products, GHK-Cu, KPV, or rehab modalities. The stack may be logical for tissue-repair hypotheses, but same-vial compatibility and additive efficacy are not clinically proven. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.

• Known unknowns: BPC-157 has not gone through the ordinary drug-development safety pathway for the uses promoted online. The main real-world risks are unknown long-term safety, contaminated or misidentified products, endotoxin exposure, injection-site infection, and overconfidence in animal data.
• Angiogenesis/cancer concern: Because BPC-157 is repeatedly discussed in relation to blood-vessel growth and repair signaling, active cancer, suspicious lesions, recent cancer treatment, or high cancer risk are major caution or contraindication factors unless a physician specifically evaluates the risk.
• Reported community side effects: Nausea, appetite change, dizziness, fatigue, head pressure, anxiety/flat mood, sleep disruption, injection-site redness, and transient “brain fog” are reported anecdotally. Frequency and causality are not well quantified.
• Other caution groups: Pregnancy, breastfeeding, pediatric use, severe kidney or liver disease, active infection, immunocompromised state, and anticoagulant use are all situations where self-directed experimentation is especially hard to justify.
• Key cautions are immunogenicity uncertainty, product-identity/purity issues, angiogenesis-related theoretical concerns, masking injury, and injection complications. It is not risk-free just because it is gastric-derived. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.

• Before a repair-focused cycle: Document the injury with a baseline pain/function score, range of motion, and, when appropriate, ultrasound or MRI. Without a baseline, subjective “it worked” claims are hard to interpret.
• General safety labs: CBC, CMP, creatinine/eGFR, liver enzymes, fasting glucose, HbA1c if metabolic disease is present, and hs-CRP/ESR if inflammation is being tracked. For gut claims, fecal calprotectin may be more relevant than CRP when IBD-like inflammation is suspected.
• Stop-and-evaluate triggers: Fever, chills, spreading injection-site redness, severe allergic symptoms, new neurological symptoms, unexplained bruising, dark urine, severe abdominal pain, or any suspected infection after injection.
• For injury use, track pain, range of motion, swelling, functional tests, imaging/clinical diagnosis when relevant, and rehab load. Subjective pain reduction without tissue healing can lead to premature return to activity. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.

• FDA/compounding: FDA scheduled BPC-157-related bulk substances for PCAC discussion on July 23, 2026 for consideration on the 503A Bulks List. Review does not equal approval, and it does not automatically make pharmacy compounding lawful until FDA completes the required process.
• Anti-doping: BPC-157 is prohibited under the WADA Prohibited List as an S0 unapproved substance. Athletes subject to anti-doping rules should treat it as banned.
• Availability: As of this guide, BPC-157 remains mainly available through research-use-only vendors and nonstandard wellness channels. Product quality is variable; Batch-specific COA review is essential.
• BPC-157 is not FDA-approved, and FDA has flagged compounded BPC-157 safety and characterization concerns. PCAC review or community popularity is not approval. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.

1. [G] U.S. Anti-Doping Agency. (2026). BPC-157: Experimental peptide prohibited.

2. [C] Lee & Burgess. (2025). Safety of intravenous infusion of BPC157 in humans. Alternative Therapies in Health and Medicine. PMID:40131143

3. [F] Sikiric et al. (2020). Stable gastric pentadecapeptide BPC 157, Robert’s stomach cytoprotection/adaptive cytoprotection/organoprotection. Gut and Liver. PMID:31158953

4. [F] Seiwerth et al. (2021). Stable gastric pentadecapeptide BPC 157 and wound healing. Frontiers in Pharmacology. PMID:34267654

5. [D] Chang et al. (2014). Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. PMID:25415472; DOI:10.3390/molecules191119066

6. [F] Vasireddi et al. (2025). Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS Journal. PMID:40756949

7. [F] McGuire et al. (2025). Regeneration or risk? A narrative review of BPC-157 in musculoskeletal medicine. Current Reviews in Musculoskeletal Medicine. PMID:40789979

8. [H] STAT / Undark. (2026). Investigation into the BPC-157 evidence base and publication integrity concerns. STAT and Undark.

9. [G] OPSS. (2025). BPC-157 supplement safety and performance warning. Operation Supplement Safety.

10. [G] U.S. Food and Drug Administration. July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee.

11. [G] U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding May Present Significant Safety Risks.

12. [G] U.S. Anti-Doping Agency. BPC-157: Experimental Peptide Creates Risk for Athletes.

13. [D] Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine. PubMed PMID: 40756949.

14. [D] Lee E, Burgess J. Safety of Intravenous Infusion of BPC157 in Humans. PubMed PMID: 40131143.

15. [D] McGuire FP, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing.

16. [E] Chang CH, et al. Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts.

17. [G] Dr. Rogers Centers. BPC-157 Dosage: A Complete Guide.

18. [G] Drip Hydration. The Wolverine Stack: Can BPC 157 and TB 500 Accelerate Injury Recovery?

19. [G] IVs in the Keys. Glow (BPC-157/TB-500/GHK-Cu).

20. [G] Bio Longevity Labs. KLOW Blend (GHK-Cu, BPC-157, TB-500, KPV).

21. [RouteEvidence] FDA. Certain bulk drug substances for use in compounding that may present significant safety risks.

22. [RouteEvidence] Sikiric et al. Stable gastric pentadecapeptide BPC 157, Robert’s stomach cytoprotection/adaptive cytoprotection, and organoprotection. 2019 review.

• Cagrilintide is a long-acting synthetic amylin analog developed by Novo Nordisk.
• In CagriSema, cagrilintide is paired with semaglutide as an investigational fixed-dose obesity product.
• Cagrilintide is a long-acting amylin analog, not a GLP-1 agonist. This distinction matters because it complements incretin drugs through satiety/amylin biology rather than duplicating GLP-1 signaling.

• Cagrilintide targets amylin and calcitonin-receptor pathways involved in satiety, meal termination, gastric emptying, and glucagon regulation.
• These pathways complement GLP-1 signaling rather than replacing it.
• The combination is intended to increase both appetite suppression and earlier meal satisfaction.
• The practical mechanism is appetite and weight regulation through amylin-receptor pathways, especially satiety and meal-size effects. It is not a glucose-control drug in the same way as GLP-1/GIP agonists. The mechanism here is a plausibility map, not proof of a clinical outcome.

• REDEFINE 1 reported 22.7% mean weight loss with full adherence for CagriSema 2.4 mg / 2.4 mg over 68 weeks.
• In the same dataset, the full-adherence monotherapy arms were semaglutide 2.4 mg at 16.1%, cagrilintide 2.4 mg at 11.8%, and placebo at 2.3%.
• Approximately 50.7% of participants with baseline obesity crossed below BMI 30 kg/m2 by the end of treatment.
• REDEFINE 2 evaluated adults with type 2 diabetes and overweight or obesity.
• REDEFINE 4 compared CagriSema with tirzepatide 15 mg and did not demonstrate noninferiority on the primary endpoint.
• Human evidence is mainly in obesity/metabolic clinical-trial contexts and especially combination development with semaglutide. The evidence base is stronger than most research peptides but still product- and indication-specific. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.

Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions.

• Protocol 1: Clinical Titration (CagriSema) [Clinical/Human Trial]; Route: Subcutaneous (SC); Dose: Clinical/investigational titration: 0.25 mg weekly → 0.50 mg weekly → 1.0 mg weekly → 1.7 mg weekly; Month 5+ target depends on trial/product context.; Frequency: Once weekly; Max: CagriSema trial/product target: 2.4 mg cagrilintide + 2.4 mg semaglutide weekly; Cagrilintide monotherapy investigational rows may cite up to 4.5 mg.; Titration/loading: Month 1: 0.25 mg weekly; Month 2: 0.50 mg weekly; Month 3: 1.0 mg weekly; Month 4: 1.7 mg weekly; Month 5+: context-specific target.; Status: No - investigational; Not FDA-approved as of the April 2026 guide/current audit context.
• Protocol 2: CagriSema investigational maintenance target [Research/Experimental]; Route: Subcutaneous (SC); Dose: 2.4 mg cagrilintide weekly when used in fixed-dose/coadministered CagriSema with semaglutide 2.4 mg weekly; Frequency: Once weekly; Duration: Maintenance; Status: No - investigational; Not FDA-approved as of the April 2026 guide/current audit context.
• Dosing turns on trial protocol, combination product context, and titration. Do not import semaglutide or tirzepatide schedules into cagrilintide unless the studied combination is named. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.

Cagrilintide is designed for once-weekly exposure. Practical pharmacokinetics depend on the final approved formulation and label.

• Time until steady state: about 4-6 weeks.
• Half-life basis: Cagrilintide 159-195 hours; Semaglutide component about 145-165 hours. This is why weekly titration and dose-escalation intervals matter; The final label controls once approved.
• Beginner translation: This estimate uses the standard four-to-five-half-life convention. It describes when plasma exposure would be expected to approach a plateau during repeated dosing, not when the desired outcome is complete.
• Long-acting design supports weekly-style research and development protocols. Delayed GI effects and appetite changes can outlast perceived peak effects, so dose escalation matters. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.

• CagriSema is already a fixed-dose combination.
• Additional incretin, amylin, or appetite-suppressing drugs may increase adverse effects and are not an evidence-based stack.
• The most important stack is with GLP-1 therapy, especially CagriSema-style combinations. Stacking with other appetite suppressants or dehydration-prone regimens can compound nausea, low intake, and gallbladder risk. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.

• Expected concerns include nausea, vomiting, constipation, delayed gastric emptying, dehydration risk, hypoglycemia risk when combined with insulin or sulfonylureas, pancreatitis warning context, and thyroid/C-cell contraindication language once final labeling is available.
• Expected issues include nausea, vomiting, reduced intake, possible hypoglycemia when combined with glucose-lowering drugs, and pancreatobiliary monitoring by class context. Avoid treating it as a harmless add-on to GLP-1 therapy. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.

• Weight, waist circumference, hydration, HbA1c, glucose, renal function during dehydration risk, and GI tolerability are the most relevant monitoring categories.
• Track weight rate, appetite, GI tolerance, hydration, glucose if diabetic or on glucose-lowering agents, gallbladder symptoms, and nutritional adequacy. Excessive weight-loss pace is a tolerability and safety signal. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.

• Investigational in the current reference context.
• It is not FDA-approved for any indication until an FDA approval action occurs.
• Availability is limited to clinical-trial or investigational settings.
• Cagrilintide remains development/product-specific rather than a general approved standalone peptide in the guide context. Combination filings or trial results do not simplify into broad approval. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.

1. [A] Garvey et al. (2025). Coadministered cagrilintide and semaglutide in adults with overweight or obesity. New England Journal of Medicine. PMID:40544433

2. [A] Davies et al. (2025). Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes. New England Journal of Medicine. PMID:40544432

3. [C] Enebo et al. (2021). Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of cagrilintide and semaglutide. Lancet. PMID:33894838

4. [B] Lau et al. (2021). Once-weekly cagrilintide for weight management in people with overweight and obesity. Lancet. PMID:34798060

5. [C] Frias et al. (2023). Efficacy and safety of co-administered once-weekly cagrilintide with semaglutide in type 2 diabetes. Lancet. PMID:37364590

6. [H] Novo Nordisk. (2026). Topline results from REDEFINE 4 comparing CagriSema with tirzepatide. Novo Nordisk company announcement.

7. [G] ClinicalTrials.gov. (2026). REDEFINE 4: CagriSema versus tirzepatide in adults with obesity. ClinicalTrials.gov. NCT06131437

• Cerebrolysin is a complex, porcine-derived (pig brain) peptide mixture. It is an enzymatically produced proteolysate that mimics the action of endogenous neurotrophic factors. Developed in Austria, it has been used clinically for decades across Europe and Asia.
• Cerebrolysin is a porcine-brain-derived peptide/amino-acid mixture, not a single defined synthetic peptide. This makes lot characterization, sourcing, and regulatory status more important than for a simple sequence-defined peptide.

Cerebrolysin is usually described as a multimodal neurotrophic-like peptide/amino-acid mixture rather than a single receptor-selective peptide.

• Proposed actions include neurotrophic-like signaling, anti-apoptotic effects, synaptic/plasticity support, and modulation of excitotoxic or oxidative injury pathways.
• Because it is a mixture, disregard reports with language that imply one clean receptor, one half-life, or one guaranteed blood-brain-barrier mechanism.
• Mechanism claims are a plausibility map for neurologic research contexts, not proof of clinical recovery in every stroke, TBI, dementia, or nootropic use case.

• Clinical literature exists in stroke, traumatic brain injury, and dementia, but results and review conclusions are mixed.
• For acute ischemic stroke, higher-quality reviews have not established a clear mortality or serious-adverse-event benefit, and some analyses raise safety uncertainty.
• Some TBI/neurorehabilitation and vascular-dementia studies report possible functional or cognitive signals, but these are suggestive and indication-specific, not settled standard-of-care proof.
• The useful takeaway is “studied in neurologic settings with heterogeneous evidence,” not “proven neurorepair.”

Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions.

• Protocol 1: Clinical/Trial Protocols [Clinical/Human Trial]; Route: IV Infusion or IM Injection; Dose: 2,152 mg – 6,456 mg (10–30 mL); Frequency: Daily for 10–21 days (Stroke/Dementia); Duration: 10 to 21 days; Max: 10,760 mg (50 mL IV); Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 2: Common Biohacker Protocols [Community/Biohacker/Anecdotal]; Route: Intramuscular (IM); Dose: 430 mg – 1,076 mg (2–5 mL); Frequency: Daily for 5–10 days; Duration: 5 to 10 days, 2–3x per year; Max: 2,152 mg (10 mL IM); Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Use is typically parenteral in medical/regional contexts, often IV or IM courses. Oral, nasal, or topical extrapolations are not supported by the product concept. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.

• Time until steady state: not calculable as a single compound.
• Half-life basis: Mixture of peptide fragments; No single active half-life. Use course design, route, and clinical-trial context rather than a single steady-state value.
• Beginner translation: this is a deliberately conservative read. A missing steady-state number does not mean the compound has no effect; It means the available human PK data are not strong enough to justify a precise accumulation estimate for common use patterns.
• Half-life: The active constituents have a short systemic half-life (approx. 30 minutes), but the biochemical “cascade” of neurogenesis lasts significantly longer.
• Delivery: Must be IV or IM. Oral ingestion is ineffective as digestive enzymes break down the peptides.
• Classical single-molecule PK is not very useful for Cerebrolysin because it is a mixture. The relevant questions are route, course duration, tolerability, and clinical endpoint timing. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.

• BDNF Boosters: Often combined with lifestyle factors like intense aerobic exercise or 7,8-DHF to maximize neuroplasticity.
• Nootropics: Stacked with Cholinergics (like Alpha-GPC) to provide the “fuel” for the new synaptic connections Cerebrolysin facilitates.
• It is sometimes combined with rehab, cognitive therapy, sleep optimization, or other neuroprotective agents. Avoid stacking multiple neuroactive agents if the goal is to interpret cognitive or neurologic response. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.

• Side Effects: “Brain fog” or “over-stimulation” if the dose is too high. Mild dizziness or heat sensations.
• Contraindications: Status Epilepticus (can lower seizure threshold) and Severe Renal Impairment.6 Allergy Warning: Derived from pig brain; Avoid if you have a pork allergy.7
• Product origin, allergy risk, injection/infusion reactions, seizure susceptibility, and disease-context monitoring matter. Mixture-based products also raise quality and authenticity concerns in gray markets. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.

• Cognitive Assessment: Baseline and post-cycle testing (MMSE, MoCA, or digital tools like Cambridge Brain Sciences).
• Kidney Function: Serum creatinine and GFR (due to the nitrogen/amino acid load).
• Vital Signs: Monitor resting heart rate and blood pressure during the initial titration.
• Track functional neurologic measures, cognition scales, sleep, headache, agitation, seizures, and infusion reactions. In stroke/TBI contexts, standardized rehab outcomes are more useful than subjective clarity. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.

• FDA: Not approved in the U.S.
• Anti-doping: do not state a absolute WADA/S2 ban claim unless a current anti-doping authority or Global DRO result confirms the exact product/status. Cerebrolysin is not FDA-approved in the U.S. and is a parenteral neuroactive peptide mixture, so competitive athletes should treat it as high-risk and verify status with Global DRO, USADA/NADO, and sport-specific rules before any exposure.
• Availability: Prescribed in 50+ countries; Sold as a “research chemical” ampoule elsewhere.
• Cerebrolysin has regional medical use but is not FDA-approved in the United States. Imported product status and prescribing context need to be explicit. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.

1. [F] Ziganshina et al. (2023). Cerebrolysin for acute ischaemic stroke. Cochrane Database of Systematic Reviews. PMID:37818733

2. [F] Vester et al. (2021). Cerebrolysin after moderate to severe traumatic brain injury: a metaanalysis of CAPTAIN trials. Neurological Sciences. PMID:33620612

3. [C] Muresanu et al. (2020). Efficacy and safety of Cerebrolysin in neurorecovery after moderate-severe traumatic brain injury: CAPTAIN II. Neurological Sciences. PMID:31897941

4. [F] Jarosz et al. (2023). Cerebrolysin in patients with traumatic brain injury: systematic review and meta-analysis. Journal of Clinical Medicine. PMID:36979317

5. [F] Cui et al. (2019). Cerebrolysin for vascular dementia. Cochrane Database of Systematic Reviews. PMID:31710397

6. [B] Guekht et al. (2011). Cerebrolysin treatment in vascular dementia: a randomized placebo-controlled trial. Journal of Stroke and Cerebrovascular Diseases. PMID:20656516

7. [G] ClinicalTrials.gov. (2012). CAPTAIN trial of Cerebrolysin in traumatic brain injury. ClinicalTrials.gov. NCT01606111

• CJC-1295 is a synthetic tetrasubstituted 29-amino acid peptide hormone, specifically acting as a Growth Hormone-Releasing Hormone (GHRH) analog.
• It was developed by ConjuChem Biotechnologies to treat muscle wasting and growth hormone deficiencies.
• It is a modified version of GRF (1-29) (Sermorelin), engineered for superior stability and a significantly longer half-life.
• CJC-1295 needs a DAC/no-DAC distinction every time. DAC forms are long-acting albumin-binding GHRH analogs; No-DAC or modified GRF(1-29)-type products behave much more like short-acting pulse agents.

CJC-1295 stimulates the pituitary gland to increase the endogenous production of Growth Hormone (GH):

• GHRH Receptor Agonism: It binds to GHRH receptors on the somatotroph cells in the anterior pituitary, triggering the synthesis and pulsatile release of GH.
• IGF-1 Elevation: Increased GH levels prompt the liver to produce Insulin-like Growth Factor 1 (IGF1), which mediates most of the peptide’s anabolic and recovery effects.
• Pulsatile Preservation: Unlike synthetic HGH, CJC-1295 (specifically the “No DAC” version) preserves the body’s natural “pulses” of growth hormone rather than shutting down natural production.
• DAC Technology: The “With DAC” (Drug Affinity Complex) version incorporates a maleimide group that binds to circulating albumin, preventing enzymatic degradation and extending its activity from minutes to days.
• The mechanism is pituitary GHRH-receptor stimulation, increasing GH pulses and downstream IGF-1. It is not the same as giving growth hormone directly, and physiologic reserve limits response. The mechanism here is a plausibility map, not proof of a clinical outcome.

• The strongest human evidence is pharmacokinetic/pharmacodynamic: CJC-1295 with DAC can produce prolonged GH and IGF-1 elevation after dosing.
• DAC and no-DAC products must be separated. DAC produces multi-day exposure; No-DAC/modified GRF behaves more like a short GHRH pulse.
• Body-composition, sleep, and injury-repair claims are often discussed in clinics and communities, but they are not established outcomes for every CJC-1295 product without direct study context.
• The exact molecule, DAC status, dose interval, and monitoring plan need to be clear before any claimed benefit means much.

Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions.

• Protocol 1: CJC-1295 (No DAC / MOD-GRF) [Research/Experimental]; Route: Injection, fasted; Dose: 100 mcg – 200 mcg; Frequency: 1 to 3 times daily; Timing: Fasted (AM or before bed); Duration: 8 to 12 weeks; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 2: CJC-1295 (With DAC) [Research/Experimental]; Route: Injection; Dose: 2,000 mcg (2 mg); Frequency: Once weekly; Timing: Any time (long-acting); Duration: 8 to 12 weeks; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Dosing must identify DAC status. 5-on/2-off logic is not pharmacokinetically meaningful for DAC forms, while short-acting forms are often used in pulse-style protocols with ipamorelin. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.

• Time until steady state: No-DAC about 2.5 hours; DAC about 4-6 weeks.
• Half-life basis: No-DAC/modified GRF: roughly 30 minutes; CJC-1295 DAC: 5.8-8.1 days in a human study.
• Beginner translation: This estimate uses the standard four-to-five-half-life convention. It describes when plasma exposure would be expected to approach a plateau during repeated dosing, not when the desired outcome is complete.
• Practical interpretation: Always state whether the product is no-DAC/modified GRF or DAC; The steady-state timelines are completely different.
• Delivery: Subcutaneous (SC) injection is the standard. Oral versions are generally considered to have poor bioavailability for this specific peptide chain.
• Route note: do not generalize intranasal/oral findings across GH secretagogues. Older GHRP-2 and hexarelin data, animal ipamorelin nasal PK, and community sermorelin/CJC nasal-buccal products are different evidence categories.
• DAC CJC-1295 has multi-day activity; No-DAC forms have short exposure. This is one of the clearest examples where a peptide name without modifier status can break a calculator. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.

• Ipamorelin: The standard, reliable stack. Pairing a GHRH (CJC) with a GHRP (Ipamorelin) creates a much larger GH release than either peptide used alone.
• BPC-157: Often added for advanced injury rehabilitation protocols.
• Common pairing with ipamorelin combines GHRH and ghrelin/GHS-R signaling. This is mechanistically plausible, but combining GH-axis agents increases IGF-1, edema, glucose, sleep-apnea, and carpal-tunnel-type monitoring needs. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.

”CJC Flush”: Many users experience a temporary rush of heat and redness in the face/neck immediately after injection; The exact mechanism is not well characterized, and it should not be attributed cleanly to the GH pulse.

• Water Retention: Can cause mild edema (swelling) or joint tingle if the dose is too high.
• Contraindications: Should be avoided by anyone with active cancer or a history of pituitary tumors, as GH can accelerate cell growth.
• Watch for flushing, tachycardia, edema, numbness/tingling, headache, glucose changes, and excessive IGF-1. Flushing is not a harmless sign that the GH pulse worked. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.

• Serum IGF-1: The primary marker used to verify that the peptide is working and the dose is appropriate.
• Fasting Glucose/HbA1c: Growth hormone can affect insulin sensitivity; Long-term users should monitor blood sugar levels.
• Prolactin: In rare cases, some GHRH analogs can slightly elevate prolactin.
• Track IGF-1 against age-adjusted range, fasting glucose/A1c, edema, blood pressure, sleep apnea symptoms, carpal tunnel symptoms, and injection reactions. Glucocorticoids, obesity, sleep, and nutrition can alter response. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.

• FDA: CJC-1295 was removed from the Category 2 “do-not-compound” list in September 2024 after nominators withdrew the original nomination. It remains under FDA review and is expected to be referred to the Pharmacy Compounding Advisory Committee at a future meeting (date not yet announced). It is not FDA-approved for any indication. This is a distinct regulatory trajectory from the 12 peptides covered by the April 15, 2026 HHS action.
• WADA: Banned under S2 (Peptide Hormones and Growth Factors).
• Availability: Continues to be compounded in practice during the review period; Check with your pharmacy on current legal status.
• CJC-1295 is not FDA-approved, and FDA has flagged serious adverse events and characterization concerns for compounded CJC-1295. DAC/no-DAC identity matters in regulatory and quality discussions. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.

1. [C] Teichman et al. (2006). Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295, a longacting analog of growth hormone-releasing hormone. Journal of Clinical Endocrinology & Metabolism. PMID:16352683

2. [C] Ionescu & Frohman. (2006). Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295. Journal of Clinical Endocrinology & Metabolism. PMID:17018654

3. [D] Sackmann-Sala et al. (2009). Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Hormone & IGF Research, 19(6), 471-477. PMID:19386527; PMCID:PMC2787983; DOI:10.1016/j.ghir.2009.03.001.

4. [G] FDA. (2024). December 4, 2024 Pharmacy Compounding Advisory Committee Briefing Document: CJC-1295-related bulk drug substances. FDA.

5. [H] aidsmap. (2006). CJC-1295 lipodystrophy study halted after patient death. aidsmap.

• Dermorphin is a natural heptapeptide first isolated from South American tree frogs.
• It contains D-alanine in its natural sequence and is a potent opioid peptide.
• Dermorphin is a potent opioid peptide that sits in a high-risk category, not a performance, recovery, or wellness category. Its history includes illicit performance manipulation concerns, which changes how you should interpret it.

• Dermorphin acts primarily through mu-opioid receptor signaling.
• Analgesic potency, endocrine changes, and CNS effects are opioid effects and carry the usual opioid risks.
• The mechanism is mu-opioid receptor agonism. Analgesia or euphoria from opioid activity is not tissue repair and can mask injury or toxicity. The mechanism here is a plausibility map, not proof of a clinical outcome.

• Human literature is historical and limited, often intrathecal or endocrine-response context rather than modern therapeutic development.
• It is not a practical peptide protocol.
• Research interest does not translate into safe self-experimentation. Human therapeutic utility is not established in the guide context, while opioid-class risks are well established. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.

Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions for you.

• Protocol 1: Intranasal Analogs [Research/Experimental]; Route: Intranasal (Analogs); Dose: 0.5 - 1.0 mcg/kg; Duration: Effect Duration: 2-4 Hours; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 2: Intravenous (Mice) [Animal/Preclinical]; Route: Intravenous (Mice); Dose: ~1.0 μmol/kg; Duration: Effect Duration: Variable; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 3: Intrathecal Clinical Trial [Clinical/Human Trial]; Route: Intrathecal (Clinical Trial); Dose: 20 mcg - 100 mcg; Duration: Effect Duration: 12+ Hours; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 4: Research-only status note [Research/Experimental]; Route: Direct spinal injection or intranasal analogs designed for better brain delivery; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Detailed community dosing is beside the point here: nonmedical use is inappropriate and dangerous. Small amount differences can be consequential with potent opioid activity. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.

• Time until steady state: not calculable.
• Half-life basis: Sequence-, route-, and analog-dependent; No routine human PK standard. Because this is a potent opioid peptide, steady-state framing is unsafe and not useful outside controlled research/medical settings.
• Beginner translation: this is a deliberately conservative read. A missing steady-state number does not mean the compound has no effect; It means the available human PK data are not strong enough to justify a precise accumulation estimate for common use patterns.
• Practical interpretation: Systemic half-life and CNS penetration depend on sequence, route, and analog design. Generalized dosing claims are not reliable.
• Short or uncertain half-life does not remove opioid risk because receptor effects, tolerance, respiratory depression, and impairment can occur during active exposure. Simple peptide calculators do not apply here. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.

• Do not stack with opioids, alcohol, benzodiazepines, sedatives, gabapentinoids, or other respiratory depressants.
• Do not stack with alcohol, benzodiazepines, sedatives, opioids, gabapentinoids, sleep drugs, or other CNS depressants. Stacking can turn an already high-risk compound into an acute overdose risk. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.

• Respiratory depression, dependence, tolerance, endocrine effects, nausea, itching, urinary retention, sedation, and overdose are central risks.
• Naloxone can reverse opioid toxicity but is not a reason to experiment.
• Primary risks are respiratory depression, dependence, withdrawal, impaired judgment, nausea, and masking serious injury. This deserves stronger safety language than most peptides in the guide. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.

• Research monitoring includes pain-response assays and endocrine markers; Clinical overdose monitoring involves airway, breathing, oxygenation, and emergency care.
• Practical monitoring is not a substitute for avoiding nonmedical use. If exposure occurs, sedation, breathing rate, oxygenation, consciousness, and emergency response are the relevant safety issues. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.

• Not approved for human or animal use.
• Banned in competitive sports and prohibited in many racing jurisdictions.
• Controlled-substance laws may apply depending on jurisdiction and analog status.
• Dermorphin is not an approved wellness peptide and may implicate controlled-substance, anti-doping, or illicit-use concerns depending on context. Its regulatory and anti-doping status is strict. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.

1. [D] Broccardo et al. (1981). Pharmacological data on dermorphins, a new class of potent opioid peptides from amphibian skin. British Journal of Pharmacology. PMID:7195758; DOI:10.1111/j.1476-5381.1981.tb16797.x

2. [C] Degli Uberti et al. (1985). The effects of dermorphin on the endocrine system in man. Peptides. PMID:3008118

3. [C] degli Uberti et al. (1983). Stimulatory effect of dermorphin, a new synthetic potent opiate-like peptide, on human growth hormone secretion. Neuroendocrinology. 37(4):280-283. PMID:6633818; DOI:10.1159/000123559

4. [C] Roti et al. (1984). Dermorphin, a new opioid peptide, stimulates thyrotropin secretion in normal subjects. Journal of Endocrinological Investigation. 7:211-214. PMID:6470436; DOI:10.1007/BF03348425

5. [F] Hesselink & Schatman. (2018). Rediscovery of old drugs: the forgotten case of dermorphin for postoperative pain and palliation. Journal of Pain Research. PMID:30538538

6. [D] Deigin et al. (2025). Neurotropic activity of novel dermorphin analogs. International Journal of Molecular Sciences. PMID:40943359

• Dihexa, also called PNB-0408, is a synthetic angiotensin IV analog.
• Chemically, it is a small modified oligopeptide described as N-hexanoyl-Tyr-Ile-(6) aminohexanoic amide.
• It was designed to overcome the usual weaknesses of short peptides: rapid degradation, poor oral exposure, and limited blood-brain barrier penetration.
• In practical terms, it sits between peptide pharmacology and small-molecule nootropic research rather than behaving like a standard hormone peptide.
• The intended therapeutic concept was neurorepair: use a stable AngIV-derived scaffold to support synapse formation and memory processes.
• That concept remains investigational. Dihexa is not FDA-approved, has no labeled human indication, and does not belong with clinically used neuroactive drugs such as prescription stimulants, cholinesterase inhibitors, or approved dementia therapies.
• Dihexa is an angiotensin-IV-derived nootropic research compound often discussed for synaptogenesis. It is distinct from ordinary peptides because it is designed for CNS penetration and strong trophic signaling hypotheses.

• The proposed mechanism is positive modulation of the hepatocyte growth factor / MET receptor system, often written HGF/c-Met or HGF/MET.
• HGF and MET are involved in cell survival, migration, tissue remodeling, neurodevelopment, and synaptic plasticity.
• Dihexa was proposed to bind or stabilize HGF in a way that enhances MET activation when HGF is present.
• This mechanism must be framed cautiously.
• The paper most often cited for the HGF/c-Met mechanism was retracted in 2025, and an earlier Dihexa paper received a formal notice of concern.
• A safer phrasing is: Dihexa has been proposed to interact with HGF/MET signaling, and later animal studies have explored related neuroplasticity pathways, but the specific mechanism is not settled enough to treat as proven.
• Once you're past the basics, the safety tension is obvious: the same pathway discussed for neuronal repair is also a major pathway in cancer biology.
• HGF/MET signaling participates in proliferation, migration, invasion, angiogenesis, and metastasis in many tumors.
• That does not mean Dihexa causes cancer, but it does mean arbitrary long-term HGF/MET potentiation without human toxicology is not a trivial risk.
• The main mechanism claim involves HGF/c-Met pathway modulation and synaptogenic signaling. Because c-Met biology is also relevant to cancer and tissue growth, mechanism language needs a benefit-risk boundary. The mechanism here is a plausibility map, not proof of a clinical outcome.

• Preclinical cognition models: The original rat work reported that Dihexa and related metabolically stabilized AngIV analogs improved performance in scopolamine-impaired and aged rats, including Morris water maze outcomes. That paper is historically important but carries an expression-of-concern notice, so the guide treats it as hypothesis-generating rather than reliable proof.
• HGF/MET synaptogenesis claims: A follow-up paper reported that Dihexa promoted hippocampal spinogenesis and synaptogenesis through HGF/c-Met signaling. That paper is now retracted. A statement such as “Dihexa is 10 million times stronger than BDNF” does not hold up, because the underlying comparison came from cell-culture claims, not clinical outcomes, and the mechanistic evidence base is compromised.
• Independent animal work: A 2021 APP/PS1 mouse study reported that intragastric Dihexa improved spatial-learning measures and increased synaptic and neuronal markers while affecting PI3K/AKT signaling. A 2025 repeated mild traumatic brain injury rat study also used Dihexa as an HGF/MET-positive modulator and reported rescue of working-memory deficits. These are useful preclinical signals, but neither establishes human efficacy, human safety, optimal route, or dose.
• Human evidence gap: No controlled human clinical trial evidence was found for Dihexa itself. There is also no published human dose-ranging, adverse-event, or pharmacokinetic program adequate for clinical risk assessment. For a beginner, this is the most important sentence in the entry.
• The most striking claims come from preclinical cognitive models, not robust human trials. It is useful to explain why researchers are interested while clearly stating that human efficacy and long-term safety are unproven. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.

Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions for you.

• Protocol 1: Preclinical oral rat dose reported in evidence review [Animal/Preclinical]; Route: Oral; Dose: 2 mg/kg; Frequency: Reported in rats; Schedule varies by study; Duration: Preclinical study context; Status: No - animal/preclinical only; Not FDA-approved for human use.
• Protocol 2: Community/clinic oral capsule range [Community/Biohacker/Anecdotal]; Route: Oral capsule; Dose: 5 mg – 20 mg; Frequency: Often once daily or divided depending on clinic/community protocol; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 3: Commercial clinic 10 mg oral capsule listing [Community/Biohacker/Anecdotal]; Route: Oral capsule; Dose: 10 mg; Frequency: Once daily; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 4: Reddit nootropic ramp anecdote [Community/Biohacker/Anecdotal]; Route: Sublingual; Dose: About 5 mg; Frequency: 2–3 times daily; Timing: User-reported; Stacked with other nootropics in anecdote; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 5: Speculative online subcutaneous exposure calculation [Community/Biohacker/Anecdotal]; Route: Subcutaneous (speculative); Dose: Approx. 0.02 mg – 0.3 mg estimated systemic-equivalent range; Frequency: Not standardized; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Community topical, oral, and injectable reports exist, but route efficacy is not established. The protocol rows are anecdotal/research-market, not clinical dosing. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.

• Time until steady state: not calculable.
• Half-life basis: no validated human elimination half-life or route-specific human PK dataset was found. Preclinical descriptions call Dihexa orally active and blood-brain-barrier permeable, but that does not provide a human half-life.
• Beginner translation: A missing steady-state estimate is not an oversight. It is the honest answer when human half-life is unavailable. Any precise claim such as “steady state in X days” would be false precision unless backed by route-specific human PK.Practical interpretation: For Dihexa, effect-duration claims are pharmacodynamic speculation. Cognitive or mood changes, if reported, do not prove plasma steady state or CNS accumulation. What is known from the public literature is qualitative rather than quantitative: Dihexa was designed to be more metabolically stable and more CNS-penetrant than native AngIV. What is not established is the human absorption fraction, Tmax, Cmax, half-life, active metabolites, CNS exposure, washout time, or accumulation pattern.
• CNS exposure and duration are central unknowns. Without human PK/PD, calculators cannot responsibly predict steady-state cognitive effects or risk windows. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.

• No evidence-based stacking protocol exists.
• Dihexa is often discussed alongside Semax, Selank, Cerebrolysin, NAD+, or mitochondrial peptides, but those stacks are community inventions unless tested directly.
• Combining multiple neuroactive agents also makes it harder to interpret anxiety, insomnia, irritability, headaches, mood elevation, or cognitive changes.
• Intermediate caution: Avoid stacking Dihexa with other growth-factor, angiogenic, neurotrophic, or cancer-biology-adjacent agents unless a clinician or formal protocol has a clear reason.
• The mechanistic overlap may be more important than the names of the products.
• Dihexa is sometimes stacked with racetams, cholinergics, semax-family peptides, or NAD/mitochondrial compounds. Avoid stacking multiple cognitive agents initially because anxiety, insomnia, headache, or mood changes become difficult to attribute. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.

• Human safety is unknown.
• There is no adequate public human toxicology package, no published long-term safety study, and no validated adverse-event profile.
• That means mild self-reported side effects cannot be used to conclude that the compound is safe.
• Theoretical concerns include tumor biology through HGF/MET signaling, unpredictable neuropsychiatric effects, seizure-threshold uncertainty, unknown drug-drug interactions, and unknown effects in pregnancy, breastfeeding, adolescents, and people with neurologic or psychiatric conditions.
• Contraindication-style cautions: active cancer, history of aggressive cancer, unexplained masses, premalignant lesions under evaluation, severe psychiatric instability, seizure disorder, pregnancy or breastfeeding, and use in minors are high-risk or inappropriate without formal medical oversight.
• Theoretical c-Met/pro-growth signaling is the main long-term concern, alongside unknown neuropsychiatric effects. A lack of adverse reports does not mean low risk. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.

• There is no validated monitoring panel for Dihexa.
• Routine labs can miss the main theoretical risks because HGF/MET signaling risk is not captured by a simple CMP, CBC, or inflammatory marker panel.
• If a research setting is evaluating Dihexa, useful monitoring would include objective cognitive testing, sleep tracking, mood/irritability screening, headache or neurologic symptom logs, and careful documentation of route, formulation, and batch.
• For any person with cancer history or suspicious lesions, medical evaluation matters more than self-monitoring.
• Track sleep, anxiety, headaches, mood lability, blood pressure if stimulant-like effects appear, cognition tasks, and any unusual growth/tumor-history concern. Subjective mental sharpness alone is not enough. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.

• FDA: Not approved for any human indication. No labeled prescription product exists. Research-use-only sales do not make it legal or validated for human use.
• Compounding: Dihexa is not an FDA-approved drug and is not part of a standard regulated peptide-compounding pathway. Any clinic or vendor presenting it as routine therapy owes you human safety data, legal basis, and source-quality documentation.
• Anti-doping: Competitive athletes should treat Dihexa as high risk under WADA S0 principles because it is not an approved therapeutic substance for human use and is marketed for biologic effects. Athletes should verify with their anti-doping organization before any exposure.
• Dihexa is a research compound, not an FDA-approved cognitive therapy. FDA has included Dihexa acetate in peptide safety/compounding discussions, but review is not approval. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.

1. [D] McCoy AT et al. Evaluation of Metabolically Stabilized Angiotensin IV Analogs as Procognitive/Antidementia Agents. Journal of Pharmacology and Experimental Therapeutics. 2013. PMID:23055539. Use: Historical Dihexa preclinical cognition claims; confidence downgraded due to journal notice of concern.

2. [G] Notice of Concern: McCoy AT et al. (2013) Evaluation of Metabolically Stabilized Angiotensin IV Analogs as Procognitive/Antidementia Agents. Journal of Pharmacology and Experimental Therapeutics. 2021. PMID:34551989. Use: Required integrity-context note for Dihexa evidence.

3. [D] Benoist CC et al. The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-Met system. Journal of Pharmacology and Experimental Therapeutics. 2014. PMID:25187433; PMCID:PMC4201273. Use: Historical HGF/c-Met Dihexa mechanism claim; cited only to explain why the claim is no longer reliable.

4. [D] Sun X et al. AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway. Brain Sciences. 2021. Use: Independent mouse-model Dihexa context; not human efficacy or safety evidence.

5. [D] Martino KA et al. Hepatocyte Growth Factor/MET Activator Rescues Working Memory Deficits after Repeated Mild Traumatic Brain Injury. 2025. Use: Rat repeated-mild-TBI HGF/MET activation context using Dihexa; not human efficacy evidence.

6. [F] Cecchi F et al. Targeting the HGF/MET signalling pathway in cancer therapy. Expert Opinion on Therapeutic Targets. 2012. PMID:22530990. Use: Safety-context source for HGF/MET as a cancer-relevant pathway; not direct Dihexa toxicity evidence.

7. [RouteEvidence] Alzheimer’s Drug Discovery Foundation Cognitive Vitality: Dihexa evidence review.

8. [RouteEvidence] FDA. Certain bulk drug substances for use in compounding that may present significant safety risks.

• DSIP is a synthetic version of a nonapeptide originally isolated from rabbit cerebral venous blood after hypnogenic electrical stimulation.
• The commonly cited sequence is Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, abbreviated WAGGDASGE.
• The molecular formula is C35H48N10O15 and the molecular weight is about 848.8 Da.
• The FDA refers to DSIP as Emideltide in the 2026 Pharmacy Compounding Advisory Committee materials.
• The substances being discussed are Emideltide free base and Emideltide acetate.
• In this guide, DSIP, delta sleep-inducing peptide, and Emideltide refer to the same standard nonapeptide unless a modified analog is explicitly named.
• Classification is difficult. It is commonly grouped as a neuropeptide or sleep-wake regulatory peptide.
• It is not a benzodiazepine, non-benzodiazepine hypnotic, orexin antagonist, melatonin agonist, opioid, or approved detoxification medication.
• It belongs in the “old clinical research / unresolved mechanism” category rather than in the “proven prescription sleep drug” category.
• DSIP/emideltide is a sleep-related neuropeptide research compound with unresolved biology, not a reliable sedative. This entry uses the name emideltide, because FDA materials use that term.

• No single DSIP receptor has been validated which is the central scientific limitation.
• Early work treated DSIP as a candidate endogenous sleep factor because of delta-wave EEG findings in animals. Later reviews concluded that the sleep-factor hypothesis is weakly documented and that DSIP-like immunoreactivity may reflect related peptides or fragments rather than one clean endocrine system.
• The most defensible mechanism language is broad: DSIP appears to interact with sleep-wake regulation, stress-axis signaling, neuroendocrine tone, and possibly opioid-related pathways.
• Proposed effects include modulation of ACTH/corticosterone stress responses, interactions with hypothalamic systems, changes in endogenous opioid signaling, and altered neuronal excitability.
• These are mechanistic hypotheses, not confirmed clinical mechanisms.
• DSIP is not a simple sedative. In some narcolepsy research it was reported to reduce daytime sleep attacks and improve alertness, which is the opposite of what a pure hypnotic model would predict.
• A more careful interpretation is that DSIP may influence sleep-wake organization or circadian regulation, but the direction and clinical reliability depend heavily on subject, route, timing, and study design.
• Proposed mechanisms touch sleep regulation, stress axis, pain, and neuroendocrine signaling, but the mechanism is not settled. It does not directly induce delta sleep in a predictable, drug-like way. The mechanism here is a plausibility map, not proof of a clinical outcome.

• Animal discovery and EEG work: The original DSIP concept came from rabbit work showing increased spindle and delta EEG activity after central administration. This supports the historical name but does not prove that peripheral DSIP products reliably improve human sleep.
• Insomnia studies: Small human studies in the 1980s and early 1990s produced mixed results. An open seven-patient study reported improvement after a series of injections, but open studies are vulnerable to expectation and selection bias. A later double-blind study in 16 chronic insomnia patients concluded that short-term DSIP was unlikely to have major therapeutic benefit. Another controlled insomnia study found some sleep-architecture changes, but the clinical significance was limited.
• Narcolepsy research: A small 1984 study reported fewer sleep attacks and better daytime alertness/performance. That finding is scientifically interesting because it suggests possible circadian or state-stabilizing effects, but it is not enough to establish DSIP as a narcolepsy treatment. Modern narcolepsy care is built around well-studied wake-promoting agents, oxybate products, and newer orexin-pathway programs, not DSIP.
• Withdrawal research: Older European studies explored DSIP for alcohol and opiate withdrawal. Reports included IV administration in patients with withdrawal symptoms and later open clinical work in opioid detoxification. These studies are historically relevant and explain why FDA listed opioid withdrawal among the reviewed uses. They are not proof that DSIP can safely replace evidence-based alcohol or opioid withdrawal management.
• Evidence synthesis: The strongest modern editorial position is conservative. DSIP is not pure nonsense, but its evidence base is old, small, heterogeneous, and mechanistically unresolved. Claims that it reliably “maximizes deep sleep,” “resets circadian rhythm,” “treats addiction,” or “fixes cortisol” need to be softened unless tied to a specific study and endpoint.
• Evidence is heterogeneous, older, and mixed. Community sleep reports are relevant to your context, but they are separate from controlled evidence of insomnia treatment. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.

Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions.

• Protocol 1: Chronic insomnia matched-pairs study [Clinical/Human Trial]; Route: Intravenous; Dose: 25 nmol/kg; Frequency: Before the 3rd, 4th, and 5th study nights; Timing: Before sleep; Duration: 3 treatment nights in study context; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 2: Insomnia sleep-cycle crossover study [Clinical/Human Trial]; Route: Intravenous; Dose: 25 nmol/kg; Frequency: During four nights; Timing: Night/sleep study context; Duration: 4 nights; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 3: Single and repeated injection insomnia reports [Clinical/Human Trial]; Route: Injection; Study used DSIP injections; Dose: 25 nmol/kg body weight; Frequency: Single injections before sleep; Repeated administrations in study reports; Timing: Before sleep; Morning dosing also studied; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 4: CRH/endocrine challenge infusion study [Clinical/Human Trial]; Route: Intravenous infusion; Dose: 3 mg or 4 mg total; Frequency: Single infusion around CRH challenge; Duration: Acute research infusion; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 5: Common clinic/community sleep range [Community/Biohacker/Anecdotal]; Route: Usually subcutaneous; Dose: 100 mcg – 500 mcg; Frequency: Often 2–3 times per week; Timing: 30–60 minutes before sleep; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 6: Community SC evening cycle [Community/Biohacker/Anecdotal]; Route: Subcutaneous; Dose: 100 mcg – 500 mcg; Frequency: As needed or nightly in short cycles; Timing: 30–60 minutes before bed; Duration: PRN or 2–4 week cycles; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 7: Biohacker 250 mcg cycle [Community/Biohacker/Anecdotal]; Route: Subcutaneous; Dose: 250 mcg; Frequency: 5 days on / 2 days off; Timing: 1–3 hours before bed; Duration: 8 weeks on / 8 weeks off; Titration/loading: Sensitive users reported starting around 100–150 mcg.; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 8: Community nasal spray protocol [Community/Biohacker/Anecdotal]; Route: Intranasal spray; Dose: 100 mcg – 500 mcg per spray; Frequency: 1–2 sprays daily; Timing: Often around 30 minutes before bed; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Community dosing is often evening/night use, but timing, route, and cycling are empirical. There is no basis for promising next-day recovery or sleep-stage correction. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.

• Time until steady state: about 30-40 minutes by the reported 7-8 minute human plasma half-life; About 60-75 minutes if using a 15-minute in-vitro enzymatic degradation estimate.
• Half-life basis: older DSIP literature reports very rapid degradation in plasma/blood, while modern route-specific human PK for common subcutaneous or intranasal products is not established.
• Beginner translation: DSIP clears quickly. A short half-life does not mean it cannot have downstream effects, but it does rule out any long accumulation window.
• Practical interpretation: Steady state is not the best endpoint for DSIP. If an effect exists, it may depend more on timing relative to circadian phase, route, brain access, and downstream signaling than on maintaining a stable blood concentration all day. Route-specific uncertainty matters. IV exposure, subcutaneous absorption, intranasal absorption, and oral exposure are not equivalent. Product salt form, pH, preservatives, degradation, and nasal mucosa condition can all change the amount reaching systemic circulation or the CNS.
• Short peptide exposure may not match sleep architecture outcomes. Without validated human PK/PD, missed-dose or steady-state calculators are not helpful. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.

• Sleep-focused stacks often combine DSIP conceptually with magnesium, glycine, melatonin, GABAergic supplements, Selank, Semax, or “recovery” peptides.
• These combinations are anecdotal. Combining several sedating or neuroactive substances makes it harder to identify which compound caused benefit, next-day impairment, mood changes, or adverse effects.
• Withdrawal-focused combinations are not appropriate for self-experimentation.
• Alcohol, benzodiazepine, and opioid withdrawal can require medical detoxification, monitoring, and evidence-based medications.
• DSIP is not a stand-alone substitute for buprenorphine, methadone, clonidine/lofexidine, benzodiazepine protocols for alcohol withdrawal, or inpatient care when indicated.
• Once you're past the basics, also consider peptide-degradation interactions. The DSIP literature notes degradation by aminopeptidase pathways; Theoretical interactions with peptidase-modifying drugs are not well characterized.
• In practice, DSIP is conceptually separate from a simple supplement stack, and it warrants clinician review when prescription medications are involved.
• Common sleep stacks include magnesium, glycine, melatonin, GABAergic agents, or peptides. Combining with sedatives can increase impairment and makes it harder to know whether sleep quality truly improved. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.

• Human safety information is limited by old and small studies. Reported tolerability in historical studies does not establish long-term safety for modern gray-market products.
• Main practical risks include unknown dose, contamination, endotoxin exposure, nasal irritation if intranasal, injection-site reactions if injectable, headache, unusual dreams, daytime fatigue or paradoxical alertness, mood changes, and sleep disruption.
• Contraindication caution is strongest for pregnancy, breastfeeding, seizure disorders, bipolar disorder or mania history, severe psychiatric instability, untreated sleep apnea, complex sedative use, active substance-use withdrawal, and use alongside alcohol, benzodiazepines, opioids, Z-drugs, barbiturates, phenibut, or other CNS depressants.
• Anyone with opioid or alcohol withdrawal symptoms needs medical care, not an experimental peptide-first plan.
• A quality-control warning belongs here, too. Because DSIP is usually encountered as RUO powder or spray, COA identity, HPLC purity, mass spectrometry, endotoxin testing, sterility where applicable, and lot matching matter.
• A “sleep peptide” label does not prove molecule identity or injection safety.
• Main concerns are next-day grogginess, paradoxical sleep disruption, mood effects, unknown endocrine effects, and interaction with sedatives or alcohol. Quality risk is also relevant because many products are RUO. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.

• For sleep: track sleep onset latency, wake after sleep onset, total sleep time, awakenings, subjective sleep quality, next-day alertness, and adverse effects. Wearables can be useful for trends but are not polysomnography. A simple sleep diary and Epworth Sleepiness Scale can be more useful than chasing “deep sleep” percentages on a consumer device.
• For suspected sleep disorders: screen for sleep apnea, restless legs, circadian rhythm disorder, medication effects, alcohol use, caffeine timing, and mood disorders before attributing insomnia to a DSIP deficiency. DSIP should not delay proper evaluation of loud snoring, witnessed apneas, morning headaches, dangerous daytime sleepiness, cataplexy, or parasomnias.
• For safety: monitor mood, anxiety, next-day sedation, headaches, blood pressure if symptomatic, injection-site or nasal irritation, and any interaction with sleep medications. For withdrawal contexts, appropriate monitoring is medical: vitals, hydration, withdrawal scales, relapse risk, suicidality, and clinician-directed medication management.
• Track sleep latency, awakenings, total sleep time, next-day function, dreams/nightmares, resting heart rate, and wearable sleep trends cautiously. Wearables are helpful for trend, not definitive sleep staging. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.

• FDA: Emideltide free base and Emideltide acetate are scheduled for discussion at the FDA Pharmacy Compounding Advisory Committee meeting on July 24, 2026. The FDA-listed uses being evaluated are opioid withdrawal, chronic insomnia, and narcolepsy. Committee review is not the same thing as FDA approval, and it is not the same thing as immediate legal compounding access. U.S. market status: DSIP/Emideltide is not an FDA-approved drug with a labeled indication. Research-use-only sale does not establish safety, efficacy, sterility, legal prescribing status, or product quality.
• Anti-doping: DSIP is not treated here as an athlete-safe substance. Even if not named specifically, a non-approved peptide marketed for biologic effects can create S0/S2 risk under anti-doping frameworks. Competitive athletes should check the current WADA list and their anti-doping organization before any exposure.
• Emideltide/DSIP is not FDA-approved. PCAC review or nomination history is compounding-list consideration only, not safety validation. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.

1. [G] U.S. Food and Drug Administration. (2026). July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee. Use: Confirms that Emideltide (DSIP) free base and acetate are scheduled for July 24, 2026 PCAC discussion and that FDA reviewed opioid withdrawal, chronic insomnia, and narcolepsy as uses.

2. [G] National Center for Biotechnology Information. PubChem Compound Summary: Delta Sleep-Inducing Peptide. Use: DSIP/Emideltide synonyms, molecular formula C35H48N10O15, CAS 62568-57-4, and molecular weight about 848.8 g/mol.

3. [D] Pollard BJ, Pomfrett CJD. (2001). Delta sleep-inducing peptide. European Journal of Anaesthesiology, 18(7), 419-422. PMID: 11437870. Use: DSIP review context and reported human plasma half-life of 7-8 minutes; notes rapid blood degradation through aminopeptidase-related pathways.

4. [D] Kovalzon VM, Strekalova TV. (2006). Delta sleep-inducing peptide (DSIP): a still unresolved riddle. Journal of Neurochemistry, 97(2), 303-309. PMID: 16539679; DOI: 10.1111/j.1471-4159.2006.03693.x. Use: Conservative evidence framing; unresolved gene/receptor/precursor biology and weak documentation of DSIP as a sleep factor.

5. [B] Bes F, Hofman W, Schuur J, van Boxtel C. (1992). Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients: a double-blind study. Neuropsychobiology, 26(4), 193-197. PMID: 1299794; DOI: 10.1159/000118919. Use: Human insomnia evidence; small double-blind study with limited therapeutic signal.

6. [C] Kaeser HE. (1984). A clinical trial with DSIP. European Neurology, 23(5), 386-388. PMID: 6391926; DOI: 10.1159/000115717. Use: Open severe-insomnia DSIP study; illustrates early clinical interest but low-certainty evidence.

7. [C] Dick P, Costa C, et al. (1983). Successful treatment of withdrawal symptoms with delta sleep-inducing peptide. PMID: 6328354. Use: Historical supervised withdrawal study; supports why withdrawal appears in FDA’s reviewed-use list, but not proof of modern self-treatment safety.

8. [C] Schneider-Helmert D. (1984). Effects of DSIP on narcolepsy. European Neurology, 23(5), 377-385. PMID: 6548968. Use: Small narcolepsy study reporting fewer sleep attacks and better daytime function; not sufficient for modern indication-level proof.

9. [C] Backmund M, Meyer K, et al. (1998). Opioid detoxification with delta sleep-inducing peptide: results of an open clinical trial. PMID: 9617990. Use: Later open opioid-detoxification evidence; reinforces low-certainty, supervised clinical context.

10. [G] World Anti-Doping Agency. (2025). International Standard: Prohibited List 2026. Use: S0 non-approved substances and peptide-hormone/growth-factor category caution for athletes using non-approved biologically active peptides.

11. [RouteEvidence] FDA. Certain bulk drug substances for use in compounding that may present significant safety risks.

• Epithalon is a synthetic tetrapeptide designed as a simplified analog associated with Epithalamin, a pineal-gland extract used in parts of Russian gerontology research.
• The short AEDG sequence is the reason it is sometimes grouped with “bioregulator” peptides rather than with hormone secretagogues, growth factors, or metabolic peptides.
• It is not FDA-approved, not EMA-approved, and not a standard prescription drug in the United States.
• It is often sold as a research chemical or discussed in anti-aging clinics, which creates a large gap between market enthusiasm and regulatory-grade evidence.
• Epithalon/epitalon is often classified as a bioregulator/longevity compound associated with pineal and telomere-related claims. It is not a proven anti-aging therapy.

Epithalon is usually discussed through four proposed mechanisms: pineal/circadian regulation, telomerase-related signaling, antioxidant or stress-response modulation, and gene-expression effects. None of these should be simplified into a single “reverse aging” mechanism. Mechanistic map:

• Pineal/circadian axis: Older studies and reviews associate Epithalon/Epithalamin with melatonin rhythm and pineal regulation, especially in aging models.
• Telomerase and telomere biology: Cell-culture work reports telomerase-related changes and telomere-length effects in human cell lines. This is biologically interesting but not proof of longer human life or lower disease risk.
• Antioxidant and stress signaling: Some preclinical work links Epithalon to oxidative-stress defenses and cellular resilience.
• Gene-expression effects: The broader bioregulator framework proposes tissue-specific gene-expression changes, but this model is not universally accepted in mainstream pharmacology.
• Mechanism discussions usually mention telomerase, circadian/pineal signaling, antioxidant effects, and gene-expression modulation. These are hypotheses and model findings, not a guarantee of lifespan extension in humans. The mechanism here is a plausibility map, not proof of a clinical outcome.

• Cell-line findings: Recent human-cell-line work supports continued interest in telomerase and telomere biology. Cell lines are useful for mechanism, but they do not establish clinical efficacy, optimal human dosing, or long-term safety.
• Animal findings: Some older animal studies reported lifespan or biomarker effects in mice, rats, flies, or primates. Other animal work did not show a clear mean-lifespan benefit. The picture is genuinely mixed, not a cherry-picked set of positive lifespan claims.
• Human-history findings: Some older clinical and gerontology reports describe effects on melatonin rhythm, immune parameters, or aging biomarkers. Many are small, older, region-specific, and not easily comparable to modern randomized, blinded, independently replicated trials.
• Best practical interpretation: Epithalon is a plausible circadian/bioregulator research peptide with interesting telomere biology. It is not a proven life-extension intervention.
• Evidence includes Russian/Eastern European bioregulator literature, cell/animal work, and limited human-context reports. Quality and reproducibility need to be explicit. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.

Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions.

• Protocol 1: Clinical/Khavinson Protocols [Clinical/Human Trial]; Route: Oral or IM/SC; Dose: Daily Dose: 5 mg – 10 mg; Frequency: Once daily (evening); Duration: 10 to 20 days; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 2: Common Biohacker Protocols [Community/Biohacker/Anecdotal]; Route: Subcutaneous (SC) or oral capsules; Dose: Daily Dose: 1 mg – 10 mg; Frequency: Once daily; Duration: 10 to 30 days; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Community protocols often use short cycles rather than continuous use. Those cycles are tradition- and market-driven more than validated by dose-finding trials. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.

• Time until steady state: not calculable from validated human pharmacokinetic data. Community sources often claim a 30-60 minute half-life, but those claims are usually not supported by route-specific, peer-reviewed human PK studies.
• Half-life basis: Reliable human elimination half-life has not been established for modern subcutaneous, intranasal, sublingual, or oral products.
• Why this matters: Epithalon is usually discussed for gene-expression, circadian, and telomerase effects. These are pharmacodynamic hypotheses, not simple steady-state blood-level targets.
• As a very small peptide, it may clear quickly, but proposed effects are downstream and not modeled by plasma persistence. Do not use simple half-life logic to infer anti-aging effects. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.

• Thymalin / thymic peptides: Often paired in Russian-style bioregulator discussions. The logic is pineal/circadian support plus thymic/immune-aging support. This is a tradition and hypothesis, not a validated combination protocol.
• Pinealon: Sometimes paired for neurocognitive or neuro-regenerative framing. Evidence remains weak and largely outside modern FDA-style drug development.
• Melatonin and sleep hygiene: Low-dose melatonin, consistent light exposure, fixed wake time, and sleep tracking are more evidence-grounded ways to interpret whether an Epithalon cycle is affecting circadian rhythm. A wearable improvement alone is not proof of telomere benefit.
• Avoid stacking noise: Combining Epithalon with multiple longevity agents such as rapamycin, metformin, NAD+, SS-31, MOTS-c, or senolytics makes it almost impossible to interpret results or adverse effects.
• It is often paired with pineal/bioregulator compounds, sleep protocols, NAD precursors, or mitochondrial peptides. Stacking multiple longevity agents increases narrative bias because endpoints are slow and nonspecific. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.

• Cancer/telomerase caution: Any peptide discussed in relation to telomerase deserves a conservative cancer-risk discussion. Telomerase activation is not automatically harmful, but active malignancy, recent cancer, suspicious lesions, or strong cancer predisposition are major caution flags.
• Reported side effects: Community reports include vivid dreams, sleep disruption, fatigue, headache, irritability, transient stimulation, and injection-site irritation. The true incidence is unknown.
• Caution groups: Pregnancy, breastfeeding, pediatric use, active malignancy, unstable psychiatric illness, severe autoimmune flare, and concurrent experimental longevity stacks all increase uncertainty.
• Long-term pro-telomerase claims create theoretical cancer-biology questions even when direct risk is not established. Short peptide size does not make it inherently safe. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.

• Sleep/circadian: Track bedtime, wake time, total sleep, REM/deep sleep estimates, subjective sleep quality, morning alertness, and nocturnal awakenings. Wearable data is trend data, not a diagnostic endpoint.
• Longevity biomarkers: Telomere testing by qPCR or methylation/biological-age tests can be noisy, and one measurement does not support strong interpretation. If used, compare baseline and follow-up under the same lab and method.
• Safety monitoring: CBC, CMP, inflammatory markers if relevant, and routine age-appropriate cancer screening matter more than chasing a single telomere number.
• Track sleep/circadian measures, mood, labs chosen for general health, and avoid overinterpreting telomere tests. Telomere length assays have variability and are not a simple treatment-response marker. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.

• FDA/compounding: FDA scheduled Epitalon-related bulk substances for PCAC discussion on July 24, 2026 for possible 503A Bulks List consideration. Review does not equal approval.
• United States/EU: Not FDA-approved or EMA-approved for anti-aging, sleep, telomere extension, or any medical indication.
• Availability: Mostly research-use-only vendors and nonstandard wellness channels. Product quality and identity should be verified with batch-specific COA, mass spec, and endotoxin data for injectable products.
• Epithalon is not FDA-approved and is scheduled for compounding-policy discussion, not drug approval. Regional/research use is separate from U.S. clinical status. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.

1. [E] Khavinson et al. (2003). Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine. PMID:12937682

2. [E] Khavinson et al. (2004). Peptide promotes overcoming of the division limit in human somatic cells. Bulletin of Experimental Biology and Medicine. DOI:10.1023/B:BEBM.0000038164.49947.8c

3. [D] Khavinson et al. (2003). Peptide Epitalon activates chromatin at old age. Bulletin of Experimental Biology and Medicine. PMID:14647006

4. [D] Anisimov et al. (2003). Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female CBA mice. Biogerontology. PMID:14501183

5. [D] Khavinson et al. (2001). Synthetic tetrapeptide Epitalon restores disturbed neuroendocrine regulation in senescent monkeys. Bulletin of Experimental Biology and Medicine. PMID:11524632

6. [F] Araj et al. (2025). Overview of Epitalon-Highly Bioactive Pineal Tetrapeptide with Promising Properties. International Journal of Molecular Sciences, 26(6), 2691. PMID:40141333; PMCID:PMC11943447; DOI:10.3390/ijms26062691.

7. [E] Al-Dulaimi et al. (2025). Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology, 26(5), 178. PMID:40908429; PMCID:PMC12411320; DOI:10.1007/s10522-025-10315-x.

8. [G] U.S. Food and Drug Administration. July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee.

9. [G] U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding May Present Significant Safety Risks.

10. [D] Araj SK, et al. Overview of Epitalon – Highly Bioactive Pineal Tetrapeptide with Promising Properties. International Journal of Molecular Sciences, 2025.

11. [E] Al-Dulaimi S, et al. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology, 2025.

12. [D] Alzheimer’s Drug Discovery Foundation. Epithalamin/Epithalon Cognitive Vitality for Researchers.

13. [G] Perfect B. Epithalon Dosage Protocol.

14. [RouteEvidence] Tyagi et al. Oral peptide delivery: translational challenges due to physiological effects. J Control Release. 2018.

• FOXO4-DRI is a D-retro-inverso peptide developed from work on the FOXO4-p53 interaction in senescent cells.
• FOXO4 is a human transcription factor; FOXO4-DRI is the engineered peptide intended to interfere with one senescent-cell survival mechanism.
• FOXO4-DRI is a senolytic research peptide concept, not a general anti-aging supplement. It is designed to disrupt FOXO4-p53 interactions in senescent cells, which is a high-consequence biology target.

• The proposed mechanism is disruption of the FOXO4-p53 interaction.
• In the model, senescent cells use FOXO4 to keep p53 in a survival-associated nuclear state.
• FOXO4-DRI is proposed to release p53, allowing apoptosis of senescent cells.
• This is a preclinical mechanism, not a validated human rejuvenation protocol.
• The intended mechanism is selective apoptosis of senescent cells through transcription-factor interaction disruption. That makes specificity, delivery, and off-target cell death central questions. The mechanism here is a plausibility map, not proof of a clinical outcome.

• The foundational 2017 mouse/cell study reported improved tissue homeostasis after targeted apoptosis of senescent cells in aging and chemotoxicity models.
• Later studies examined chondrocytes, Leydig cells, fibrosis, and endothelial senescence.
• These findings are useful for biological context but remain preclinical or mechanistic.
• Human translation remains unresolved.
• The key missing pieces are human PK, biodistribution, target engagement, dose-response, immunogenicity, organ-specific toxicity, cancer-context safety, and long-term follow-up.
• The key evidence is preclinical. There is not a mature human efficacy or safety base for wellness use, so senolytic claims are experimental. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.

Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions.

• Protocol 1: Animal-Equivalent Research [Animal/Preclinical]; Route: Subcutaneous (SC) or Intraperitoneal (IP); Dose: ~2 mg to 5 mg per injection; Frequency: Every other day (3 doses total); Duration: Short "Pulse" (1 week); Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 2: Experimental Longevity Pulse Dose [Research/Experimental]; Route: Subcutaneous (SC) or Intraperitoneal (IP); Dose: 1 mg – 2 mg; Frequency: Once every 3–7 days; Duration: 2 to 3 weeks; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Community cycles are not established senolytic regimens. Route, cell penetration, purity, and species translation are unresolved. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.

• Time until steady state: not calculable.
• Half-life basis: no reliable human elimination half-life or validated human route-specific PK data are available. D-retro-inverso design suggests protease resistance, but it does not provide a numeric human half-life.
• Beginner translation: This is why Section 5 does not give a fake number. A claim such as “steady state in X hours” would be unsupported without human PK.Practical interpretation: For a senolytic pulse concept, steady-state exposure is not the main endpoint. The relevant questions are tissue exposure, senescent-cell selectivity, apoptosis timing, organ handling of debris, and recovery after the pulse. The biological effect of apoptosis, where it occurs, can outlast plasma exposure. That does not allow a plasma half-life to be inferred from the duration of fatigue, soreness, or any subjective response.
• Plasma half-life is less important than cellular uptake, tissue distribution, and whether active intracellular concentrations are reached. Calculators cannot model senescent-cell clearance. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.

• No evidence-based stack exists.
• Dasatinib/quercetin comparisons are conceptual, not proof that FOXO4-DRI is safer or more selective in humans.
• Pairing with BPC-157, NAD+, growth factors, or mitochondrial peptides is speculative and may obscure adverse effects.
• FOXO4-DRI is often discussed with fisetin, quercetin/dasatinib concepts, NAD, or mitochondrial support. Combining senolytics can magnify uncertainty and adverse inflammatory responses. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.

• Major concerns include off-target apoptosis, impaired wound-healing biology, immune activation, kidney or liver burden from cell clearance, and cancer-biology uncertainty.
• Being a peptide does not make the compound benign.
• Active cancer, immunosuppression, pregnancy, organ disease, or recent surgery would be high-risk contexts.
• Concerns include off-target apoptosis, tissue stress, inflammatory debris clearance, immune effects, and unknown cancer/repair implications. It calls for high caution. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.

• Research monitoring could include CBC, CMP, cystatin C, urinalysis, hs-CRP, IL-6, functional measures, and senescence-associated markers in a formal study.
• Consumer-grade telomere tests are not a validated way to prove FOXO4-DRI efficacy.
• Useful monitoring would include functional measures, inflammatory symptoms, CBC/CMP, liver/kidney markers, and adverse-event tracking. Consumer biological-age tests are not proof of senolysis. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.

• FOXO4-DRI is not FDA-approved and has no established lawful prescription indication.
• It is sold, where available, as a research chemical. Athletes should treat use as high-risk under anti-doping rules for unapproved substances and peptide-related agents.
• FOXO4-DRI is not an approved senolytic drug. Research availability does not imply suitability for human use. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.

1. [D] Baar et al. (2017). Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. Cell. PMID:28340339

2. [D] Huang et al. (2021). Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes. Frontiers in Bioengineering and Biotechnology, 9, 3. PMID:33996787; PMCID:PMC8116695; DOI:10.3389/fbioe.2021.677576.

3. [D] Zhang et al. (2020). FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice. Aging (Albany NY), 12, 1272-1284. PMID:31959736; PMCID:PMC7053614; DOI:10.18632/aging.102682.

4. [D] Li et al. (2024). FOXO4-DRI improves spermatogenesis in aged mice through reducing senescence-associated secretory phenotype secretion from Leydig cells. Experimental Gerontology, 195, 6. PMID:39025385; DOI:10.1016/j.exger.2024.112522.

5. [D] Han et al. (2022). FOXO4 peptide targets myofibroblast ameliorates bleomycin-induced pulmonary fibrosis in mice through ECM-receptor interaction pathway. Journal of Cellular and Molecular Medicine, 26(11), 3269-3280. PMID:35510614; PMCID:PMC9170815; DOI:10.1111/jcmm.17333.

6. [E] Bourgeois et al. (2025). The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI. Nature Communications, 16(1), 5672. PMID:40593617; DOI:10.1038/s41467-025-60844-9.

7. [D] Hu et al. (2026). FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway. Frontiers in Bioengineering and Biotechnology. PMID:41625068; PMCID:PMC12852416; DOI:10.3389/fbioe.2025.1729166.

• GHK-Cu is a naturally occurring tripeptide (Glycyl-L-histidyl-L-lysine) with a high affinity for copper ions.
• Discovered in 1973 by Dr. Loren Pickart, it was first isolated from human plasma.
• It is classified as a carrier peptide and a signaling fragment, playing a fundamental role in tissue remodeling, collagen synthesis, and gene regulation.
• GHK-Cu is a naturally occurring copper-binding tripeptide complex best supported in topical skin/wound/cosmetic contexts. Injectable/systemic GHK-Cu is a separate, less-established route category.

GHK-Cu is best framed as a copper-binding signaling tripeptide, not as a proven whole-body DNA-reset therapy.

• Copper transport/signaling: GHK binds copper strongly and may influence copper-dependent enzymes and local tissue signaling in skin and wound-repair models.
• Extracellular-matrix remodeling: experimental and review literature discuss collagen, elastin, glycosaminoglycans, and matrix-remodeling pathways, especially in skin contexts.
• Any gene-expression effects here stay at the mechanistic level. GHK-Cu does not reset human DNA or return genes to a youthful state as a clinical outcome.
• Systemic claims such as nerve repair, organ repair, or lung repair are preliminary unless tied to a specific route, formulation, and human endpoint.
• Mechanisms include copper delivery, extracellular-matrix remodeling, anti-inflammatory signaling, collagen organization, and wound-repair pathways. Systemic rejuvenation claims do not follow from topical skin biology. The mechanism here is a plausibility map, not proof of a clinical outcome.

• Topical/cosmetic skin: some human/cosmetic and mechanistic literature supports local skin-quality and extracellular-matrix discussion, but superiority over vitamin C, retinoids, or other actives is not established without a specific comparative trial.
• Wound healing: preclinical and investigational human work make GHK-Cu scientifically plausible, but do not present it as an established treatment for chronic wounds, diabetic ulcers, or surgical incisions.
• Hair/scalp: topical/scalp use is common. Claims comparable to 5% minoxidil do not hold unless tied to a specific formulation and controlled endpoint.
• Systemic/lung/organ repair: keep as preliminary or mechanistic. Do not frame systemic GHK-Cu as a validated emphysema, COPD, or organ-repair protocol.
• Topical/local evidence and mechanistic literature are stronger than injectable wellness evidence. Community popularity of GLOW/KLOW blends is not the same as validated human outcomes. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.

Below you'll find reported clinical-label, research, and community-use dosing contexts where available. Educational reference only, not dosing instructions.

• Protocol 1: Topical (Skin/Hair) [Topical/Cosmetic]; Route: Topical; Dose: Apply 1–2 times daily; Frequency: Daily; Duration: Indefinite; Max: 5% (Scalp focus); Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 2: Subcutaneous (Systemic) [Community/Biohacker/Anecdotal]; Route: Subcutaneous (SC); Dose: 1 mg – 2 mg daily; Frequency: Once daily; Duration: 30 days on / 30 days off; Max: 5 mg daily (Acute injury); Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Topical concentration, vehicle, pH, irritation, and consistency matter. Injectable or blended use requires much stricter quality and compatibility caution than cosmetic serum use. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.

• Time until steady state: not reliably calculable for common topical, microneedling-adjacent, or injectable community products.
• Half-life basis: short plasma persistence is reported, but consistent route-specific human systemic PK is not established for common topical/injectable use.
• For topical use, local tissue exposure, skin-barrier condition, vehicle, pH, copper complexation, concentration, and irritation matter more than plasma steady state.
• Topical absorption does not generalize. The stratum corneum remains a major barrier; Penetration depends on formulation and any enhancement method such as microneedling or iontophoresis.
• Topical evidence does not establish meaningful systemic exposure.
• For topical use, local penetration and formulation stability matter more than plasma half-life. For injectable use, public PK and systemic safety are not sufficiently established. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.

• BPC-157 + TB-500 + GHK-Cu is commonly marketed as a GLOW-style repair/skin stack. This is a community/market category, not a standardized clinical product.
• KLOW-style stacks add KPV for gut/skin/mucosal anti-inflammatory rationale. This is mechanistically plausible but not proven as a superior human regimen.
• If GHK-Cu is paired with BPC-157, KPV, or TB-500-family products, keep the TB-500 identity distinction: LKKTETQ fragment, full-length Tβ4, and unresolved vendor TB-500 are not interchangeable.
• Topical pairings such as retinoids, niacinamide, minoxidil, or microneedling are common discussions, but timing and formulation matter. Avoid same-application mixing with strong acids or harsh actives unless the product is designed for that combination.
• GHK-Cu may be paired with retinoids, microneedling, moisturizers, BPC/KPV/TB-family blends, or hair products. Copper chemistry means same-vial compatibility is exact-formulation dependent. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.

Injection “Sting”: GHK-Cu is notorious for causing a sharp, temporary stinging sensation at the injection site. This can be mitigated by diluting the solution with more bacteriostatic water.

• Copper Toxicity: While rare at standard doses, chronic high-dose use without breaks could potentially lead to copper imbalance.
• Contraindications: History of Wilson’s Disease (copper storage disorder) or active skin infections at the site of topical application.
• Topical irritation is commonest; Injectable concerns include sterility, endotoxin, immune response, copper-related chemistry, and unknown systemic effects. Do not call copper blends universally safe because chelation exists. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.

• Skin Elasticity: Subjective and objective tracking of skin “snap back” and texture.
• Hair Density: Tracking follicle count and thickness in cases of androgenetic alopecia.
• Serum Copper/Ceruloplasmin: Only necessary for long-term, highdose systemic users to ensure mineral balance.
• Track irritation, barrier disruption, hyperpigmentation/staining, wound response, photos, and product interactions with acids/retinoids. For any injection research context, monitor local reactions and systemic symptoms more conservatively. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.

• FDA: The April 15, 2026 action treated GHK-Cu’s two nominations differently by dosage form. Injectable GHK-Cu was among the 12 bulk substances HHS directed FDA to remove from Category 2 on April 15, 2026. It is expected to be reviewed at a future PCAC meeting (not on the July 23-24, 2026 agenda). Compounding-pharmacy injectable preparation remains blocked until the FDA issues a final determination.
• FDA (topical): GHK-Cu remains widely available as a cosmetic ingredient under existing cosmetic regulations. No change.
• WADA: Not on the prohibited list.
• Availability: Topical formulations are freely available; Injectable formulations via research-use-only vendors pending FDA reclassification.
• GHK-Cu appears in cosmetic and compounding discussions, but injectable routes carry stronger regulatory/safety concern. Non-injectable category status does not justify injections. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.

1. [F] Pickart & Margolina. (2018). Regenerative and protective actions of the GHK-Cu peptide in the light of new gene data. International Journal of Molecular Sciences. PMID:29986520

2. [F] Pickart et al. (2008). The human tri-peptide GHK and tissue remodeling. Journal of Biomaterials Science, Polymer Edition. PMID:18644225

3. [F] Pickart et al. (2012). The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions. Oxidative Medicine and Cellular Longevity. PMID:22666519

4. [F] Pickart et al. (2015). GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. BioMed Research International. PMID:26236730

5. [F] Pickart, Vasquez-Soltero, & Margolina (2017). The Effect of the Human Peptide GHK on Gene Expression Relevant to Nervous System Function and Cognitive Decline. Brain Sciences, 7(2), 20. PMID:28212278; PMCID:PMC5332963; DOI:10.3390/brainsci7020020.

6. [D] Parker et al. (2013). Effects of Topical Copper Tripeptide Complex on Wound Healing in an Irradiated Rat Model. Otolaryngology-Head and Neck Surgery. PMID:23744835; DOI:10.1177/0194599813492644.

7. [F] Mortazavi et al. (2025). Topically applied GHK as an anti-wrinkle peptide: advantages, problems and prospective. BioImpacts. 15:30071. PMID:39963574

8. [RouteEvidence] FDA. Certain bulk drug substances for use in compounding that may present significant safety risks.

9. [RouteEvidence] Pickart et al. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. 2015 review.

10. [RouteEvidence] Dou et al. The potential of GHK as an anti-aging peptide. 2020 review.

• GHRP-2 and GHRP-6 are synthetic growth-hormone-releasing peptides in the older growth-hormone secretagogue family.
• They act at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a.
• GHRP-2 and GHRP-6 are ghrelin/GHS-R agonist secretagogues, not GHRH analogs. They are often grouped, but hunger, cortisol/prolactin spillover, and potency can differ.

• Both compounds trigger pituitary GH release and interact with hypothalamic-pituitary regulation.
• GHRP-6 is more strongly associated with hunger stimulation.
• GHRP-2 is generally described as less appetite-provoking but still less selective than ipamorelin.
• The GH pulse is also shaped by sleep, nutrition, blood glucose, free fatty acids, somatostatin tone, endogenous GHRH, age, adiposity, and prior secretagogue exposure.
• That is why response varies and why repeated stimulation can lose effect.
• They stimulate GH release through GHS-R and work best conceptually when pituitary GH reserve exists. GHRP-6 is more hunger-promoting; GHRP-2 is often described as stronger GH-releasing but less selective than ipamorelin. The mechanism here is a plausibility map, not proof of a clinical outcome.

• Human endocrine studies show that GHRP-6 can stimulate GH secretion and that GHRP-2 can increase food intake and pituitary hormone release.
• Comparative endocrine studies also show that older GHRPs can raise ACTH/cortisol and prolactin more than cleaner secretagogues.
• Pharmacokinetic evidence is limited but useful.
• GHRP-6 has a published human IV PK study in nine healthy men; GHRP-2 has pediatric IV PK/PD data in short-stature children.
• These are not the same as modern wellness-clinic subcutaneous protocols.
• Human endocrine studies show GH release, but body-composition and anti-aging outcomes are not proven at community protocol level. Desensitization/attenuation with repeated exposure is biologically plausible. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.

Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions for you.

• Protocol 1: GHRP-2 Acetate [Research/Experimental]; Route: Subcutaneous (SC); Dose: Saturation Dose: 100 mcg; Frequency: 2-3x Daily; Timing: Fasted Rule: no food 2 hours before or 30-60 mins after; Max: 200 mcg (diminishing returns); Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 2: GHRP-6 Acetate [Research/Experimental]; Route: Subcutaneous (SC); Dose: Saturation Dose: 100 mcg; Frequency: 2-3x Daily; Timing: Fasted Rule: no food 2 hours before or 30-60 mins after; Max: 150 mcg; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 3: Combined research/anecdotal pattern [Community/Biohacker/Anecdotal]; Route: Subcutaneous (SC); Dose: Typically 100 mcg per injection; Frequency: 2 to 3 times daily; Timing: Empty stomach / avoid elevated blood glucose or fatty acids; Duration: 8 to 12 weeks with rest periods; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Pulse-style use and 5-on/2-off cycles are common, but the exact schedule is not proven necessary. Food timing matters because glucose/fatty acids and somatostatin tone can blunt GH response. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.

• Time until steady state: GHRP-2 about 2 to 3 hours by IV pediatric terminal half-life math; GHRP-6 about 10 to 13 hours by adult IV terminal half-life math.
• Half-life basis: GHRP-2 beta half-life 0.55 +/- 0.14 hours in a small pediatric IV PK/PD study; GHRP-6 distribution half-life 7.6 +/- 1.9 minutes and elimination half-life 2.5 +/- 1.1 hours in nine healthy adult men after IV bolus dosing.
• Beginner translation: The steady-state number is less important here than the GH pulse. These drugs are used for transient signaling; A flat constant exposure is not usually the intended physiology.
• Practical interpretation: Do not copy IV PK numbers directly into subcutaneous self-use assumptions. Route, dose, assay method, and population matter. Monitor IGF-1, fasting glucose, edema, appetite, prolactin/cortisol symptoms, and sleep quality. GHRP-6 may have a longer terminal phase than many community summaries suggest. That does not mean the GH pulse lasts all day; The endocrine response rises and falls much faster than terminal elimination alone implies.
• Route note: do not generalize intranasal/oral findings across GH secretagogues. Older GHRP-2 and hexarelin data, animal ipamorelin nasal PK, and community sermorelin/CJC nasal-buccal products are different evidence categories.
• Short half-lives support pulse-based interpretation. Short plasma exposure does not eliminate receptor desensitization or downstream IGF-1/glucose issues. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.

• The classic mechanistic pairing is with a GHRH analog such as CJC-1295 without DAC or sermorelin.
• In that model, the GHRH signal encourages GH synthesis/release readiness and the GHRP signal triggers a release pulse. This is an endocrine concept, not a guarantee of clinical benefit.
• Do not stack multiple GHRPs together just to increase stimulation. Combining GHRP-2, GHRP-6, hexarelin, ipamorelin, or GH itself can amplify edema, glucose disruption, carpal-tunnel-like symptoms, blood-pressure changes, and pituitary-axis noise.
• GHRP-6 may be chosen in research discussions when appetite stimulation is part of the hypothesis; GHRP-2 may be chosen when appetite stimulation is unwanted.
• Often stacked with CJC-1295/no-DAC or sermorelin to combine GHRH and GHS-R signals. Avoid adding multiple GH-axis agents without IGF-1/glucose monitoring. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.

• Expected issues include flushing, hunger, lethargy, water retention, headache, sleepiness, numbness/tingling, glucose changes, and injection-site irritation.
• Prolactin and cortisol elevation are more relevant with older GHRPs than with ipamorelin.
• Avoid in active malignancy, uncontrolled diabetes, untreated sleep apnea, intracranial hypertension risk, pregnancy, and any setting where fluid retention or glucose worsening would be dangerous.
• Watch appetite surges, water retention, tingling, carpal-tunnel symptoms, prolactin/cortisol effects, sleep apnea worsening, and glucose changes. Cancer history and uncontrolled diabetes are important caution contexts. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.

• Useful monitoring includes IGF-1, fasting glucose, HbA1c, fasting insulin if available, blood pressure, edema, weight trend, sleep apnea symptoms, prolactin, cortisol context, and symptom logs.
• A single IGF-1 value does not prove safety or body-composition benefit.
• Track IGF-1, fasting glucose/A1c, weight/waist, edema, blood pressure, sleep apnea symptoms, hunger, and prolactin/cortisol if symptoms suggest spillover. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.

• FDA: not approved; Classified as investigational research chemicals. Both were on the original 19-peptide Category 2 list and are expected to stay there, and neither was among the 12 peptides HHS directed FDA to remove in April 2026.
• Compounding: as of late 2025 many US compounding pharmacies stopped making them under new FDA Bulks List restrictions, shifting practitioners toward ipamorelin or tesamorelin. Access is not expected to return.
• WADA/USADA: banned under S2 and detectable in urine for up to 7 to 10 days after a dose.
• Caveat: commentary cites cortisol and prolactin elevation (especially with GHRP-6) and variable gray-market purity.
• GHRP-2/GHRP-6 are not FDA-approved wellness drugs and may be anti-doping-prohibited. Research-market availability is separate from lawful clinical use. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.

1. [C] Lei et al. (1995). Growth hormone-releasing peptide-6 stimulates growth hormone secretion. Journal of Clinical Endocrinology & Metabolism. PMID:7772238

2. [C] Pandya et al. (1998). Growth hormone-releasing peptide-6 requires endogenous growth hormone-releasing hormone for maximal GH response. Journal of Clinical Endocrinology & Metabolism. PMID:9543138

3. [F] Camanni et al. (1998). Growth hormone-releasing peptides and their analogs. Frontiers in Neuroendocrinology. PMID:9465289

4. [C] Laferrère et al. (2005). Growth hormone-releasing peptide-2, like ghrelin, increases food intake in healthy men. Journal of Clinical Endocrinology & Metabolism. PMID:15699539

5. [C] Arvat et al. (1997). Effects of growth hormone-releasing peptide-2 and hexarelin on GH, ACTH, and cortisol secretion. Journal of Clinical Endocrinology & Metabolism. PMID:9285939

6. [E] Cabrales et al. (2013). Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP 6) in nine male healthy volunteers. European Journal of Pharmaceutical Sciences, 48(1-2), 40-46. PMID:23099431.

7. [E] Thomas et al. (2011). Detection of growth hormone releasing peptides in human urine. Drug Testing and Analysis. PMID:21298258

8. [G] WADA. (2026). International Standard: Prohibited List. World Anti-Doping Agency.

9. [RouteEvidence] Lewis et al. Intranasal human growth hormone induces IGF-1 comparable with SC injection with lower systemic exposure. 2015.

10. [RouteEvidence] Pihoker et al. Intranasal GHRP-2 in children of short stature. PubMed record.

11. [RouteEvidence] Johansen et al. Pharmacokinetic evaluation of ipamorelin and other peptidyl GH secretagogues with emphasis on nasal absorption. PubMed record.

• Glutathione is an endogenous tripeptide composed of glutamate, cysteine, and glycine.
• Although not a therapeutic peptide in the same sense as many entries, it is included because injectable and IV glutathione are common in peptide-clinic practice.
• Glutathione is a tripeptide antioxidant, not a hormone-like peptide. Route and form matter: reduced GSH, S-acetyl-GSH, liposomal products, topical products, inhaled/nasal, and IV are not interchangeable.

It cycles between reduced (GSH) and oxidized (GSSG) forms; The GSH/GSSG ratio is the meaningful redox readout, not a single value.

• Antioxidant defense: directly scavenges reactive oxygen species and free radicals, protecting DNA, lipids, and proteins.
• Detoxification: in the liver it binds toxins, heavy metals, and pollutants (Phase II conjugation), making them water-soluble for excretion.
• Recharges other antioxidants: regenerates vitamins C and E so they stay active longer.
• Mitochondrial protection: a primary defender of the mitochondria, keeping energy production efficient.
• Melanogenesis inhibition: in skin it inhibits tyrosinase and shifts pigment from darker eumelanin toward lighter pheomelanin.
• Its biology centers on redox buffering, detoxification conjugation, mitochondrial protection, and recycling with NADPH-dependent systems. More glutathione is not always better; Redox balance matters. The mechanism here is a plausibility map, not proof of a clinical outcome.

• Bioavailability: standard oral glutathione is poorly absorbed, but liposomal and S-acetyl forms largely bypass gut degradation and raise systemic levels.
• Neuroprotection: work in Parkinson's and Alzheimer's models points to reduced neuroinflammation by limiting oxidative bursts in the brain.
• Immune support: replenishing GSH has been reported to increase natural-killer-cell cytotoxicity substantially, aiding antiviral response.
• Skin: randomized trials support systemic skin-lightening, though results depend on the length of the loading phase.
• Caveat: evidence is stronger for correcting deficiency and specific oxidative-stress contexts than for broad detox or longevity claims.
• Human evidence varies by route and indication. Oral forms can affect body stores over time, topical evidence is local/cosmetic, and IV use is common clinically but not a universal wellness fix. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.

Below you'll find reported clinical-label, research, and community-use dosing contexts where available. Educational reference only, not dosing instructions for you.

• Protocol 1: Wellness/Longevity - Oral Liposomal [Community/Biohacker/Anecdotal]; Route: Oral (Liposomal); Dose: 500 mg daily; Timing: Morning fast / empty stomach for liposomal and acetyl forms; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 2: Clinical/Skin Lightening - Oral Liposomal [Clinical/Human Trial]; Route: Oral (Liposomal); Dose: 1,000 mg daily; Timing: Morning fast / empty stomach for liposomal and acetyl forms; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 3: Wellness/Longevity - S-Acetyl-GSH [Community/Biohacker/Anecdotal]; Route: S-Acetyl-GSH; Dose: 200 mg daily; Timing: Morning fast / empty stomach for liposomal and acetyl forms; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 4: Clinical/Skin Lightening - S-Acetyl-GSH [Clinical/Human Trial]; Route: S-Acetyl-GSH; Dose: 400 mg – 600 mg daily; Timing: Morning fast / empty stomach for liposomal and acetyl forms; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 5: Wellness/Longevity - IV [Community/Biohacker/Anecdotal]; Route: Intravenous (IV); Dose: 600 mg weekly; Timing: Morning fast / empty stomach for liposomal and acetyl forms; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 6: Clinical/Skin Lightening - IV [Clinical/Human Trial]; Route: Intravenous (IV); Dose: 1,200 mg – 2,400 mg weekly; Timing: Morning fast / empty stomach for liposomal and acetyl forms; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 7: Wellness/Longevity - NAC precursor [Community/Biohacker/Anecdotal]; Route: Precursors (NAC); Dose: 600 mg twice daily; Timing: Morning fast / empty stomach for liposomal and acetyl forms; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 8: Clinical/Skin Lightening - NAC precursor [Clinical/Human Trial]; Route: Precursors (NAC); Dose: 1,200 mg twice daily; Timing: Morning fast / empty stomach for liposomal and acetyl forms; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Form and route matter before any amount is meaningful. NAC/glycine precursor strategies are separate from direct glutathione administration. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.

• Time until steady state: not a single calculable number.
• Half-life basis: plasma glutathione handling is short and compartmental, while intracellular pools depend on synthesis, recycling, oxidative load, and precursor availability.
• Beginner translation: If you're new, glutathione is more like a cellular redox pool than a weekly drug. Blood levels, cellular levels, and symptom changes can move differently.
• Practical interpretation: Track clinical context, oxidative-stress markers where appropriate, liver enzymes, renal function, and adverse effects instead of relying on plasma half-life.
• Comparison note: reduced glutathione, liposomal glutathione, S-acetyl glutathione, NAC, glycine, and methylation support can affect the glutathione system differently. Route and formulation determine what is being tested.
• Oral absorption and intracellular conversion are form-dependent. Plasma spikes after IV are different from sustained intracellular redox changes. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.

• Common supportive pairings include NAC, glycine, selenium, vitamin C, alpha-lipoic acid, and adequate protein intake.
• These are biochemical supports, not proof that a stack treats disease.
• Avoid combining high-dose antioxidant protocols with chemotherapy or radiation without oncology approval.
• Common pairings include NAC, glycine, vitamin C, alpha-lipoic acid, NAD precursors, and mitochondrial peptides. Overlapping antioxidants can blunt adaptive training signals in some contexts. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.

• Generally well tolerated: high oral doses may cause mild bloating, cramping, or loose stools.
• Zinc depletion: long-term, high-dose use can lower zinc over time.
• IV risks: intravenous use carries higher risk, including allergic reactions and, rarely, liver or kidney stress at extreme unmonitored doses, so it needs sterility, rate control, and oversight.
• Asthma warning: inhaled glutathione can trigger bronchospasm in sensitive airways.
• Possible issues include bronchospasm with inhaled forms, GI upset, headache, sulfur sensitivity, and unclear effects in active chemotherapy/radiation contexts. IV quality and sterility matter. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.

• GSH/GSSG ratio: the gold standard for redox status; A higher ratio indicates a healthier, better-protected cell.
• 8-OHdG: a urinary marker of oxidative DNA damage that a working protocol would lower.
• GGT (gamma-glutamyl transferase): elevated levels can signal trouble recycling glutathione, often tied to liver stress.
• Context tracking: liver enzymes, renal function, CBC, and asthma symptoms with nebulized use, alongside symptom response.
• Track goal-specific endpoints: oxidative-stress markers if available, liver enzymes when relevant, symptoms, skin outcomes for topical use, and respiratory tolerance for inhaled/nasal routes. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.

• FDA: recognized as "Generally Recognized as Safe" for food use, but the agency has warned against injectable skin-lightening drips, which lack standardized safety data for that use.
• WADA: not a prohibited substance, but IV infusions over 100 mL per 12-hour period are banned regardless of contents unless medically necessary.
• Clinical use: widely sold as a supplement and used in hospitals (usually via the precursor NAC) as the antidote for acetaminophen poisoning.
• Availability does not prove efficacy; Athletes should check product ingredients and anti-doping rules.
• Glutathione exists in supplement, cosmetic, compounded, and clinical-use contexts. Regulatory status depends heavily on route, claims, and product category. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.

1. [F] Wu et al. (2004). Glutathione metabolism and its implications for health. Journal of Nutrition. PMID:14988435

2. [B] Richie et al. (2015). Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. European Journal of Nutrition. PMID:24791752

3. [C] Allen & Bradley. (2011). Effects of oral glutathione supplementation on systemic oxidative stress biomarkers in human volunteers. Journal of Alternative and Complementary Medicine. PMID:21875351

4. [B] Kalamkar et al. (2022). Long-term glutathione supplementation in adults aged 55 years and older. Clinical, Cosmetic and Investigational Dermatology. PMID:35624890

5. [C] Aebi, Assereto, & Lauterburg (1991). High-dose intravenous glutathione in man. Pharmacokinetics and effects on cyst(e)ine in plasma and urine. European Journal of Clinical Investigation, 21(1), 103-110. PMID:1907548.

6. [D] Ammon, Melien, & Verspohl (1986). Pharmacokinetics of intravenously administered glutathione in the rat. Journal of Pharmacy and Pharmacology, 38(10), 721-725. PMID:2878990; DOI:10.1111/j.2042-7158.1986.tb04478.x.

7. [F] Sarkar et al. (2025). Glutathione as a skin-lightening agent and in melasma: a systematic review. International Journal of Dermatology, 64(6), 992-1004. PMID:39444151; DOI:10.1111/ijd.17535.

8. [F] Dilokthornsakul et al. (2019). The clinical effect of glutathione on skin color and other related skin conditions: A systematic review. Journal of Cosmetic Dermatology, 18(3), 728-737. PMID:30895708; DOI:10.1111/jocd.12910.

9. [RouteEvidence] Mischley et al. Phase IIb study of intranasal glutathione in Parkinson’s disease. PubMed.

10. [RouteEvidence] Richie et al. Randomized controlled trial of oral glutathione supplementation on body stores. PubMed.

11. [RouteEvidence] Watanabe et al. Topical oxidized glutathione double-blind placebo-controlled trial. PMC.

• Hexarelin is a synthetic hexapeptide and potent agonist of the growth hormone secretagogue receptor.
• It is chemically related to older GHRPs and is generally considered more intense and more prone to desensitization than gentler options.
• Hexarelin is a potent synthetic GHS-R agonist in the GH-secretagogue family. It is distinct from ipamorelin because it is less selective and has stronger desensitization and off-target endocrine concerns.

• Direct pituitary stimulation: binds GHS-R receptors to release a large GH pulse, widely considered the most potent GHRP for the sheer height of the spike.
• Somatostatin inhibition: suppresses the body's natural brake on GH release.
• Cardioprotection: uniquely also binds CD36 receptors in the heart and blood vessels, and research shows it can protect heart cells from ischemic damage.
• Tissue repair: like other GHRPs it raises IGF-1, aiding muscle protein synthesis and systemic repair.
• Hormonal bleed: more than ipamorelin, it can nudge ACTH, cortisol, and prolactin in some settings.
• It stimulates GH release via GHS-R and may affect ACTH/cortisol/prolactin more than selective secretagogues. Cardiac research signals exist, but that does not make it a cardioprotective therapy. The mechanism here is a plausibility map, not proof of a clinical outcome.

• Heart-failure recovery: data suggests it helps restore cardiac function after myocardial infarction by reducing scar tissue and improving ejection fraction.
• Bone density: particularly effective at increasing bone mineral density, making it a candidate for osteoporosis research.
• Neuroprotection: recent findings explore reduced brain inflammation after traumatic brain injury.
• Fast desensitization: it is more prone to tachyphylaxis (rapidly diminishing response) than ipamorelin or GHRP-2, a practical limit on frequent use.
• Caveat: the cardiovascular literature is mechanistic and small-scale, and does not generalize into an anti-aging or performance therapy.
• Human endocrine data support GH stimulation; Long-term wellness outcomes are not established. Attenuation with repeated exposure is better supported for hexarelin-like agents than for many peptide protocols. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.

Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions for you.

• Protocol 1: Maximum GH Pulse [Research/Experimental]; Route: Subcutaneous (SC); Dose: 100 mcg; Frequency: 2 to 3 times daily; Timing: Fasted (Morning/Night); Duration: 4 to 8 weeks (Max); Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 2: Cardiovascular Support (Research) [Research/Experimental]; Route: Subcutaneous (SC); Dose: 50 mcg – 100 mcg; Frequency: Once daily (Nightly); Timing: Nightly; Duration: 2 to 4 weeks; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Cycling/breaks are more defensible here than with ipamorelin because of desensitization concerns. Still, exact 5-on/2-off scheduling is a convention, not a proven optimum. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.

• Time until steady state: roughly 5 to 6.5 hours by half-life math.
• Half-life basis: a human kinetics/disposition study reported an IV half-life of 75.9 +/- 9.3 minutes and subcutaneous bioavailability around 64%, with no clear accumulation across studied subcutaneous doses.
• Beginner translation: If you're new, this does not mean the desired outcome appears in 6 hours. It means drug exposure would approach a plateau if repeated on a constant interval, while the GH pulse itself rises and falls over a shorter window.
• Practical interpretation: Because hexarelin is used for pulse signaling and can desensitize receptors, monitoring response and side effects matters more than chasing constant exposure.
• Comparison note: Hexarelin generally produces a stronger GH pulse and higher desensitization risk than GHRP-2 or ipamorelin. Ipamorelin is usually framed as cleaner, while hexarelin is framed as more forceful.
• Route note: do not generalize intranasal/oral findings across GH secretagogues. Older GHRP-2 and hexarelin data, animal ipamorelin nasal PK, and community sermorelin/CJC nasal-buccal products are different evidence categories.
• Short exposure and strong receptor signaling can coexist. Receptor responsiveness, pituitary reserve, and downstream IGF-1 matter more than half-life alone. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.

• Mechanistic pairings include a GHRH analog such as CJC-1295 without DAC or sermorelin.
• BPC-157 pairings are anecdotal injury-recovery stacks, not controlled evidence.
• Avoid combining with other GH secretagogues or GH without clinician oversight because side effects can compound.
• Stacking with GHRH analogs can amplify GH/IGF-1; Stacking with other appetite/metabolic agents can complicate glucose and fluid effects. Avoid stacking with CJC-DAC unless monitoring is explicit. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.

• Risks include flushing, headache, lethargy, edema, numbness/tingling, glucose disruption, cortisol/prolactin changes, blood-pressure effects, and rapid loss of response with frequent exposure.
• Avoid in active malignancy, uncontrolled diabetes, untreated sleep apnea, pregnancy, or significant cardiovascular instability unless in a formal protocol.
• Main concerns include cortisol/prolactin spillover, edema, numbness, glucose changes, appetite, desensitization, and theoretical cardiac/endocrine complexity. It is not the gentle default GH secretagogue. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.

• Monitor IGF-1, fasting glucose, HbA1c, blood pressure, edema, sleep apnea symptoms, prolactin/cortisol context, and symptom response.
• Cardiovascular research settings may use echocardiography or functional endpoints.
• Track IGF-1, fasting glucose/A1c, edema, sleep apnea symptoms, blood pressure, prolactin/cortisol if symptomatic, and changes in libido or mood. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.

• Hexarelin is not FDA-approved for general human use and is prohibited for athletes under peptide-hormone/secretagogue anti-doping rules.
• It is generally encountered as a research chemical rather than a regulated clinical product.
• Hexarelin is not FDA-approved for anti-aging/body composition. Anti-doping and research-market caveats matter here. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.

1. [C] Imbimbo et al. (1994). Growth hormone releasing activity of hexarelin in humans. European Journal of Clinical Pharmacology. PMID:7957536

2. [C] Arvat et al. (1997). Effects of growth hormone-releasing peptide-2 and hexarelin on GH, ACTH, and cortisol secretion. Journal of Clinical Endocrinology & Metabolism. PMID:9285939

3. [C] Arvat et al. (2001). Endocrine activities of ghrelin, a natural growth hormone secretagogue, and hexarelin in humans. Journal of Clinical Endocrinology & Metabolism. PMID:11238504

4. [C] Bisi et al. (1999). Cardiac effects of hexarelin in hypopituitary adults. European Journal of Pharmacology, 381, 31-38. PMID:10528131.

5. [C] Broglio et al. (2002). Effects of acute hexarelin administration on cardiac performance in patients with coronary artery disease during by-pass surgery. European Journal of Pharmacology, 448(2-3), 193-200. PMID:12144941; DOI:10.1016/S0014-2999(02)01934-9.

6. [D] Locatelli et al. (1999). Growth hormone-independent cardioprotective effects of hexarelin in the rat. Endocrinology, 140(9), 4024-4031. PMID:10465272; DOI:10.1210/endo.140.9.6948.

7. [F] Mao et al. (2014). The cardiovascular action of hexarelin. Journal of Geriatric Cardiology. PMID:25278975

8. [G] WADA. (2026). International Standard: Prohibited List. World Anti-Doping Agency.

9. [RouteEvidence] Lewis et al. Intranasal human growth hormone induces IGF-1 comparable with SC injection with lower systemic exposure. 2015.

10. [RouteEvidence] Pihoker et al. Intranasal GHRP-2 in children of short stature. PubMed record.

11. [RouteEvidence] Johansen et al. Pharmacokinetic evaluation of ipamorelin and other peptidyl GH secretagogues with emphasis on nasal absorption. PubMed record.

• HGH Fragment 176-191 is a synthetic fragment derived from amino acids 176 to 191 of human growth hormone.
• It is discussed as a metabolic fragment rather than a full GH receptor agonist.
• HGH Fragment 176-191 is the C-terminal hGH fragment conceptually related to AOD-9604, but product naming can be inconsistent. It is not full growth hormone.

• The proposed action involves lipolysis-related signaling without the broader growth-promoting effects of full hGH.
• This proposed selectivity is not the same as proven clinical fat loss.
• The proposed mechanism is lipolysis/fat-metabolism modulation without broad hGH growth signaling. The mechanism is narrower than hGH, but clinical fat-loss effect remains uncertain. The mechanism here is a plausibility map, not proof of a clinical outcome.

• Preclinical and mechanistic literature is not sufficient to present HGH Fragment 176-191 as an effective obesity therapy.
• These claims cannot borrow evidence from full hGH, GLP-1 drugs, or AOD-9604 unless the exact molecule and endpoint match.
• Preclinical and early development rationale exists, but robust human fat-loss evidence is weak. It is best described as a fat-loss research peptide with limited validation. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.

Below you'll find reported clinical-label, research, and community-use dosing contexts where available. Educational reference only, not dosing instructions for you.

• Protocol 1: Standard Fat Loss Protocol [Community/Biohacker/Anecdotal]; Route: Injection; Dose: 250 mcg to 500 mcg; Frequency: Once daily (Morning); Timing: Fasted (at least 2 hours post-meal); Duration: 8 to 12 weeks; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 2: Aggressive Recomposition [Community/Biohacker/Anecdotal]; Route: Injection; Dose: 500 mcg to 1,000 mcg; Frequency: Twice daily (Morning / Pre-workout); Timing: Fasted (Morning & Afternoon); Duration: 12+ weeks; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Community SC protocols are common, but oral or topical claims are not a safe assumption. Dosing cannot be borrowed from AOD or hGH unless the exact compound is defined. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.

• Time until steady state: not calculable.
• Half-life basis: reliable human half-life for common HGH Fragment 176-191 products is not established. Do not borrow AOD-9604 or full hGH PK values.
• Beginner translation: A missing number here is intentional. The molecule is marketed as simple, but human exposure data are not strong enough to calculate an honest steady-state estimate.
• Practical interpretation: Evaluate body-composition outcomes and metabolic markers rather than assuming the fragment produces predictable exposure.
• Comparison note: AOD-9604 and HGH Fragment 176-191 are related concepts but are not interchangeable FDA-approved drugs. AOD has more safety/metabolism context, but neither is a proven injectable fat-loss therapy.
• Human PK is not well established for community formulations. Rapid clearance does not prove safety or lack of systemic effect. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.

• Stacking with AOD-9604 is generally redundant.
• Pairing with GLP-1/GIP drugs, GH secretagogues, L-carnitine, or fasting protocols is anecdotal, not evidence-based care.
• Often stacked with diet, exercise, carnitine, GH secretagogues, or GLP-1 drugs. Because lifestyle changes drive most fat-loss outcomes, stacking can easily over-credit the peptide. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.

• Safety uncertainty is the main issue.
• Potential risks include injection-site reactions, headaches, nausea, glucose changes, product contamination, and unexpected endocrine effects.
• Avoid use in pregnancy, breastfeeding, active malignancy, uncontrolled diabetes, or complex endocrine disease without clinician oversight.
• Main concerns are injection quality, immune reactions, glucose/metabolic uncertainty, and false expectations. It does not burn fat without lifestyle constraints. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.

• If studied, relevant markers include body composition, waist circumference, fasting glucose, HbA1c, fasting insulin if available, lipids, blood pressure, edema, and adverse effects.
• Scale weight alone is insufficient.
• Track weight trend, waist, body composition if available, fasting glucose/A1c, lipids, and adverse reactions. Appetite, diet adherence, and training changes should be logged. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.

• HGH Fragment 176-191 is not FDA-approved as a drug.
• Athletes should treat GH fragments and unapproved metabolic peptides as high-risk under anti-doping rules.
• Availability through research vendors does not equal approval or quality assurance.
• HGH Fragment 176-191 is not FDA-approved for weight loss. Research-market status is not prescription legitimacy. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.

1. [D] Ng et al. (2000). Metabolic studies of a synthetic lipolytic domain of human growth hormone. Hormone Research. PMID:11146367

2. [D] Heffernan et al. (2001). The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism. Endocrinology. PMID:11713213

3. [D] Heffernan et al. (2001). Increase of fat oxidation and weight loss in obese mice caused by a synthetic fragment of human growth hormone. International Journal of Obesity. PMID:11673763

4. [E] Cox et al. (2015). Detection and in vitro metabolism of AOD9604. Drug Testing and Analysis. PMID:25208511

5. [G] WADA. (2026). International Standard: Prohibited List. World Anti-Doping Agency.

• hMG, or menotropins, contains follicle-stimulating hormone activity with luteinizing hormone activity depending on the product.
• It is a prescription gonadotropin used in fertility medicine.
• hMG is a gonadotropin preparation containing FSH and LH activity, not a peptide repair or wellness compound. It belongs in fertility/endocrine therapy, where monitoring is central.

• FSH activity stimulates ovarian follicle development in females and Sertoli-cell support of spermatogenesis in males.
• LH activity can support steroidogenesis.
• The biology unfolds over weeks to months, not merely over the plasma half-life.
• It directly stimulates gonadal function through FSH/LH receptor pathways. In women this can drive follicular development; In men it can support spermatogenesis when used in appropriate endocrine contexts. The mechanism here is a plausibility map, not proof of a clinical outcome.

• Evidence is strongest in medically supervised fertility contexts such as ovulation induction, assisted reproduction, and hypogonadotropic hypogonadism.
• Claims about general optimization or post-cycle recovery require much narrower framing.
• Fertility/ART evidence is clinical and regulated, but male wellness or HPTA-stack use is a different evidence category. Do not merge labeled ART dosing with off-label male fertility protocols. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.

Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions for you.

• Protocol 1: Fertility Restoration (Aggressive) [Clinical/Human Trial]; Route: Subcutaneous (SC); Dose: 75 IU – 150 IU; Frequency: 3 times per week; Duration: 3 to 6 months; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 2: Maintenance/HPTA Support [Community/Biohacker/Anecdotal]; Route: Subcutaneous (SC); Dose: 37.5 IU – 75 IU; Frequency: 2 times per week; Duration: Duration of suppressive cycle; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 3: MENOPUR FDA-label controlled ovarian stimulation protocol [FDA/Approved/Label]; Route: Subcutaneous injection into abdomen; Dose: 225 IU SC daily initial dose for ART protocol; Individualize after 5 days based on ovarian response; Frequency: Daily during ART stimulation; Timing: Beginning cycle day 2 or 3; Duration: Continue until adequate follicular development; Therapy should not exceed 20 days; Max: Do not exceed 450 IU daily; Titration/loading: Adjust after 5 days based on ultrasound follicular growth and serum estradiol; Do not adjust more frequently than every 2 days or by more than 150 IU per adjustment.; Status: Yes - FDA-approved label/product protocol for labeled ART/controlled ovarian stimulation indication only.
• Dose is usually expressed in IU, not micrograms. Protocols require sex, goal, baseline hormones, and monitoring because too much stimulation can be harmful. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.

• Time until steady state: about 2 to 3 days for the FSH component by label data.
• Half-life basis: Menopur labeling reports FSH elimination half-life about 11 to 13 hours after multiple dosing; LH activity is product- and patient-dependent.
• Beginner translation: This does not mean fertility response occurs in 2 to 3 days. Follicular development and spermatogenesis take much longer.
• Practical interpretation: Use endocrine and fertility monitoring rather than half-life alone: estradiol, follicles, testosterone context, semen analysis, and adverse-event surveillance.
• FSH/LH bioactivity and ovarian/testicular response matter more than simple half-life. Response often evolves over days to weeks. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.

• hCG is the most common medically relevant pairing in male hypogonadotropic contexts because it provides LH-like signaling while hMG supplies FSH activity.
• Clomiphene or enclomiphene may be used in some recovery strategies, but only in clinician-guided protocols.
• hMG is often paired with hCG in male fertility contexts or with ART protocols in female fertility care. Combining gonadotropins without monitoring can raise estradiol, ovarian hyperstimulation, or testicular side effects. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.

• Ovarian hyperstimulation (OHSS): a serious risk in women without careful monitoring, with fluid buildup in the abdomen and chest.
• Estrogen elevation: like hCG, it can raise aromatization of testosterone to estrogen, causing water retention or nipple sensitivity.
• Multiple gestation: in women it notably raises the chance of twins or triplets.
• Injection-site pain: often reported as more stinging than hCG, alongside the usual thromboembolic caution in high-risk settings.
• Risks include ovarian hyperstimulation, multiple gestation, injection reactions, estrogen-related symptoms, and endocrine overcorrection. Medical supervision is not optional in fertility contexts. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.

• Monitoring may include ultrasound, estradiol, LH/FSH, testosterone, semen analysis, inhibin B, pregnancy testing, CBC/CMP in selected contexts, and symptom review.
• OHSS warning signs require urgent medical attention.
• Monitor estradiol, ultrasound follicles in ovarian protocols, LH/FSH/testosterone/estradiol in male contexts, semen analysis when relevant, and symptoms of OHSS or estrogen excess. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.

• hMG products such as Menopur are prescription fertility medications.
• They are not over-the-counter peptides. hMG is prohibited for male athletes under anti-doping rules because it can stimulate endogenous testosterone production.
• Approved hMG products exist for specific fertility indications. Research-market hMG or non-label uses are separate from labeled ART use. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.

1. [C] Ley & Leonard (1985). Male hypogonadotropic hypogonadism: factors influencing response to human chorionic gonadotropin and human menopausal gonadotropin, including prior exogenous androgens. Journal of Clinical Endocrinology & Metabolism, 61(4), 746-752. PMID:3928676; DOI:10.1210/jcem-61-4-746.

2. [A] Finkel et al. (1985). Stimulation of spermatogenesis by gonadotropins in men with hypogonadotropic hypogonadism. New England Journal of Medicine. PMID:3927163

3. [F] Büchter et al. (1998). Pulsatile GnRH or human chorionic gonadotropin/human menopausal gonadotropin as effective treatment for men with hypogonadotropic hypogonadism: a review of 42 cases. European Journal of Endocrinology, 139(3), 298-303. PMID:9758439; DOI:10.1530/eje.0.1390298.

4. [C] Depenbusch et al. (2002). Maintenance of spermatogenesis in hypogonadotropic hypogonadal men with human chorionic gonadotropin alone after hMG induction. Journal of Clinical Endocrinology & Metabolism. PMID:12444893

5. [F] Boeri et al. (2021). Gonadotropin Treatment for the Male Hypogonadotropic Hypogonadism. Current Pharmaceutical Design, 27(24), 2775-2783. PMID:32445446; DOI:10.2174/1381612826666200523175806.

6. [F] van Wely et al. (2003). Human menopausal gonadotrophin versus recombinant folliclestimulating hormone for ovarian stimulation. Cochrane Database. PMID:12535497

7. [G] FDA / Menopur label. (2024). Menopur (menotropins for injection) prescribing information. FDA AccessData / DailyMed.

• hCG is a naturally occurring glycoprotein hormone produced by the syncytiotrophoblast cells of the placenta during pregnancy.
• In a research and clinical context, it is derived from either the urine of pregnant women or manufactured via recombinant DNA technology.
• It is classified as a gonadotropin and acts as a biological “mimic” of Luteinizing Hormone (LH).
• hCG is a glycoprotein hormone with LH-like activity, not a small synthetic peptide. Its relevance is fertility, testicular steroidogenesis, and specific endocrine indications.

hCG shares an identical alpha subunit with Luteinizing Hormone (LH) and a very similar beta subunit, allowing it to bind to the same receptors:

• Testicular Activation: It binds to the LH/hCG receptors on the Leydig cells of the testes. This triggers the conversion of cholesterol into pregnenolone, ultimately stimulating the endogenous production of testosterone.
• Ovarian Stimulation: In females, it triggers ovulation and supports the corpus luteum for progesterone production.
• Bypassing the Pituitary: hCG acts directly on the gonads. It provides a signal for hormone production even when the pituitary gland is suppressed (e.g., during HRT, TRT, or anabolic use).
• Intratesticular Testosterone (ITT): Crucially, hCG maintains high levels of ITT, which is essential for spermatogenesis (sperm production) and preventing testicular atrophy.
• hCG activates LH receptors, stimulating Leydig-cell testosterone production and supporting ovarian processes depending on sex and context. It can raise testosterone and estradiol downstream. The mechanism here is a plausibility map, not proof of a clinical outcome.

• HPTA Maintenance: Research in 2025 has solidified hCG as the “gold standard” for preventing the “shutdown” of the Hypothalamic-Pituitary-Testicular Axis (HPTA).
• Neurosteroid Production: Emerging studies show that hCG stimulation of the Leydig cells also increases neurosteroids like pregnenolone and DHEA, which are often depleted during hormonal suppression and contribute to “brain fog.” Metabolic Impact: While the “hCG Diet” (500 calories + hCG) has been largely debunked as ineffective for fat loss specifically, recent 2026 data suggest hCG helps maintain lean mass and metabolic rate during extreme caloric deficits.
• Fertility Recovery: 2025 clinical meta-analyses confirm that lowdose, frequent hCG administration is significantly more effective at maintaining fertility than high-dose, infrequent “bolus” injections.
• hCG has established clinical use in fertility/endocrinology, but weight-loss or casual testosterone-stack claims are separate from evidence-based fertility/endocrinology claims. The discredited hCG diet concept is not evidence-based weight management. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.

Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions for you.

• Protocol 1: HPTA Maintenance (On-Cycle) [Community/Biohacker/Anecdotal]; Route: Subcutaneous (SC) or Intramuscular (IM); Dose: 250 IU – 500 IU; Frequency: 2 to 3 times weekly; Duration: Length of suppressive cycle; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 2: Post-Cycle Therapy (PCT) [Community/Biohacker/Anecdotal]; Route: Subcutaneous (SC) or Intramuscular (IM); Dose: 1,000 IU – 2,500 IU; Frequency: Every other day (for 2 weeks); Duration: 10–14 days; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 3: Pregnyl FDA-label male hypogonadotropic hypogonadism regimen 1 [FDA/Approved/Label]; Route: Intramuscular injection; Dose: 500 USP units – 1,000 USP units; Frequency: 3 times per week for 3 weeks, then same dose 2 times per week for 3 weeks; Duration: 6-week labeled regimen; Status: Yes - FDA-approved label/product protocol for labeled indication only.
• Protocol 4: Pregnyl FDA-label male hypogonadotropic hypogonadism regimen 2 [FDA/Approved/Label]; Route: Intramuscular injection; Dose: 4,000 USP units, then 2,000 USP units; Frequency: 4,000 USP units 3 times per week for 6–9 months; Then 2,000 USP units 3 times per week for 3 months; Duration: 9–12 months labeled regimen; Status: Yes - FDA-approved label/product protocol for labeled indication only.
• Protocol 5: Pregnyl FDA-label ovulation trigger context [FDA/Approved/Label]; Route: Intramuscular injection; Dose: 5,000 USP units – 10,000 USP units; Frequency: One dose; Timing: One day following last dose of menotropins, per labeled ovulation-induction context; Status: Yes - FDA-approved label/product protocol for labeled indication only.
• Doses are in IU and are goal-specific. Fertility induction, hypogonadotropic hypogonadism, and post-anabolic recovery claims are not interchangeable protocols. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.

hCG has a notably long biological half-life (~36 hours) compared to native LH, allowing for less frequent dosing. Subcutaneous and intramuscular routes both yield similar bioavailability for clinical use. Peak serum levels occur 6 to 12 hours post-injection, with sustained Leydig cell stimulation for 48 to 72 hours after a single dose.

• Time until steady state: about 6-8 days.
• Half-life basis: Terminal half-life about 29-37 hours depending preparation/source. The LH-like endocrine effect can persist for days after a dose; Steady-state timing does not equal time to spermatogenesis or fertility response.
• Beginner translation: This estimate uses the standard four-to-five-half-life convention. It describes when plasma exposure would be expected to approach a plateau during repeated dosing, not when the desired outcome is complete.
• hCG has longer biological action than native LH. Effects on testosterone/estradiol may persist beyond the injection window, so weekly totals and lab timing matter. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.

hMG (Human Menopausal Gonadotropin): Often stacked with hCG for infertility cases. While hCG mimics LH (testosterone), hMG mimics FSH (sperm maturation).

• TRT (Testosterone Replacement): Used as an “ancillary” to maintain testicular size and fertility while on TRT.
• Enclomiphene: Used after an hCG “kickstart” to signal the pituitary to resume its own LH production.
• Common stacks include hMG/FSH for spermatogenesis or testosterone-management contexts. Combining with testosterone, SERMs, aromatase inhibitors, or gonadotropins requires endocrine logic and labs. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.

• Estrogen Spikes: Because hCG is a potent stimulator of the aromatase enzyme in the testes, it often causes a significant rise in Estradiol (E2).
• Gynaecomastia: High doses can cause nipple sensitivity or breast tissue growth due to the aforementioned estrogen rise.
• Acne and Hair Loss: Resulting from the rapid increase in testosterone and subsequent DHT conversion.
• Leydig Cell Desensitization: Chronic high-dose use may eventually make the testes less responsive to LH/hCG signals.
• Risks include gynecomastia, acne, mood changes, water retention, fertility-protocol complications, and estrogen excess. In women, ovarian hyperstimulation and multiple gestation are major concerns. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.

• Total & Free Testosterone: To ensure the gonads are responding to the signal.
• Estradiol (Sensitive): Critical to monitor, as hCG-driven estrogen spikes often require management with an Aromatase Inhibitor (AI).
• Hematocrit: Like testosterone, hCG can stimulate red blood cell production, though usually to a lesser degree.
• Track testosterone, estradiol, LH/FSH suppression context, semen analysis, testicular volume if relevant, pregnancy/ovarian monitoring in women, and symptoms of estrogen excess. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.

• FDA Status: FDA-approved for the treatment of hypogonadotropic hypogonadism and ovulation induction. However, in 2020, the FDA reclassified hCG as a biological product, which limited its production by many traditional compounding pharmacies.
• WADA: Strictly Banned for males at all times (as it increases testosterone production). It is not banned for females unless used as a masking agent.
• Availability: Requires a prescription. In 2026, many researchers source it through “Fertility Clinics” or specialized HRT providers.
• hCG has approved medical uses, but some marketed weight-loss uses and research-market products are not equivalent to approved prescribing. Product source matters. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.

1. [C] Coviello et al. (2005). Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression. Journal of Clinical Endocrinology & Metabolism. PMID:15713727

2. [C] Roth et al. (2010). Dose-dependent increase in intratesticular testosterone by very low-dose human chorionic gonadotropin in normal men with experimental gonadotropin deficiency. Journal of Clinical Endocrinology & Metabolism. PMID:20484472

3. [C] Hsieh et al. (2013). Concomitant intramuscular human chorionic gonadotropin preserves spermatogenesis in men undergoing testosterone replacement therapy. Journal of Urology. PMID:23260550

4. [F] Lee & Ramasamy. (2018). Indications for the use of human chorionic gonadotropic hormone for the management of infertility in hypogonadal men. Translational Andrology and Urology. PMID:30159241

5. [F] Brannigan et al. (2024). Updates to male infertility: AUA/ASRM guideline. Journal of Urology. PMID:39145501

6. [G] AUA/ASRM. (2024). Diagnosis and treatment of infertility in men: guideline. American Urological Association / ASRM.

7. [G] FDA / Pregnyl label. (2023). Pregnyl (chorionic gonadotropin) prescribing information. FDA AccessData / DailyMed.

• Humanin is a mitochondrial-derived peptide encoded within the MT-RNR2 region, the gene region that also encodes mitochondrial 16S rRNA.
• The commonly listed 24-amino-acid human sequence is MAPRGFSCLLLLTSEIDLPVKRRA.
• Some sources distinguish a 21-amino-acid mitochondrial-translated form from a 24-amino-acid cytosolic form, and both have been discussed as biologically active.
• Chemically, PubChem lists Humanin with formula C119H204N34O32S2 and molecular weight about 2687.2 g/mol.
• That makes it substantially larger than ultrashort bioregulators such as Vilon, but much smaller than protein hormones.
• In this guide it belongs with mitochondrial-derived peptides and cytoprotective research peptides, adjacent to MOTS-c but mechanistically distinct.
• A major beginner mistake is to treat Humanin, MOTS-c, SHLP2, and NAD+ as interchangeable mitochondrial products. They are not.
• Humanin is mainly discussed as an anti-apoptotic and stress-resistance signal. MOTS-c is more often discussed around metabolic signaling and exercise adaptation. NAD+ is not a peptide at all.
• Humanin is a mitochondrial-derived peptide family concept, not a conventional hormone replacement. Analogs and native humanin are distinct, because potency and stability can differ.

• Humanin is usually described as cytoprotective and anti-apoptotic.
• Proposed intracellular actions include binding or interfering with pro-apoptotic proteins such as Bax, Bid/tBid, and BimEL, thereby reducing stress-triggered cell death. This is one reason the peptide appears often in neurodegeneration and ischemia-reperfusion discussions.
• Humanin also has extracellular signaling models. Reviews describe interaction with a receptor complex involving CNTF receptor alpha, WSX-1, and gp130, and also interaction with formyl peptide receptor-like receptors such as FPRL1/FPR2.
• These pathways connect Humanin to STAT3, ERK, and AKT signaling, inflammatory tone, oxidative stress handling, and cellular survival responses.
• The IGF axis matters. Humanin and analogs can associate with IGF-binding proteins, especially IGFBP-3, which may influence circulating duration and tissue exposure. That makes simplistic claims like “Humanin just repairs mitochondria” inaccurate.
• Its biology is broader: apoptosis control, stress signaling, inflammatory modulation, endocrine cross-talk, and mitochondrial function all overlap.
• Mechanisms involve cytoprotection, mitochondrial stress signaling, apoptosis modulation, insulin sensitivity, and neuroprotection hypotheses. These are broad stress-response pathways, not one validated clinical endpoint. The mechanism here is a plausibility map, not proof of a clinical outcome.

• Neuroprotection: Humanin was originally discovered in the context of protection against neuronal cell death related to Alzheimer’s disease-associated insults. Later reviews and models describe protection against amyloid-beta toxicity, cellular stress, synaptic injury, and other neurodegenerative stressors. This is biologically meaningful, but it is not the same thing as a proven treatment for Alzheimer’s disease or cognitive decline.
• Metabolism and insulin sensitivity: Humanin analogs, especially HNG, have been studied in animal models of insulin resistance, obesity, and diabetes. Findings include improved metabolic parameters and stress resilience in several models. These data support research interest but do not establish a clinical metabolic protocol for humans.
• Cardiovascular and ischemic stress: Humanin-family peptides have been studied in models of vascular dysfunction, myocardial stress, and ischemia-reperfusion injury. The recurring theme is reduced apoptosis, oxidative injury, and inflammatory stress. The human relevance remains investigational.
• Aging and healthspan: A 2020 study linked Humanin biology with healthspan and lifespan markers across species. Circulating Humanin levels have been reported to decline with age and to differ in centenarian-related cohorts. Importantly, biomarker association is not proof that injecting Humanin extends human life. In mouse work, HNG treatment started in midlife improved some metabolic features but did not necessarily extend lifespan.
• Clinical translation gap: Humanin has human observational and biomarker evidence, but no well-established, label-quality clinical evidence showing that exogenous Humanin supplementation treats a disease or slows aging. So this one is scientifically interesting but clinically unproven.
• Most evidence is preclinical or biomarker/association-based. Human therapeutic use remains exploratory, so longevity and metabolic claims require conservative wording. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.

Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions for you.

• Protocol 1: HNG APP/PS1 mouse insulin-sensitivity protocol [Animal/Preclinical]; Route: Intraperitoneal; Dose: 50 mcg/kg or 100 mcg/kg; Frequency: Study-specific animal protocol; Duration: Preclinical APP/PS1 mouse context; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 2: HNG age-related cognition mouse protocol [Animal/Preclinical]; Route: Intraperitoneal; Dose: 4 mg/kg; Frequency: Biweekly; Timing: Started in middle-aged/older mice in reported preclinical studies; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 3: Community standard HNG/Humanin range [Community/Biohacker/Anecdotal]; Route: Subcutaneous; Dose: 0.5 mg – 2 mg daily; Frequency: Once daily; Timing: Often morning; Duration: Community cycles often 8–12 weeks on, 4–8 weeks off; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 4: Community beginner protocol [Community/Biohacker/Anecdotal]; Route: Subcutaneous; Dose: 200 mcg – 300 mcg daily; Frequency: Once daily; Duration: 4–6 weeks; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 5: Community intermediate protocol [Community/Biohacker/Anecdotal]; Route: Subcutaneous; Dose: 500 mcg – 750 mcg daily; Frequency: Once daily or split morning/evening; Duration: 6–8 weeks on, 4 weeks off; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 6: Community advanced optimization protocol [Community/Biohacker/Anecdotal]; Route: Subcutaneous; Dose: 1 mg – 2 mg daily; Frequency: Once daily or split into two doses; Duration: 8–12 weeks on, 6–8 weeks off; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Community dosing reports are not trial-validated. Because analog identity matters, the exact analog and route need stating before any comparison. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.

• Time until steady state: not calculable from human data.
• Half-life basis: rodent data show major species and analog dependence. HNG has been described around 30 minutes in wild-type mouse plasma, while humanin analog exposure in rats has been reported as greater than 4 hours. These values are not validated human half-lives.
• Beginner translation: A short blood half-life does not mean the cell-survival signal is useless, and a longer animal half-life does not make it a safe human longevity drug.
• Practical interpretation: If Humanin is discussed in research, specify the exact analog, species, route, and assay. Do not generalize animal IP injection data to human subcutaneous, intranasal, oral, or IV use. Distribution is another uncertainty. Rodent work found Humanin-family signal highest in plasma, present in liver, and not detected in brain or heart under the tested conditions. That matters because many marketing claims are brain-focused. Intranasal preclinical studies may bypass some barriers, but they do not establish ordinary human product exposure.
• Public human PK is limited. Downstream stress-response effects may not correlate with a simple plasma half-life. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.

• Humanin is often grouped with MOTS-c, SHLP2, NAD+, exercise, mitochondrial nutrients, and anti-inflammatory lifestyle interventions.
• Mechanistically, that grouping makes sense as a mitochondrial-stress theme. Clinically, it does not prove additive benefit.
• Stacking multiple mitochondrial or growth-factor-adjacent agents can blur monitoring. Humanin has IGF/IGFBP interactions, MOTS-c affects metabolic signaling, GLP-1 drugs affect weight and glucose, and NAD+ protocols can affect symptoms without changing the same endpoints. Combining them can make it impossible to know what helped or what caused side effects.
• The conservative approach is to avoid stacking Humanin with other investigational peptides unless there is a clinician-directed reason and a clear monitoring plan.
• It should not be used to justify stopping evidence-based treatment for neurodegenerative disease, diabetes, heart disease, infertility, or mitochondrial disorders.
• Humanin is often discussed with MOTS-c, SS-31, NAD precursors, or metabolic protocols. Mitochondrial stacks can be conceptually coherent but endpoint attribution is poor if all are started together. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.

• Formal human safety data for exogenous Humanin are limited.
• Potential concerns include injection-site reactions, immune reactions to impurities, contamination/endotoxin exposure, unknown effects in pregnancy and breastfeeding, and unknown effects in children outside supervised research.
• The anti-apoptotic theme creates a theoretical cancer caution. Humanin may protect stressed cells from programmed death; That can be beneficial in injury models but is not automatically desirable in active malignancy or in a person under cancer surveillance.
• This is theoretical rather than proven clinical harm, but it is enough to avoid casual use in active cancer or unexplained masses. Use extra caution with insulin resistance, diabetes medications, fertility or hormone therapies, GH/IGF-axis agents, autoimmune disease, transplant medicine, and immune suppression.
• These are areas where Humanin biology overlaps with endocrine, inflammatory, or survival pathways.
• Unknown long-term effects, immune response, cancer-biology uncertainty, and product quality are key concerns. Broad cytoprotective signaling is not automatically desirable in every disease context. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.

• For metabolic research questions, useful markers include fasting glucose, fasting insulin, HbA1c, lipids, waist circumference, blood pressure, hs-CRP, and body composition.
• For neurocognitive questions, standardized cognitive testing and sleep/mood tracking are more useful than vague “brain fog” notes.
• For safety, monitor CBC, comprehensive metabolic panel, injection-site reactions, allergic symptoms, unexpected edema, headaches, mood changes, sleep changes, and any change in glucose control.
• Cancer history, new unexplained symptoms, or active surveillance push the decision toward avoidance unless part of formal research.
• Do not use commercial Humanin blood levels as a simple treatment target.
• Circulating Humanin is a developing biomarker area, and measurement platforms, biological variability, age, disease state, and exercise can affect interpretation.
• Track metabolic labs, energy/fatigue scales, exercise tolerance, glucose/insulin markers, and adverse symptoms. Objective baseline and follow-up are important because subjective energy is highly confounded. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.

• Humanin is not an FDA-approved drug with a labeled therapeutic indication.
• It is generally encountered as a research chemical or laboratory peptide.
• Any product sold for injection is unapproved unless it is part of a legitimate regulated clinical context.
• Anti-doping: Humanin is not treated in this guide as athlete-safe.
• A biologically active, non-approved peptide can create S0 non-approved-substance risk, and some peptide-related effects may overlap with prohibited growth-factor or metabolic categories.
• Competitive athletes should verify status with WADA/USADA or their sport’s anti-doping authority before exposure.
• Humanin and related analogs are not FDA-approved therapies. Research use is separate from mitochondrial disease treatment claims. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.

1. [G] National Center for Biotechnology Information. PubChem Compound Summary: Humanin. Use: Humanin molecular formula C119H204N34O32S2 and molecular weight about 2687.2 g/mol.

2. [G] UniProt Consortium. UniProtKB Q8IVG9: MT-RNR2 – Humanin – Homo sapiens. Use: Humanin protein identity and MT-RNR2 link.

3. [D] Lee C, Yen K, Cohen P. (2013). Humanin: a harbinger of mitochondrial-derived peptides? Trends in Endocrinology & Metabolism, 24(5), 222-228. PMID: 23402768; DOI: 10.1016/j.tem.2013.01.005. Use: Humanin discovery, mitochondrial-derived peptide framing, and evidence limitations.

4. [D] Yen K, Lee C, Mehta H, Cohen P. (2013). The emerging role of the mitochondrial-derived peptide humanin in stress resistance. Journal of Molecular Endocrinology, 50(1), R11-R19. PMID: 23239898; DOI: 10.1530/JME-12-0203. Use: Humanin mechanisms, stress resistance, receptor models, and cytoprotection context.

5. [D] Chin YP, et al. (2013). Pharmacokinetics and tissue distribution of humanin and its analogues in male rodents. Endocrinology, 154(10), 3739-3744. PMID: 23836030. Use: Rodent PK, species/analog dependence, HNG mouse half-life context, rat exposure greater than 4 hours, and tissue distribution cautions.

6. [D] Yen K, et al. (2020). The mitochondrial derived peptide humanin is a regulator of lifespan and healthspan. Aging, 12(12), 11185-11199. PMID: 32575074; PMCID: PMC7343442. Use: Humanin levels, healthspan/lifespan associations, age-related decline, and limits of translating biomarkers to treatment.

7. [D] Coradduzza D, et al. (2023). Humanin and Its Pathophysiological Roles in Aging: A Systematic Review. Biology, 12(4), 558. PMID: 37106758; DOI: 10.3390/biology12040558. Use: Aging-pathophysiology overview and clinical-translation caution.

8. [G] World Anti-Doping Agency. (2025). International Standard: Prohibited List 2026. Use: S0 non-approved-substance and S2 peptide-hormone/growth-factor category caution for athletes using non-approved biologically active peptides.

• IGF-1 LR3 is a modified IGF-1 analog with altered binding characteristics and prolonged activity relative to native IGF-1.
• IGF-1 LR3 is a modified long-acting IGF-1 analog used in research/bodybuilding contexts, not standard mecasermin therapy. LR3 modification changes binding-protein interaction and risk profile.

• It promotes anabolic and glucose-disposal signaling through IGF-related pathways.
• It activates IGF-1 receptor signaling involved in growth, glucose disposal, and anabolic pathways. That same biology creates hypoglycemia and growth-signaling concerns. The mechanism here is a plausibility map, not proof of a clinical outcome.

• Bodybuilding claims and animal data are not approved therapeutic evidence.
• Approved recombinant IGF-1 products have specific indications and labels that do not validate gray-market LR3 use.
• Clinical evidence for LR3 as a performance or physique peptide is not established. Extrapolating from IGF-1 biology or mecasermin does not validate LR3 research-market use. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.

Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions for you.

• Protocol 1: Conservative Anabolic Phase [Research/Experimental]; Route: Subcutaneous (SC); Dose: 20 mcg – 40 mcg; Frequency: Once Daily; Timing: Post-Workout (with Carbs); Duration: 4 weeks ON / 4 weeks OFF; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 2: Advanced Recovery Protocol [Research/Experimental]; Route: Subcutaneous (SC); Dose: 50 mcg – 80 mcg; Frequency: Once Daily; Timing: Post-Workout or Morning; Duration: 4 weeks ON / 4 weeks OFF; Source also contains wrapped text '6 weeks ON / 6 weeks OFF'; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Dosing claims are uncertain because potency, route, concentration, and acidic reconstitution practices vary. It should not be casually blended with neutral peptides. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.

IGF-1 LR3 has a dramatically extended half-life (~20 to 30 hours) compared to native IGF-1 (~10 to 12 minutes free / 15 hours bound) due to its low affinity for IGFBPs. This allows once-daily subcutaneous dosing while maintaining sustained receptor activation. Tissue distribution is systemic, with peak skeletal-muscle exposure within 4 to 6 hours of injection.

• Time until steady state: about 4-6 days if that estimate is used.
• Half-life basis: Commonly reported 20-30 hours, but not from an FDA-approved human label. Because IGF-1 LR3 is a potent growth-factor analog, this estimate is not a validated human dosing model.
• Beginner translation: This estimate uses the standard four-to-five-half-life convention. It describes when plasma exposure would be expected to approach a plateau during repeated dosing, not when the desired outcome is complete.
• LR3 is designed for longer activity than native IGF-1, but public human PK for community products is weak. Effects on glucose can be clinically important even when subjective effects are subtle. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.

• Growth Hormone (HGH): HGH signals the liver to produce IGF-1. Stacking exogenous IGF-1 LR3 with HGH creates a “saturated” environment for maximum cellular growth.
• Testosterone: IGF-1 LR3 enhances the androgen receptor sensitivity, making a given dose of testosterone more effective at the cellular level.
• Stacking with insulin, GH, GH secretagogues, or anabolic agents increases hypoglycemia and growth-signal concerns. Avoid same-vial mixing, especially with acidic-solvent preparations. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.

• Hypoglycemia: Because it mimics insulin, a sudden drop in blood sugar is the most immediate risk.
• Organ Growth (Visceromegaly): Long-term, high-dose abuse can theoretically lead to the growth of non-skeletal muscle tissues (intestines, heart).
• Mitogenic Risk: Since it promotes cell division, it should never be used by anyone with active cancer or a history of malignancies, as it may accelerate the growth of existing tumors. “Peptide Bloat”: Temporary water retention or “puffy” joints.
• Major practical risks include hypoglycemia, edema, jaw/soft-tissue symptoms, neuropathy-like symptoms, and theoretical tumor-growth concerns. This is not a beginner peptide. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.

• Fasting Blood Glucose: To ensure the peptide isn’t causing metabolic stress.
• Serum IGF-1 Levels: To track the total systemic load.
• Body Composition (DEXA): To distinguish between true hyperplasia and mere water retention.
• Monitor fasting and post-dose glucose, hypoglycemia symptoms, IGF-1 context, edema, blood pressure, and any history of malignancy. Keep carbohydrate intake and timing documented in research contexts. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.

• FDA: Not approved for human use; Strictly for research and laboratory purposes.
• WADA: Strictly Banned in all sports (S2 Category). It is highly detectable via modern mass spectrometry (LC-MS).
• Clinical Outlook: While not currently in mainstream medical use, it remains a primary tool in research for muscle wasting diseases and regenerative medicine.
• IGF-1 LR3 is not an FDA-approved therapeutic product. It may also trigger anti-doping issues and is high-risk in sports contexts. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.

1. [D] Tomas et al. / Bryant et al. (1996). Design and characterisation of long-R3-insulin-like growth factor-I analogs. Growth Factors. PMID:8919023; DOI:10.3109/08977199609003227.

2. [D] Conlon et al. (1995). Long R3 insulin-like growth factor-I (IGF-I) infusion stimulates whole body protein retention in lambs. Journal of Endocrinology. PMID:7561636; DOI:10.1677/joe.0.1460247.

3. [D] Hill et al. (1999). Effects of Long R3 IGF-I on protein metabolism in beef heifers. Journal of Animal Science. PMID:10370861

4. [D] Prelle et al. (2001). Insulin-Like Growth Factor I (IGF-I) and Long R3IGF-I Differently Affect Development and Messenger Ribonucleic Acid Abundance for IGF-Binding Proteins and Type I IGF Receptors in in Vitro Produced Bovine Embryos. Endocrinology, 142(3), 1309-1316. PMID:11181549.

5. [E] Mongongu et al. (2021). Detection of LongR3-IGF-I and related analogs for doping control. Drug Testing and Analysis. PMID:33587816

6. [D] White et al. (2025). IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep. American Journal of Physiology-Endocrinology and Metabolism, 328(1), E116-E125. PMID:39679943; PMCID:PMC11901354.

7. [G] USADA / WADA. (2026). Insulin-like growth factor-1 and prohibited growth factors. USADA / WADA.

• A synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) and selective agonist of the ghrelin receptor (GHS-R1a).
• Developed in the late 1990s by Novo Nordisk as a third-generation growth-hormone-releasing peptide (GHRP).
• Known as the “cleanest” GHRP: it has the highest selectivity for growth-hormone release, without the cross-reactivity seen in earlier GHRPs.
• Ipamorelin is a selective ghrelin/GHS-R agonist GH secretagogue. It is distinct from GHRP-2/GHRP-6/hexarelin because its appeal is lower cortisol/prolactin spillover, not simply stronger GH release.

• Selective GH release: triggers a GH pulse at the ghrelin receptor but, unlike GHRP-2 or GHRP-6, does not meaningfully raise ACTH, cortisol, or prolactin even at higher doses.
• Preserved pulsatility: it enhances the body's natural pulsatile GH pattern rather than forcing a constant, unphysiological release.
• Somatostatin inhibition: suppresses the body's main GH off-switch, letting the natural GHRH signal work more effectively.
• Secondary IGF-1 rise: downstream liver IGF-1 increases and drives systemic repair. IGF-1 is the usual marker but not a complete safety or efficacy endpoint.
• It stimulates GH pulses through GHS-R while generally being described as more selective in endocrine spillover. Pituitary reserve, sleep, nutrition, and age influence response. The mechanism here is a plausibility map, not proof of a clinical outcome.

• Sleep architecture: noted for increasing slow-wave (deep) sleep, the main window for physiological repair.
• Bone mineral density: recent data suggests it stimulates osteoblast activity, a focus for age-related bone-loss research.
• Gut motility: originally studied for post-operative ileus, with trials exploring restart of gut motility without the hunger spikes of older ghrelin mimetics.
• Muscle preservation: anti-catabolic properties may preserve lean mass during stress or caloric restriction without disrupting blood glucose.
• Caveat: clinical applications remain largely investigational; Common anti-aging or recovery claims are not equivalent to approved therapy.
• Human endocrine evidence supports GH release, but body-composition, anti-aging, and recovery outcomes are not proven at community-protocol level. The evidence is better for mechanism than outcomes. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.

Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions for you.

• Protocol 1: Anti-Aging / Wellness [Community/Biohacker/Anecdotal]; Route: Subcutaneous (SC); Dose: 100 mcg – 200 mcg; Frequency: Once Daily (at Night); Timing: Fasted (Before Bed); Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 2: Performance / Recovery [Community/Biohacker/Anecdotal]; Route: Subcutaneous (SC); Dose: 200 mcg – 300 mcg; Frequency: 2 to 3 Times Daily; Timing: Fasted (Morning/Pre-workout); Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Often paired with CJC/no-DAC or sermorelin in pulse-style evening protocols. 5-on/2-off is common but not proven necessary for once-nightly short-acting exposure. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.

• Time until steady state: about 10 hours.
• Half-life basis: human PK/PD modeling reports a terminal half-life of roughly 2 hours. The relevant effect is a GH pulse, not a constant exposure target.
• Beginner translation: A 10-hour steady-state estimate does not mean the GH pulse lasts 10 hours. The endocrine response rises and falls around each exposure.
• Practical interpretation: Monitor IGF-1, fasting glucose, edema, sleep quality, and symptoms; Do not use constant exposure as the goal.
• Comparison note: Ipamorelin is usually framed as cleaner than GHRP-2 and GHRP-6, with less hunger and less cortisol/prolactin spillover. It is still a hormone-axis drug and still carries risk.
• Route note: do not generalize intranasal/oral findings across GH secretagogues. Older GHRP-2 and hexarelin data, animal ipamorelin nasal PK, and community sermorelin/CJC nasal-buccal products are different evidence categories.
• Short exposure supports pulse logic. However, IGF-1 and tissue effects are downstream, so half-life alone cannot predict benefit or risk. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.

• The classic pairing is with CJC-1295 without DAC or sermorelin to mimic the GHRH plus ghrelin dual signal. Stacking with tesamorelin or other GH-axis agents should be clinician-guided because side effects overlap.
• The common CJC/ipamorelin stack is mechanistically coherent but is not automatically safe or same-vial compatible. Additive GH-axis exposure needs monitoring. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.

• Potential issues include water retention, headache, numbness/tingling, injection-site irritation, glucose worsening, sleep apnea worsening, and theoretical risk in active malignancy.
• Lower prolactin/cortisol spillover does not mean no risk.
• Watch edema, tingling, appetite change, sleep apnea, glucose changes, headache, and injection reactions. Risk rises with high IGF-1 or stacking with other GH-axis agents. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.

• Monitor IGF-1, fasting glucose, HbA1c, edema, blood pressure, sleep apnea symptoms, and symptom response.
• Body composition and recovery metrics are more meaningful than subjective “GH feeling.”
• Track IGF-1, fasting glucose/A1c, sleep quality, edema, blood pressure, carpal-tunnel symptoms, weight/waist, and subjective recovery with training load noted. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.

• FDA: not approved; Classified as investigational. It was removed from the Category 2 do-not-compound list in September 2024 after nominators withdrew, and on February 27, 2026 HHS named it among roughly 14 peptides expected to return to Category 1 for legal compounding access.
• Still under review: expected to be referred to a future Pharmacy Compounding Advisory Committee meeting; Not approved for any indication.
• WADA: banned under S2 (peptide hormones and growth factors) and detectable in urine and blood for several days after a dose.
• Availability: widely compounded in wellness practice; Verify current status with the pharmacy.
• Ipamorelin is not FDA-approved for wellness/body composition. FDA has flagged compounded ipamorelin safety and characterization concerns. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.

1. [D] Raun et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. PMID:9849822

2. [C] Gobburu et al. (1999). Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research. PMID:10496658

3. [B] Beck et al. (2014). Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for management of postoperative ileus. International Journal of Colorectal Disease. PMID:25331030

4. [D] Greenwood-Van Meerveld et al. (2012). Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus. Journal of Experimental Pharmacology, 4, 1495. PMID:27186127; PMCID:PMC4863553; DOI:10.2147/JEP.S35396.

5. [F] Mosińska et al. (2017). Role of relamorelin and other ghrelin receptor agonists. Journal of Neurogastroenterology and Motility.

6. [G] WADA. (2026). International Standard: Prohibited List. World Anti-Doping Agency.

7. [H] NCI Drug Dictionary. (2026). Ipamorelin definition. National Cancer Institute.

8. [RouteEvidence] Lewis et al. Intranasal human growth hormone induces IGF-1 comparable with SC injection with lower systemic exposure. 2015.

9. [RouteEvidence] Pihoker et al. Intranasal GHRP-2 in children of short stature. PubMed record.

10. [RouteEvidence] Johansen et al. Pharmacokinetic evaluation of ipamorelin and other peptidyl GH secretagogues with emphasis on nasal absorption. PubMed record.

• KPV is a naturally occurring tripeptide sequence, lysine-proline-valine, derived from the C-terminal region of alpha-MSH.
• It is much smaller than most peptides in this guide and is an anti-inflammatory peptide concept, not a broad immune cure.

• Proposed mechanisms include NF-kB modulation, cytokine reduction, antimicrobial effects, intestinal barrier support, and epithelial/immune signaling.
• These are mostly preclinical or formulation-specific.
• Mechanisms discussed include melanocortin-related anti-inflammatory signaling, NF-kB/inflammasome modulation, and epithelial barrier effects. Route matters because gut-local and topical effects are more plausible than systemic claims. The mechanism here is a plausibility map, not proof of a clinical outcome.

• IBD, dermatology, mast-cell, antimicrobial, and wound-healing claims require exact citations.
• Nanoparticle or colon-delivery studies do not generalize to ordinary oral capsules.
• Preclinical gut and skin inflammation evidence is the main base. FDA has not identified adequate human exposure data for compounded KPV drug products, so human claims need conservative wording. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.

Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions for you.

• Protocol 1: Gut Health / IBD - Oral [Research/Experimental]; Route: Oral (Capsule); Dose: 250 mcg – 500 mcg; Frequency: 1 to 2 times daily; Timing: Empty stomach; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 2: Systemic Inflammation - Oral [Research/Experimental]; Route: Oral (Capsule); Dose: 500 mcg; Frequency: Once daily; Timing: Empty stomach; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 3: Gut Health / IBD - Injectable [Research/Experimental]; Route: Injectable (SC); Dose: 200 mcg – 300 mcg; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 4: Systemic Inflammation - Injectable [Research/Experimental]; Route: Injectable (SC); Dose: 200 mcg – 400 mcg; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 5: Local Skin / Topical Inflammation - Topical [Topical/Cosmetic]; Route: Topical (Cream); Dose: Applied twice daily to site; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Community oral use is usually gut-focused and topical use skin-focused. Do not say oral KPV has validated systemic bioavailability just because PepT1 transport is discussed. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.

• Time until steady state: not calculable.
• Half-life basis: human PK is not established across oral, topical, nanoparticle, and subcutaneous formulations. Route and formulation dominate exposure.
• Beginner translation: Because KPV is tiny, it may behave differently by route, but the guide still needs human PK to calculate steady state.
• Practical interpretation: Do not generalize colon-delivery or nanoparticle data to ordinary capsules, creams, or injections.
• Comparison note: KPV is best framed as proposed anti-inflammatory signaling; BPC-157 is framed as proposed tissue-repair/cytoprotective signaling. Both evidence bases remain limited.
• As a tripeptide, KPV may be handled differently from larger peptides, but human systemic PK is not established. Local exposure can be more relevant than plasma exposure. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.

• KPV is often paired with BPC-157 or TB-500 in community discussions for inflammation plus repair.
• That is plausible as a framework but not controlled clinical evidence.
• Larazotide or gut-barrier agents are separate mechanisms.
• Often paired with BPC-157, GHK-Cu, TB-family products, or gut protocols. In blends, KPV is chemically simple, but final-formulation compatibility still requires data. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.

• Systematic human safety data are limited.
• Possible issues include GI symptoms, local irritation, allergic reaction, injection-site reaction, and product-contamination risk.
• The major issue is the unknown human safety database, not a known dramatic toxicity. Topical irritation, GI intolerance, immune effects, and product quality all matter. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.

• Relevant monitoring may include CRP, fecal calprotectin, symptom scores, skin-assessment tools, flare frequency, and adverse effects, depending on the research context.
• Track skin lesions, GI symptoms, stool patterns, inflammatory disease activity if relevant, photos for topical use, and adverse reactions. Avoid changing multiple gut interventions at once. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.

• KPV-related bulk-substance status is subject to FDA compounding review.
• PCAC discussion is not FDA approval and does not create immediate compounding permission.
• Athletes should verify current anti-doping status and treat unapproved peptide use as high-risk.
• KPV is not FDA-approved, and 2026 PCAC review concerns compounding-list status rather than drug approval. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.

1. [D] Getting et al. (2002). The melanocortin peptide KPV inhibits inflammatory signaling pathways independently of classical melanocortin receptors. Journal of Immunology. PMID:12421969

2. [D] Xiao et al. (2017). Orally targeted delivery of tripeptide KPV via hyaluronic acidfunctionalized nanoparticles efficiently alleviates ulcerative colitis. Molecular Therapy, 25(7), 1628-1640. PMID:28625369; PMCID:PMC5498804.

3. [D] Bonfiglio et al. (2006). Effects of the COOH-terminal tripeptide alpha-MSH(11-13) on corneal epithelial wound healing: role of nitric oxide. Experimental Eye Research, 83(6), 1366-1372. PMID:16965771; DOI:10.1016/j.exer.2006.07.014.

4. [E] Pawar et al. (2017). Transdermal Iontophoretic Delivery of Lysine-Proline-Valine (KPV) Peptide Across Microporated Human Skin. Journal of Pharmaceutical Sciences, 106(7), 1814-1820. PMID:28343991; DOI:10.1016/j.xphs.2017.03.017.

5. [E] Land et al. (2012). Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists. International Journal of Physiology, Pathophysiology and Pharmacology, 4(2), 59-73. PMID:22837805; PMCID:PMC3403564.

6. [F] Brzoska et al. (2008). Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, anti-inflammatory and protective effects. Endocrine Reviews. DOI:10.1210/er.2007-0027

7. [D] Sung et al. (2025). Lysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-kappaB pathway. Tissue and Cell, 95, 102837. PMID:40073467; DOI:10.1016/j.tice.2025.102837.

8. [RouteEvidence] FDA. Certain bulk drug substances for use in compounding that may present significant safety risks.

9. [RouteEvidence] Dalmasso et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008.

10. [RouteEvidence] Pawar et al. Transdermal iontophoretic delivery of KPV. Drug Development and Industrial Pharmacy. 2017.

Melanotan I is a synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH). Its pharmaceutical name is afamelanotide. The molecule is a 13-amino-acid melanocortin analog with substitutions that make it more stable than native alpha-MSH, including norleucine at position 4 and D-phenylalanine at position 7. The approved drug form is SCENESSE, a bioresorbable 16 mg subcutaneous implant.

• This is important: the approved product is not a vial of powder for home injection. It is inserted by a trained healthcare professional and has a controlled-release pharmacokinetic profile.
• Classification: melanocortin receptor agonist, primarily discussed as an MC1R-focused pigmentation and photoprotection agent. It is related to Melanotan II, but it is not the same molecule. Melanotan II is cyclic, nonselective, and unapproved; Afamelanotide is linear, more MC1R-focused, and approved for a narrow medical indication.
• The FDA-approved afamelanotide/SCENESSE implant context is separate from unapproved Melanotan I research/cosmetic products. The approved product is a controlled-release implant for erythropoietic protoporphyria, not a generic tanning powder protocol.

• Afamelanotide binds predominantly to melanocortin-1 receptor (MC1R) on melanocytes. MC1R activation increases cyclic AMP signaling and stimulates eumelanin production.
• Eumelanin is the darker pigment associated with increased photoprotection compared with pheomelanin.
• For EPP, this does not cure the porphyrin pathway defect. Instead, it increases the skin pigment barrier and raises the amount of light exposure a patient can tolerate before phototoxic pain occurs.
• Patients are still advised to maintain sun and light protection measures.
• Compared with Melanotan II, afamelanotide is less defined by MC3R/MC4R central effects. This is why the libido, spontaneous erection, appetite, and severe nausea profile associated with MT-II does not carry over to Melanotan I as if the two were identical.
• MT1 primarily activates MC1R to increase eumelanin and photoprotection. This differs from Melanotan II, which has broader melanocortin activity and more libido/erectile effects. The mechanism here is a plausibility map, not proof of a clinical outcome.

• Erythropoietic protoporphyria (EPP): The FDA-approved indication is to increase pain-free light exposure in adult patients with a history of phototoxic reactions from EPP. In the label-described trials, patients received 16 mg implants every two months and recorded sunlight exposure and phototoxic pain. SCENESSE-treated patients had more pain-free light exposure than vehicle-treated patients.
• Clinical trial synthesis: Randomized trials published in the medical literature found improved light tolerance and quality-of-life measures in EPP, with adverse events generally described as mild. The benefit is disease-specific, not a general “sunless tanning” intervention for healthy users.
• Vitiligo research: Afamelanotide has been studied as an adjunct to narrowband UVB phototherapy. A multicenter randomized trial in nonsegmental vitiligo reported faster and greater repigmentation when afamelanotide implants were combined with NB-UVB compared with NB-UVB alone. This is dermatology-supervised research and does not equal approval for cosmetic tanning.
• Gray-market risk: Unregulated alpha-MSH analog products sold online may be mislabeled, impure, contaminated, or different from the claimed compound. The clinical safety data for SCENESSE do not validate products sold as loose Melanotan I powder or nasal/injectable cosmetic kits.
• Afamelanotide has legitimate clinical evidence and approval for EPP phototoxicity reduction. That evidence does not validate unapproved powders, nasal products, or cosmetic tanning use. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.

Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions for you.

• Protocol 1: SCENESSE FDA label protocol for EPP [FDA/Approved/Label]; Route: Subcutaneous implant inserted by trained healthcare professional; Dose: 16 mg afamelanotide implant; Frequency: Every 2 months; Timing: Above anterior supra-iliac crest; Duration: Chronic labeled use per prescribing information; Status: Yes - FDA-approved label/product protocol for EPP only.
• Protocol 2: EPP clinical trial implant protocol [Clinical/Human Trial]; Route: Subcutaneous implant; Dose: 16 mg implant; Frequency: Every 2 months; Duration: 6 months in trial registry protocol; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 3: Historical afamelanotide SC PK/PD daily-dose study [Clinical/Human Trial]; Route: Subcutaneous injection; Dose: 0.08 mg/kg – 0.21 mg/kg; Frequency: Daily; Duration: 10 daily doses; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 4: Community acute pre-sun exposure protocol [Community/Biohacker/Anecdotal]; Route: Subcutaneous injection; Dose: 0.25 mg; Frequency: As-needed exposure protocol; Timing: ~30 minutes before sun exposure; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 5: Community loading and maintenance protocol [Community/Biohacker/Anecdotal]; Route: Subcutaneous injection; Dose: 0.25 mg – 0.5 mg loading; Maintenance 0.25 mg – 0.5 mg; Frequency: Daily loading; Then 1–2 times per week maintenance; Duration: Loading often around 10 days; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 6: Community higher loading/maintenance range [Community/Biohacker/Anecdotal]; Route: Subcutaneous injection; Dose: 0.5 mg – 1 mg; Frequency: Daily during loading; 2–3 times weekly maintenance; Duration: Loading often 1–2 weeks; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Approved-product dosing is implant-based and clinician-administered. Reconstituted powder dosing is not equivalent to Scenesse pharmacokinetics. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.

• Time until steady state: about 2.5 to 3 days by half-life math for the approved implant PK, but repeated-dose steady state is not clinically meaningful with an every-two-month implant schedule.
• Half-life basis: the FDA label reports median Tmax of 36 hours and apparent half-life of about 15 hours after the controlled-release subcutaneous implant.
• Beginner translation: The drug level rises slowly from the implant, clears over days, and the pigmentation/photoprotection effect can last longer than measurable plasma drug. Do not confuse the half-life of the molecule with the duration of the skin-pigment effect.
• Practical interpretation: This estimate applies to the approved controlled-release implant. It does not extrapolate to unapproved injectable powders, nasal sprays, topical products, or other formulations marketed as Melanotan I. The implant formulation changes the PK. A free peptide injection could have different absorption and elimination, but robust public human PK for gray-market Melanotan I formulations is not available. If you're new, the correct comparison is not “Melanotan I vs Melanotan II dose”; It is “approved implant PK vs unverified product PK.”
• Implant release drives afamelanotide exposure. Bolus assumptions and calculator half-lives do not apply to the implant product. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.

• EPP care: Afamelanotide is used alongside, not instead of, sun and light protection. Protective clothing, avoidance strategy, and disease-specific clinician guidance remain central.
• Vitiligo research: The most clinically relevant stack is afamelanotide plus narrowband UVB phototherapy under dermatology supervision. This pairing is not casual tanning; It is a controlled phototherapy context where dose, timing, skin type, and lesion response are monitored. Avoid combining with Melanotan II or tanning-bed/high-UV behavior. The point of an MC1R-focused drug is not to justify unsafe UV exposure or to mask changing moles with darker pigment.
• Stacking with UV exposure is a safety issue, not just a tanning strategy. Photoprotection claims are no license for sunburn, tanning beds, or reduced sunscreen vigilance. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.

• Label warnings include serious hypersensitivity reactions, including anaphylaxis, and the need for possible implant removal if a serious reaction occurs.
• Known severe hypersensitivity to afamelanotide or implant excipients is a contraindication.
• Skin monitoring is central. Afamelanotide can darken pre-existing nevi and ephelides because of its pharmacologic effect.
• The FDA label recommends a full-body skin examination twice yearly to monitor pre-existing and new pigmentary lesions.
• Common adverse reactions in the label include implant-site reactions, nausea, oropharyngeal pain, cough, fatigue, dizziness, skin hyperpigmentation, somnolence, melanocytic nevus, respiratory-tract infection, non-acute porphyria, and skin irritation.
• Pregnancy and lactation lack adequate human safety data.
• Monitor nevi, pigmentation changes, nausea, injection/implant reactions, and melanoma-risk context. Cosmetic tanning use can create behavioral risk by increasing UV exposure. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.

• Dermatology: baseline and twice-yearly full-body skin examination; Track new, changing, asymmetric, bleeding, or rapidly darkening lesions. Standardized photos can help distinguish expected generalized pigmentation from concerning mole changes.
• EPP outcomes: patient diary of pain-free light exposure, phototoxic episodes, rescue behavior, quality of life, and seasonal exposure. EPP care may also require disease-specific monitoring such as porphyrin-related labs and liver assessment under specialist guidance.
• Implant safety: monitor insertion site for persistent pain, infection, extrusion, nodules, or allergic symptoms. Any throat tightness, wheezing, facial swelling, generalized hives, or systemic allergic reaction requires urgent medical evaluation.
• Dermatologic exams, baseline mole photos, EPP phototoxicity diaries in approved context, and sun-exposure behavior are useful. Any changing lesion warrants medical evaluation. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.

• FDA: Approved as SCENESSE (afamelanotide) implant for adult patients with a history of phototoxic reactions from erythropoietic protoporphyria. Initial U.S. approval was in 2019; The current label describes the implant, professional administration, warnings, and PK.
• Not approved for cosmetic tanning: Afamelanotide approval for EPP does not authorize gray-market cosmetic tanning injections or powder kits. Products sold online as Melanotan I are not automatically pharmaceutical afamelanotide, and the guide’s sourcing/COA rules apply to them.
• Anti-doping: Afamelanotide is not the same regulatory category as unapproved Melanotan II. Competitive athletes should still verify status through GlobalDRO, USADA, or their sport governing body because product identity, prescription status, and jurisdiction matter.
• Afamelanotide/Scenesse is FDA-approved for a specific EPP indication. Melanotan I research powders or tanning-market products are not the same regulatory entity. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.

1. [G] FDA. SCENESSE (afamelanotide) implant, prescribing information, revised August 2024. Use: Melanotan I/afamelanotide indication, professional implant administration, 16 mg every-two-month dosing, hypersensitivity warning, skin monitoring, common adverse reactions, and PK (Tmax 36 hours; apparent half-life about 15 hours).

2. [A] Langendonk JG et al. Afamelanotide for Erythropoietic Protoporphyria. New England Journal of Medicine. 2015. PMID:26132941. Use: EPP randomized-trial evidence for increased pain-free light exposure and quality-of-life context.

3. [B] Lim HW et al. Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial. JAMA Dermatology. 2015. PMID:25230094. Use: Dermatology-supervised vitiligo research context; not cosmetic tanning approval.

4. [F] Habbema L et al. Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. International Journal of Dermatology. 2017. PMID:28266027. Use: Safety context for unregulated melanotan I/II products and cutaneous complications.

5. [C] Hadeler E et al. Evaluation of synthetic alpha-melanocyte-stimulating hormone analogs: an observational study of unregulated, online-available drugs. Journal of the American Academy of Dermatology. 2022. PMID:34333078. Use: Product-quality risk context for online alpha-MSH analogs.

• Melanotan II is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH).
• It is an unapproved melanocortin agonist; Unregulated tanning use is not an approved medical use.
• Melanotan II is a cyclic melanocortin agonist with broader receptor activity than Melanotan I/afamelanotide. It is higher-risk and non-approved, not a cosmetic equivalent.

• MT-II acts on melanocortin receptors, including MC1R in melanocytes and CNS melanocortin receptors.
• This explains both tanning effects and systemic adverse effects such as nausea, flushing, appetite change, libido effects, yawning, and blood-pressure or cardiovascular symptoms.
• Its melanocortin activity affects pigmentation, appetite, sexual function, nausea, and autonomic symptoms. The same broad receptor activity that users seek can create adverse effects. The mechanism here is a plausibility map, not proof of a clinical outcome.

• Early human studies showed tanning and sexual-function effects, but the compound was not developed into an approved tanning product.
• Safety concerns include mole darkening, dysplastic nevi, melanoma-case reports, rhabdomyolysis/renal events in case reports, and unpredictable gray-market product quality.
• Human cosmetic/tanning efficacy is not the same as safety validation. Reports and case literature around priapism, nevus changes, and adverse reactions temper community enthusiasm. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.

Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions for you.

• Protocol 1: Clinical/Trial Protocols - Loading [Clinical/Human Trial]; Route: Subcutaneous (SC); Dose: Loading Dose: 0.025 mg/kg daily; Duration: 2 weeks (Loading); Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 2: Clinical/Trial Protocols - Libido/ED [Clinical/Human Trial]; Route: Subcutaneous (SC); Dose: Libido/ED: 0.025 mg/kg (single dose); Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 3: Common Biohacker Protocols - Loading [Community/Biohacker/Anecdotal]; Route: Subcutaneous (SC); Dose: 0.25 mg – 0.5 mg daily; Duration: Until desired shade is reached; Titration/loading: Many community users start as low as 50-100 mcg (0.1 mg) to assess tolerance before moving to 250 mcg.; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 4: Common Biohacker Protocols - Maintenance [Community/Biohacker/Anecdotal]; Route: Subcutaneous (SC); Dose: 0.5 mg – 1 mg (1–2× per week); Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 5: Common Biohacker Protocols - Libido/ED [Community/Biohacker/Anecdotal]; Route: Subcutaneous (SC); Dose: 0.5 mg – 1 mg (PRN / as needed); Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 6: Community Nasal Spray note [Community/Biohacker/Anecdotal]; Route: Nasal spray; Dose: 1 mg - 2 mg to achieve similar effects to a 0.25 mg injection; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Community titration is common but not medically standardized. Nasal spray exposure is especially variable and is not safer than injection by default. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.

• Time until steady state: not calculable.
• Half-life basis: Published human PK is not consistent enough for a reliable common-use estimate. Pigmentation and mole changes can outlast measurable exposure; Monitoring skin changes matters more than plasma steady state.
• Beginner translation: this is a deliberately conservative read. A missing steady-state number does not mean the compound has no effect; It means the available human PK data are not strong enough to justify a precise accumulation estimate for common use patterns.
• Practical interpretation: Published pharmacokinetic details vary by route and formulation. Downstream pigmentation effects can outlast measurable exposure.
• Public PK for unapproved products is limited, and route variability is high. Pigmentation can persist beyond active exposure, making dose-response interpretation difficult. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.

• UV exposure combined with MT-II increases dermatologic effects.
• Do not combine with tanning beds or deliberate high-UV exposure.
• Avoid stacking with PDE5 inhibitors or other pro-erectile agents without strong caution because priapism risk is plausible. UV exposure is a risk amplifier. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.

• Known risks include nausea, flushing, appetite suppression, spontaneous erections, fatigue, yawning, mole darkening, dysplastic nevi, melanoma concern, blood-pressure effects, priapism risk, kidney injury/rhabdomyolysis case reports, and product-contamination risk.
• Avoid in personal/family melanoma history, dysplastic nevus syndrome, Fitzpatrick I-II skin with heavy mole burden, cardiovascular disease, kidney disease, pregnancy, or concurrent PDE5-inhibitor use unless reviewed by a clinician.
• Major concerns include nausea, flushing, blood pressure effects, spontaneous erections/priapism, mole darkening, melanoma diagnostic confusion, and product impurity. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.

• Dermatologic mole checks, blood pressure, renal function if systemic symptoms occur, and urgent evaluation for priapism or severe cardiovascular symptoms.
• Track skin lesions with photos, blood pressure symptoms, nausea, sexual side effects, and sun/UV exposure. Changing moles or prolonged erections are urgent red flags. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.

• FDA: not approved.
• Australia/TGA: melanotan products are unapproved therapeutic goods and cannot be lawfully supplied without appropriate authorization.
• UK/EU: not authorized.
• WADA: high-risk under S0 for athletes as a non-approved substance.
• Melanotan II is not FDA-approved and is included in safety/compounding concern discussions. Online tanning-product availability does not equal legal or clinical acceptance. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.

1. [B] Dorr et al. (1996). Evaluation of Melanotan-II, a superpotent cyclic melanotropic peptide, in a pilot phase-I clinical study. Life Sciences. PMID:8637402

2. [C] Wessells et al. (2000). Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. International Journal of Impotence Research. PMID:11035391

3. [C] Hjuler & Lorentzen. (2014). Melanoma associated with the use of Melanotan II. Dermatology Reports. PMID:24355990

4. [C] Paurobally, Jason, Dezfoulian, & Nikkels (2011). Melanotan-associated melanoma. British Journal of Dermatology, 164(6), 1403-1405. PMID:21564053; DOI:10.1111/j.1365-2133.2011.10273.x.

5. [C] Ong & Bowling (2012). Melanotan-associated melanoma in situ. Australasian Journal of Dermatology, 53(4), 301-302. PMID:22724573; DOI:10.1111/j.1440-0960.2012.00915.x.

6. [C] Nelson et al. (2012). Melanotan II injection resulting in systemic toxicity and rhabdomyolysis. Clinical Toxicology. 50(10):1169-1173. PMID:23121206; DOI:10.3109/15563650.2012.740637

7. [F] Brennan, Wells, & Van Hout (2014). An unhealthy glow? A review of melanotan use and associated clinical outcomes. Performance Enhancement & Health, 3(2), 78-92. DOI:10.1016/j.peh.2015.06.001.

8. [G] Therapeutic Goods Administration. (2025). Do not risk using tanning products containing melanotan. Australian TGA.

9. [RouteEvidence] Therapeutic Goods Administration. Don’t risk using tanning products containing melanotan. 2025.

10. [RouteEvidence] FDA. Certain bulk drug substances for use in compounding that may present significant safety risks.

• MOTS-c is encoded within the mitochondrial 12S rRNA region and is classified as a mitochondrial-derived peptide.
• Unlike many peptides in the guide that imitate endocrine hormones, MOTS-c is better understood as a cell-stress and metabolic-signaling molecule.
• It is not an approved drug.
• FDA and anti-doping agencies treat it as an experimental compound, and FDA has previously highlighted the lack of human exposure data for compounded MOTS-c products.
• MOTS-c is a mitochondrial-derived peptide associated with metabolic stress signaling. It is not a simple stimulant or guaranteed fat-loss peptide.

MOTS-c is usually discussed through AMPK-related metabolic signaling, glucose handling, skeletal-muscle adaptation, and nuclear gene regulation. In simplified terms, it appears to communicate mitochondrial stress and energy status to the rest of the cell. Mechanistic map:

• AMPK and metabolic stress: MOTS-c is associated with AMPK-linked signaling, which helps cells respond to low-energy states and metabolic stress.
• Insulin sensitivity and glucose handling: Animal and cell data suggest effects on glucose metabolism and insulin sensitivity. This is why hypoglycemia risk and diabetes-medication interactions matter.
• Exercise adaptation: Human and animal research links MOTS-c to exercise-responsive biology. It is exercise-related signaling, not an exercise substitute.
• Nuclear gene regulation: MOTS-c can translocate or influence nuclear gene-expression programs under metabolic stress, which helps explain why effects may outlast a short plasma exposure.
• Mechanisms include AMPK-related metabolic adaptation, mitochondrial-nuclear communication, insulin sensitivity, and exercise-mimetic hypotheses. These are context-dependent pathways. The mechanism here is a plausibility map, not proof of a clinical outcome.

• Exercise and aging biology: A 2021 Nature Communications study described MOTS-c as an exercise-induced mitochondrial-encoded regulator of skeletal-muscle metabolism and reported improved physical performance and healthspan measures in older mice. This is a strong mechanistic/animal rationale, not a direct human protocol.
• Metabolic disease direction: MOTS-c and related analog programs have been investigated for metabolic dysfunction, insulin resistance, obesity, and fatty-liver biology. Early clinical development around MOTS-c analogs suggests interest in the pathway, but it does not validate gray-market MOTS-c products.
• Human evidence gap: Human outcome data for injectable MOTS-c are sparse. FDA has stated that it has not identified human exposure data for drug products containing MOTS-c administered by any route in the compounding safety-risk context.
• Most evidence is preclinical with limited human exposure data. Metabolic promise is exploratory rather than established clinical efficacy. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.

Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions for you.

• Protocol 1: Clinical/Human Pilot Dosing [Clinical/Human Trial]; Route: Subcutaneous (SC); Dose: 5 mg – 10 mg; Frequency: 2 to 3 times per week; Timing: Before exercise or morning; Duration: 4 to 10 weeks; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 2: Common Biohacker Protocols [Community/Biohacker/Anecdotal]; Route: Subcutaneous (SC); Dose: 5 mg; Frequency: 1 to 3 times per week; Timing: 30–60 mins before fasted cardio; Duration: 4 to 6 weeks; Titration/loading: Popular community "load": 5 mg daily for 10 days, then 5 mg twice weekly for 4 weeks.; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Community SC cycles are reported, but no validated human dosing standard exists for wellness use. Exercise, calorie intake, and insulin sensitivity strongly confound outcomes. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.

• Time until steady state: not calculable from validated human injection PK. Circulating/endogenous MOTS-c can change with exercise and may return toward baseline within hours, but that is not the same as an elimination half-life for injected MOTS-c.
• Half-life basis: Human therapeutic half-life after injection has not been established. Some secondary sources describe a short expected exposure, while exercise literature describes changing endogenous levels after activity.
• Why this matters: MOTS-c is a signaling peptide. Blood-level accumulation is only part of the picture. What matters is whether repeated exposure changes metabolism, glucose handling, sleep, heart rate, and training adaptation.
• Public PK is not enough for precision calculators. Downstream metabolic adaptation may matter more than plasma persistence. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.

• SS-31 / elamipretide: Often framed as the complementary mitochondrial stack: MOTS-c as a metabolic signal and SS-31 as a cardiolipin/mitochondrial-structure stabilizer. This is a mechanistic rationale, not a proven combination. NAD+ / NR / NMN: Often paired to support redox and energy metabolism. Benefits are hard to interpret if multiple mitochondrial agents are started together.
• Exercise: Zone-2 cardio and resistance training are the most defensible “stack” because MOTS-c biology is closely tied to exercise signaling. Any peptide claim stands or falls on training, sleep, protein intake, and glucose metrics.
• Diabetes medications and AMPK-active agents: Metformin, GLP-1/GIP drugs, insulin, sulfonylureas, thiazolidinediones, and fasting protocols can all change glucose dynamics. Stacking without glucose monitoring can create avoidable risk.
• Often paired with NAD precursors, SS-31, Humanin, GLP-1s, or exercise programs. Mitochondrial/metabolic stacks should start slowly because fatigue, glucose changes, and training changes can be hard to attribute. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.

• Known unknowns: Long-term human safety is not established. Reported self-experimenter side effects include injection-site irritation, insomnia, fever-like symptoms, increased heart rate, and palpitations.
• Metabolic caution: People with diabetes, hypoglycemia, eating disorders, adrenal instability, or use of glucose-lowering drugs should not treat MOTS-c as a casual wellness peptide.
• Other caution groups: Pregnancy, breastfeeding, active malignancy, severe cardiovascular disease, arrhythmia history, severe kidney/liver disease, and competitive athletes subject to testing.
• Concerns include immune response, glucose effects, unknown long-term metabolic signaling, and product-quality issues. FDA has noted lack of human exposure data for MOTS-c drug products. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.

• Metabolic markers: Fasting glucose, fasting insulin, HbA1c, triglycerides, HDL, ALT/AST if fatty liver is a concern, and waist circumference. CGM data can help detect unexpected hypoglycemia or glucose variability.
• Performance markers: Resting heart rate, HRV, sleep quality, training log, Zone-2 tolerance, grip strength, or VO2-related estimates. Track these before adding stacks.
• Stop-and-evaluate triggers: Palpitations, chest pain, fainting, fever, severe insomnia, unexplained hypoglycemia, or marked anxiety/agitation.
• Track fasting glucose, A1c, lipids, resting heart rate, exercise tolerance, fatigue, body composition, and adverse reactions. Training and diet should be logged. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.

• FDA/compounding: FDA scheduled MOTS-c-related bulk substances for PCAC discussion on July 23, 2026. Review does not equal approval and does not automatically authorize compounding.
• Anti-doping: USADA describes MOTS-c as prohibited at all times under the WADA Prohibited List as a metabolic modulator/AMPK activator. Athletes should treat it as banned.
• Availability: Mostly research-use-only vendors and nonstandard wellness channels. COA, mass-spec identity, endotoxin, sterility, and lot matching are especially important for injectable products.
• MOTS-c is not FDA-approved and is under compounding-policy review contexts, not approval. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.

1. [D] Lee et al. (2015). The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. PMID:25738459; DOI:10.1016/j.cmet.2015.02.009

2. [D] Kim et al. (2019). The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity. Physiological Reports, 7(13), e14171. PMID:31293078; PMCID:PMC6640593; DOI:10.14814/phy2.14171.

3. [F] Lee et al. (2016). MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism. Free Radical Biology & Medicine, 100, 182-187. PMID:27216708; DOI:10.1016/j.freeradbiomed.2016.05.015.

4. [D] Lu et al. (2019). Mitochondrial-derived peptide MOTS-c increases adipose thermogenic activation to promote cold adaptation. International Journal of Molecular Sciences, 20(10), 2456. PMID:31109005; PMCID:PMC6567243.

5. [C] Dieli-Conwright et al. (2021). Effect of aerobic and resistance exercise on the mitochondrial peptide MOTS-c in Hispanic and Non-Hispanic White breast cancer survivors. Scientific Reports. 11:16916. PMID:34413391; PMCID:PMC8376922; DOI:10.1038/s41598-021-96419-z

6. [F] Alser et al. (2022). The Effect of Chronic Endurance Exercise on Serum Levels of MOTS-c and Humanin in Professional Athletes. Reviews in Cardiovascular Medicine, 23(5), 181. PMID:39077591; PMCID:PMC11273660; DOI:10.31083/j.rcm2305181.

7. [C] Feng et al. (2025). Endurance training enhances skeletal muscle mitochondrial respiration by promoting MOTS-c secretion. Free Radical Biology and Medicine, 227, 619-628. PMID:39706498.

8. [G] U.S. Food and Drug Administration. July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee.

9. [G] U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding May Present Significant Safety Risks.

10. [G] U.S. Anti-Doping Agency. What is the MOTS-c peptide?

11. [D] Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications, 2021.

12. [D] Zheng Y, et al. MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation.

13. [D] Alzheimer’s Drug Discovery Foundation. MOTS-c Cognitive Vitality for Researchers.

14. [C] Wang X, et al. A first-in-human randomized, double-blind, single- and multiple-dose Phase I study of recombinant human thymosin beta-4 (NL005).

15. [G] Perfect B. MOTS-c Dosage Protocol.

16. [G] Peptides Explorer. MOTS-c Peptide Dosage.

• NAD+ is a central redox coenzyme involved in energy metabolism, sirtuin biology, DNA-repair signaling, and cellular stress response.
• NAD+ is a coenzyme rather than a peptide, but it belongs in the guide because it is often used in the same clinics and stacks. NAD+ itself is distinct from precursors like NR, NMN, niacin, and tryptophan-pathway strategies.

• NAD+ participates in oxidation-reduction reactions and serves as substrate for enzymes such as sirtuins and PARPs.
• NAD biology supports redox reactions, sirtuins, PARPs, CD38-related consumption, and mitochondrial metabolism. Raising NAD markers does not automatically mean improved clinical outcomes. The mechanism here is a plausibility map, not proof of a clinical outcome.

• Claims about aging, long COVID, addiction recovery, and mitochondrial optimization are broad and need endpoint-specific human evidence.
• IV NAD+ clinic claims are not established therapy without clinical-trial support.
• Human evidence is stronger for some oral precursors raising NAD-related metabolites than for broad disease or anti-aging outcomes. IV NAD+ has community and clinic use but less rigorous endpoint evidence. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.

Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions for you.

• Protocol 1: Clinical/IV Protocols [Clinical/Human Trial]; Route: IV Infusion (Slow drip); Dose: 250 mg – 1,000 mg; Frequency: 1 to 3 sessions (Loading); Duration: 4 to 10 days (intensive); Max: 1,500 mg (under supervision); Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 2: Common Biohacker Protocols [Community/Biohacker/Anecdotal]; Route: Subcutaneous (SC) Injection; Dose: 50 mg – 200 mg; Frequency: 2 to 3 times per week; Duration: 4 to 8 weeks; Max: 250 mg (daily in loading); Titration/loading: Loading example: 100 mg daily for 7-10 days, then 100 mg twice weekly.; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 3: Oral precursors [Research/Experimental]; Route: Oral NMN or NR; Dose: 300 mg - 1,000 mg daily; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Route and infusion rate matter greatly for tolerability. Oral precursor dosing does not convert into IV NAD+ dosing or vice versa. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.

• Time until steady state: not meaningfully calculable as a simple drug half-life.
• Half-life basis: Endogenous coenzyme with rapid extracellular metabolism and intracellular pool dynamics. Intracellular NAD biology does not map cleanly onto a plasma steady-state model.
• Beginner translation: this is a deliberately conservative read. A missing steady-state number does not mean the compound has no effect; It means the available human PK data are not strong enough to justify a precise accumulation estimate for common use patterns.
• Half-life: Systemic half-life is very short (estimated minutes). However, the increase in the intracellular NAD+ “pool” can persist for several days.
• Delivery: IV provides 100% bioavailability but must be infused slowly (2-4 hours) to avoid intense side effects. Subcutaneous injection is sometimes used outside clinics, but home self-administration is not a validated protocol and should involve clinician oversight.
• NAD+ metabolism is compartmentalized; Blood levels and intracellular tissue effects are not the same. Precursors may work by different transport and salvage-pathway steps. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.

• CD38 Inhibitors: Apigenin and quercetin are proposed to slow CD38-mediated NAD+ breakdown, but this stacking is investigational and not clinically validated.
• Sirtuin Activators: Often paired with Resveratrol or Pterostilbene to ensure the newly provided NAD+ is effectively utilized by the sirtuin longevity pathways.
• Peptide Synergy: Frequently stacked with MOTS-c (for mitochondrial power) or CJC-1295/Ipamorelin (to maximize growth hormone-related repair).
• Often paired with glutathione, methyl donors, mitochondrial peptides, exercise, or fasting protocols. Consider methylation and B-vitamin context when using high-dose precursor approaches. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.

The “NAD+ Sickness”: If injected or infused too quickly, users experience a distinctive sensation of chest pressure, stomach cramping, and nausea. This is temporary and subsides within minutes of stopping the drip or injection.

• Active Malignancy: Like all therapies that boost cellular energy, there is a theoretical concern that NAD+ could fuel the high metabolic demands of existing cancer cells.
• Methylation Depletion: High-dose NAD+ can “soak up” methyl groups. Many practitioners recommend taking TMG (Trimethylglycine) or a B-Complex to prevent methyl depletion.
• Common issues include nausea, flushing, chest tightness/anxiety during rapid infusions, methylation imbalance symptoms, and uncertain long-term effects in cancer contexts. Infusion quality matters. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.

Intracellular NAD+ Testing: Modern “at-home” dried blood spot tests (e.g., Jinfiniti) now allow users to measure their actual NAD+ levels in micromolar (mcM) units.

• Inflammatory Markers: Tracking hs-CRP to see the systemic anti-inflammatory effects of sirtuin activation. Energy &
• Sleep: Subjective tracking of “afternoon slumps” and deep sleep quality.
• Track energy/fatigue, sleep, heart-rate symptoms during infusions, liver enzymes if high-dose supplements are used, methylation markers when relevant, and glucose/lipids for metabolic goals. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.

• FDA: Not approved as a drug for anti-aging.
• However, it is widely available in “Wellness Clinics” and via compounding pharmacies as a supplement or injectable.
• 2026 Update: Some longevity clinics now offer whole-blood NAD+ testing, but it remains investigational rather than an established, evidence-based clinical standard.
• NAD+ and precursors appear in supplement, compounding, and clinic markets with different regulatory statuses. Claims determine regulatory risk. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.

1. [C] Grant et al. (2019). A pilot study investigating changes in the human plasma and urine NAD+ metabolome during a 6-hour intravenous infusion of NAD+. Frontiers in Aging Neuroscience.

2. [C] Reyna et al. (2026). Intravenous NAD+ compared with nicotinamide riboside: preliminary real-world data. PMC. PMID:41704678

3. [C] Martens et al. (2018). Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications. PMID:29599478

4. [C] NR-SAFE investigators. (2023). High-dose nicotinamide riboside safety trial in Parkinson disease. Nature Communications.

5. [F] Gindri et al. (2024). Evaluation of safety and effectiveness of NAD in different clinical conditions: a systematic review. American Journal of Physiology-Endocrinology and Metabolism, 326(4), E417-E427. PMID:37971292; DOI:10.1152/ajpendo.00242.2023.

6. [F] Gallagher et al. (2026). NAD+ supplementation for anti-aging and wellness: systematic review. ScienceDirect. PMID:41655607

7. [F] Radenkovic & Verdin. (2020). Clinical evidence for targeting NAD therapeutically. Pharmacological Reviews.

8. [RouteEvidence] Nicotinamide riboside / NAD+ precursor oral bioavailability review.

• Pinealon is a synthetic tripeptide often grouped with Khavinson-style peptide bioregulators.
• It is usually discussed in neuro-aging and cognitive-repair contexts rather than as a single-receptor drug.
• Pinealon is a short synthetic tripeptide bioregulator associated with neuro/cognitive and longevity claims. It is low-evidence, not a proven brain-aging therapy.

• Proposed mechanisms include gene-expression modulation, antioxidant effects, peptide bioregulation, and neuronal-protection signaling. These are broad hypotheses with limited direct human validation. The mechanism here is a plausibility map, not proof of a clinical outcome.

• The available evidence is preliminary.
• Claims about DNA repair, dementia improvement, or anti-aging effects need exact sources and do not generalize from cell or animal work.
• Evidence is largely regional, preclinical, or low-volume. Community use is worth including, but those claims are exploratory. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.

Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions for you.

• Protocol 1: Clinical/Oral Trial Protocols [Clinical/Human Trial]; Route: Oral; Dose: Starting Dose: 0.2 mg (2 pills); Max Dose: 0.4 mg (daily); Frequency: Twice daily (BID); Duration: 20 to 30 days; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 2: Common Biohacker Protocols [Community/Biohacker/Anecdotal]; Route: Oral; Dose: Starting Dose: 1.0 mg (1 pill); Max Dose: 2.0 mg (daily); Frequency: Once daily; Timing: Morning or early afternoon; Duration: 20 to 30 days; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Community short cycles exist, but dosing is not based on strong dose-ranging trials. Route and product identity matter. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.

• Time until steady state: not calculable.
• Half-life basis: reliable human PK is not established. Bioregulator effect claims are not plasma steady-state claims.
• Beginner translation: The compound may be discussed as a bioregulator, but the guide cannot honestly assign a blood steady-state time without human PK.Practical interpretation: Track objective cognition, sleep, mood, and adverse effects rather than relying on duration claims.
• As a tripeptide, it likely clears quickly, but proposed gene-expression effects would be downstream. Half-life calculators are not very useful. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.

• Pinealon is sometimes discussed with Epithalon, Semax, Selank, NAD+, or Cerebrolysin, but these combinations are anecdotal. Multiple neuroactive compounds make it harder to identify benefits or side effects.
• Often paired with Epithalon, Vilon, Semax/Selank, or NAD/mitochondrial support. Avoid too many low-evidence longevity compounds at once. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.

• Human safety data are limited.
• Potential issues include headache, sleep disruption, mood changes, injection-site reaction, product contamination, and unpredictable neuroactive effects.
• Pregnancy, breastfeeding, seizure disorders, bipolar disorder, or active neurologic disease require clinician review.
• Short peptide size may reduce some concerns but does not establish long-term safety. Product quality and unknown CNS effects remain relevant. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.

• Use sleep logs, mood logs, standardized cognitive tasks, headache tracking, blood pressure if symptomatic, and adverse-effect review.
• Consumer claims about DNA age or telomeres are not validation.
• Track sleep, mood, cognition tasks, headaches, and general labs if part of a broader longevity protocol. Use baseline and follow-up, not vague impressions. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.

• Pinealon is not FDA-approved for human use and is generally sold as a research chemical or in non-U.S. bioregulator markets.
• Athletes should verify status before use.
• Regional bioregulator use is not U.S. therapeutic approval. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.

1. [D] Arutjunyan et al. (2012). Pinealon protects the rat offspring from prenatal hyperhomocysteinemia. International Journal of Clinical and Experimental Medicine, 5(2), 179-185. PMID:22567179; PMCID:PMC3342713

2. [F] Khavinson et al. (2021). Neuroprotective Effects of Tripeptides, Epigenetic Regulators in Mouse Model of Alzheimer’s Disease. Pharmaceuticals (Basel), 14(6), 515. PMID:34071923; PMCID:PMC8227791; DOI:10.3390/ph14060515

3. [E] Kraskovskaya et al. (2024). Short Peptides Protect Fibroblast-Derived Induced Neurons from Age-Related Changes. International Journal of Molecular Sciences. 25(21):11363. PMID:39518916; PMCID:PMC11546785; DOI:10.3390/ijms252111363

4. [RouteEvidence] Tyagi et al. Oral peptide delivery: translational challenges due to physiological effects. J Control Release. 2018.

• Developed by Eli Lilly under the code LY3437943, retatrutide is a single synthetic peptide (not a combination of drugs), engineered so one molecule activates three receptors at once.
• First-in-class “triple G” agonist: it targets the GLP-1, GIP, and glucagon receptors together, and is the first such tri-agonist to reach Phase 3 development.
• Long-acting by design: an albumin-binding fatty-acid chain extends its half-life to about six days, supporting once-weekly subcutaneous dosing (see Section 5).
• Class & status: an investigational incretin/glucagon receptor agonist (metabolic). It is not an FDA-approved drug as of this edition and has no approved label.
• Studied for obesity, obesity with knee osteoarthritis (TRIUMPH program), type 2 diabetes, and metabolic-associated steatotic liver disease (MASLD).
• Retatrutide is an investigational triple agonist at GIP, GLP-1, and glucagon receptors. It is distinct from semaglutide and tirzepatide rather than simply a stronger GLP-1.

One molecule, three receptor “arms,” all class B, G s -coupled GPCRs that signal through cAMP:

• GLP-1 receptor: glucose-dependent insulin release, hypothalamic satiety, and slowed gastric emptying, the appetite-and-intake arm shared with semaglutide.
• GIP receptor: adds a β-cell insulin response and adipose nutrient handling, and is thought to help blunt the nausea of GLP-1 activation, the same arm tirzepatide adds.
• Glucagon receptor, the differentiator: raises energy expenditure and drives hepatic fat oxidation/lipolysis, which underlies both the larger weight loss and the marked liver-fat reduction not seen with dual agonists.
• The balancing act: glucagon on its own would raise hepatic glucose output, so the GLP-1/GIP insulin arms must offset it; In trials net glucose control still improved. The glucagon arm also helps explain the dose-dependent rise in heart rate (Section 7).
• Its profile combines incretin satiety/glucose effects with glucagon-receptor activity that may increase energy expenditure and hepatic/metabolic effects. That broader mechanism may also broaden tolerability and monitoring issues. The mechanism here is a plausibility map, not proof of a clinical outcome.

• Two Phase 3 trials in the TRIUMPH program have now reported positive topline results: TRIUMPH-4 (Dec 2025, obesity plus knee osteoarthritis) reported about 28.7% mean weight loss at 68 weeks at the 12 mg dose, and TRIUMPH-1 (May 2026, obesity/overweight with at least one weight-related comorbidity) reported about 28.3% at 80 weeks at 12 mg, with continued loss in a higher-BMI extension.
• Earlier Phase 2 data had shown substantial weight-loss signals.
• Positive topline readouts are not the same as full peer-reviewed publication or regulatory approval, and additional TRIUMPH and TRANSCEND readouts plus dedicated cardiovascular-outcomes data remain pending; Long-term safety is not yet established.
• Large trial programs have produced strong weight-loss signals, but full peer-reviewed data and final regulatory labeling matter. Sponsor topline language stays topline until published/adjudicated. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.

Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions for you.

• Protocol 1: TRIUMPH-4 Protocol (12 mg target) [Clinical/Human Trial]; Route: Subcutaneous, abdomen preferred; Dose: Starting dose: 2 mg weekly (weeks 1–4); Frequency: Once weekly; Duration: Trial escalation/maintenance; Max: 12 mg weekly; Titration/loading: Step up every 4 weeks on a fixed schedule; Typical step size 2–3 mg (2, 4, 6, 9, 12); Scheduled escalation regardless of response.; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 2: Community Slow Titration [Community/Biohacker/Anecdotal]; Route: Subcutaneous, abdomen preferred; Dose: Starting dose: 0.5 mg – 1 mg weekly; Frequency: Once weekly; Max: 12 mg weekly, only if truly needed; Titration/loading: Hold current dose unless weight loss has stalled or cravings/appetite returned; Typical step size 0.5 – 1 mg; Escalate only when plateaued.; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 3: Community dose-hold/reduction and missed-dose rules [Community/Biohacker/Anecdotal]; Route: Subcutaneous; Dose: No fixed dose; Applies to any current retatrutide dose during slow titration.; Frequency: Once weekly SC dosing context; Timing: If tolerability issues occur at a dose step, hold that dose longer or reduce to the prior tolerated dose.; Duration: Hold current dose an additional 1-4 weeks before retrying escalation, or step back to prior tolerated dose.; Max: 12 mg weekly ceiling in guide/trial context; Community slow titration typically seeks lowest effective dose.; Titration/loading: Dose changes are not fully felt for roughly 3-4 weeks because of ~6-day half-life and steady-state drift.; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Dosing is trial- and product-specific, with titration. Do not import tirzepatide or semaglutide schedules into research-market retatrutide. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.

• Time until steady state: about 30 days, or roughly 4-5 weeks.
• Half-life basis: Approximately 6 days in phase 2 obesity literature. This supports once-weekly dosing in trials; Final prescribing information will control after approval.
• Beginner translation: This estimate uses the standard four-to-five-half-life convention. It describes when plasma exposure would be expected to approach a plateau during repeated dosing, not when the desired outcome is complete.
• Practical interpretation: Retatrutide is designed for weekly dosing, but final label pharmacokinetics and dose escalation come from the approved label if approval occurs.
• Long-acting weekly design is expected, but clinical titration is driven by tolerability and metabolic response rather than half-life alone. GI effects may lag dose changes. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.

• It is already a “stack in one molecule”: three receptor arms are combined by design, so adding another incretin or amylin drug is redundant receptor pressure, not synergy, the same-pathway problem this guide flags elsewhere (the Stacking Calculator scores incretin + incretin as a penalty).
• Do not combine with semaglutide, tirzepatide, liraglutide, CagriSema, cagrilintide, or other GLP-1/GIP/amylin agents outside a trial: expect additive GI distress, gallbladder disease, dehydration/AKI, and hypoglycemia.
• With insulin or sulfonylureas the hypoglycemia risk is greatest; In diabetes these combinations typically require lowering the insulin/sulfonylurea dose under medical supervision.
• Supportive care is not a stack: hydration and anti-nausea measures during titration address tolerability, and they are not efficacy or “performance” stacking.
• Stacking with other GLP-1/GIP/amylin agents calls for high caution because mechanisms overlap. Combining with insulin/secretagogues or appetite suppressants increases safety complexity. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.

Gastrointestinal (expected, dose-dependent).

• At the 12 mg dose in TRIUMPH-4: nausea 43.2%, diarrhea 33.1%, constipation 25.0%, vomiting 20.9%, decreased appetite 18.2%.
• At 9 mg: nausea 38.1%, diarrhea 34.7%, constipation 21.8%, vomiting 20.4%.
• Placebo nausea: 10.7%. Most events were mild to moderate, clustered around each dose step, and improved at stable maintenance. Roughly 18.2% of 12 mg patients discontinued for adverse events; Lilly’s topline TRIUMPH-4 disclosure states that some discontinuations due to adverse events included “perceived excessive weight loss”; Treat this as sponsor-reported topline wording, not a fully published discontinuation taxonomy until full trial data are available. The slow-titration approach described in Section 4 is designed specifically to keep patients below the dose range where these rates emerge. Dysesthesia (Phase 3 signal, but not unique to retatrutide, a known GLP-1 class effect; The high-dose 7.2 mg semaglutide label reports ~22%). Abnormal skin sensations (tingling, burning, prickling, altered touch) reported in 20.9% of 12 mg patients and 8.8% of 9 mg patients, vs 0.7% on placebo. Phase 2 had shown a smaller signal (~7%). Events were mild, rarely led to discontinuation, did not always localize to the injection site, and most resolved during the trial. Mechanism unknown; Leading hypotheses involve glucagon-receptor activation on peripheral nerves or rapid metabolic shifts producing small-fiber neuropathic symptoms. This is not seen with semaglutide or tirzepatide and is currently the most distinctive non-GI finding of the TRIUMPH program. Heart rate. Dose-dependent increase of 5 to 10 bpm, peaking around week 24. Cardiac arrhythmias in 2 to 11% of retatrutide participants vs 2% placebo; None classified as serious. No MACE increase reported; Dedicated cardiovascular-outcomes data (TRIUMPH-3) not yet available. Liver enzymes. Transient ALT/AST elevations greater than 3 times ULN in approximately 1% of Phase 2 participants, usually tied to dose escalation. Mean ALT decreased or stayed stable at 48 weeks; A Phase 2a MASLD sub-analysis showed 86% of 12 mg participants achieved normal liver fat by 24 weeks.
• Serious class-level risks: pancreatitis (rare, class effect), gallbladder disease (gallstones, cholecystitis; Rapid weight loss raises baseline risk), acute kidney injury from dehydration secondary to GI losses, and diabetic retinopathy worsening (reported with semaglutide; Not yet characterized for retatrutide).
• Boxed-warning class concern: thyroid C-cell tumors in rodent studies apply to the entire GLP-1 class. Retatrutide has no FDA label yet, so the following are expected class cautions / trial-exclusion criteria rather than established contraindications: personal or family history of Medullary Thyroid Carcinoma (MTC) or MEN 2.
• Expected cautions (GLP-1 class / trial exclusions): personal or family history of MTC or MEN 2; Prior pancreatitis; Active gallbladder disease; Pregnancy, breastfeeding, or active attempts to conceive; Severe renal impairment (insufficient data); Severe hepatic impairment (insufficient data).
• Expected concerns include GI adverse effects, dehydration, gallbladder disease, pancreatitis signals, heart-rate changes, glucose effects, and excessive weight loss. Glucagon activity makes liver/metabolic context important. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.

A pragmatic baseline-and-escalation panel:

• Baseline (before first dose): CBC, CMP, HbA1c, fasting glucose, fasting insulin, lipid panel, TSH with free T4, amylase, lipase, ALT, AST, GGT, creatinine, eGFR, Cystatin C (more sensitive than creatinine during rapid weight loss), pregnancy test where applicable.
• At each dose change (slow titration): ALT/AST, creatinine, amylase/lipase. Catches early liver stress, dehydration-driven AKI, or pancreatic irritation before it becomes symptomatic.
• At stable maintenance (every 8 to 12 weeks): full repeat panel.
• Efficacy tracking: body weight and waist circumference (waist-to-height ratio captures visceral loss better than scale weight); Body composition by DEXA every 3 to 6 months to distinguish fat loss from sarcopenia; HbA1c (expect 1.3% to 2.0% reduction in diabetic subjects); Blood pressure (expect ~14 mmHg systolic reduction at 12 mg; Smaller at lower doses); Liver enzymes (expect improvement in ALT over 24 weeks if MASLD at baseline); Resting heart rate (track 5 to 10 bpm increase; Flag if greater than 15 bpm sustained).
• Safety tracking: pancreatic enzymes at baseline and if symptomatic; Gallbladder ultrasound if right-upper-quadrant pain develops; Neurological check at each visit for dysesthesia (document distribution, severity, whether progressive); Mental-health screen (rapid weight loss changes body image and may destabilize eating-disorder history).
• Track weight-loss rate, GI tolerance, hydration, glucose/A1c, lipids, liver enzymes, gallbladder symptoms, pulse, blood pressure, and nutrition/protein intake. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.

• FDA: Investigational in the current reference context. With TRIUMPH-1 and TRIUMPH-4 positive, an NDA filing is anticipated around late 2026 or 2027, contingent on the remaining pivotal readouts.
• Projected approval timeline: 2027, likely initially for obesity with comorbidities.
• GlobalData analyst projections: $15.6B peak annual sales by 2031.
• Anti-doping: while investigational and not approved as a therapeutic product, retatrutide can create S0 non-approved-substance risk for athletes. Do not claim it will automatically be S2-prohibited upon approval; GLP-1 agents have been monitored by WADA but are not automatically prohibited. If retatrutide is later approved, verify current status through WADA/Global DRO/USADA rather than assuming a class ban.
• Availability (April 2026): Clinical-trial settings only. No legal, FDA-approved commercial source. Gray-market “research chemical” vendors do offer retatrutide, but quality analyses have found significant purity and potency variability. For athletes, investigational retatrutide is high-risk under WADA S0 (non-approved pharmacological substance); If it is later approved, verify anti-doping status directly through WADA, USADA, or Global DRO. Gray-market warning Unapproved retatrutide products can involve mislabeling, incorrect dose, wrong molecule, contamination, or counterfeit supply. FDA enforcement letters and safety warnings around compounded or counterfeit incretin products are relevant cautionary context.
• Retatrutide is investigational and not FDA-approved. Research-market products are not equivalent to trial material or future approved labeling. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.

1. [A] Jastreboff et al. (2023). Triple-hormone-receptor agonist retatrutide for obesity. New England Journal of Medicine. PMID:37366315

2. [B] Rosenstock et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for type 2 diabetes. Lancet. PMID:37385280

3. [B] Sanyal et al. (2024). Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. PMID:38858523

4. [B] Coskun et al. (2025). Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. The Lancet Diabetes & Endocrinology, 13(8). PMID:40609566; DOI:10.1016/S22138587(25)00092-0.

5. [F] Abouelmagd et al. (2025). Efficacy and safety of retatrutide: systematic review and metaanalysis. PMC.

6. [H] Eli Lilly. (2026). Retatrutide clinical development / press information. Eli Lilly company communication.

7. [G] ClinicalTrials.gov. (2026). Retatrutide compared with tirzepatide in adults with obesity. ClinicalTrials.gov. NCT06662383

• Selank is a synthetic heptapeptide developed from the immunomodulatory peptide tuftsin.
• It is commonly grouped as an anxiolytic/nootropic peptide.
• Selank is a tuftsin-derived anxiolytic/nootropic peptide used mainly intranasally in regional/community contexts. It is distinct from Semax because its intended profile is more anxiolytic than activating.

• Proposed mechanisms include modulation of enkephalinase activity, GABAergic tone, serotonergic signaling, immune-cytokine effects, and stress-response gene expression.
• These mechanisms are not equivalent to a single approved-drug pathway.
• Mechanisms discussed include GABAergic modulation, monoamine effects, immune-neuropeptide signaling, and stress-response gene expression. It does not deliver immediate, benzodiazepine-like anxiolysis. The mechanism here is a plausibility map, not proof of a clinical outcome.

• The evidence base includes Russian clinical and mechanistic work plus community experience.
• It is stronger than pure forum lore but weaker than large multicenter FDA-style trials for anxiety disorders.
• Regional human and preclinical literature exists, but Western regulatory-grade evidence is limited. Community reports are useful context but not definitive efficacy proof. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.

Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions for you.

• Protocol 1: Clinical/Trial Protocols [Clinical/Human Trial]; Route: Intranasal; Dose: 0.1% Solution: 2–3 drops per nostril; Daily Dose Total: 400 mcg – 1,200 mcg; Frequency: 2 to 3 times daily; Timing: During acute anxiety / chronically; Duration: 14 days; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 2: Common Biohacker Protocols [Community/Biohacker/Anecdotal]; Route: Intranasal; Dose: 250 mcg – 500 mcg (per dose); Daily Dose Total: 500 mcg – 1,000 mcg; Frequency: 1 to 2 times daily; Timing: Morning or before stress events; Duration: 2 to 4 weeks (or as needed); Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 3: Subcutaneous researcher note [Research/Experimental]; Route: Subcutaneous (SC); Dose: 100 mcg - 300 mcg; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Intranasal is the dominant route in community and regional use. Dose-per-spray, concentration, nasal technique, and preservative tolerance matter. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.

• Time until steady state: not calculable.
• Half-life basis: reliable modern human PK by common intranasal and injectable products is not established. Reported effects may last longer than measurable plasma exposure.
• Beginner translation: Selank is better thought of as a short-acting neuroactive signal with uncertain exposure, not a drug with a validated accumulation schedule.
• Practical interpretation: Track anxiety scales, sleep, mood, nasal irritation, and interactions with other neuroactive substances.
• Intranasal exposure depends heavily on formulation and technique. CNS effects cannot be assumed from simple nasal administration, and degradation may be rapid. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.

• Selank is often paired conceptually with Semax: Semax for drive/focus and Selank for calm.
• Combining with benzodiazepines, alcohol, phenibut, SSRIs, stimulants, or other psychoactive agents requires caution and clinician input.
• Often paired with Semax, magnesium, anxiolytic supplements, or sleep protocols. Combining with sedatives or many CNS agents can obscure whether anxiety truly improved. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.

• Potential side effects include nasal irritation, altered taste, headache, fatigue, mood changes, or sleep disruption.
• Bipolar disorder, seizure disorders, pregnancy, breastfeeding, or complex psychiatric medication regimens require clinician review.
• Possible issues include nasal irritation, headache, sedation or paradoxical activation, and mood changes. Long-term use data remain limited. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.

• Use GAD-7 or similar anxiety scales, sleep tracking, mood logs, HRV if helpful, nasal tolerability, and adverse-event tracking.
• Do not use subjective calm as the only safety marker.
• Track anxiety scales, panic frequency, sleep, daytime sedation, irritability, nasal symptoms, and use of rescue anxiolytics. Objective symptom logs are more useful than single-day impressions. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.

• FDA: among the 12 peptides HHS removed from Category 2 on April 15, 2026. A specific PCAC review date is not yet set, and compounding-pharmacy access remains blocked pending final FDA action.
• Russia: approved since the late 1990s as an anxiolytic (Registry No. R N002514/01, IBP RAS); No new status change.
• WADA: not currently prohibited.
• Selank is not FDA-approved. Regional availability is distinct from U.S. approval or compounding acceptance. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.

1. [C] Zozulia et al. (2008). [Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia]. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 108(4), 38-48. PMID:18454096.

2. [D] Volkova et al. (2016). Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Frontiers in Pharmacology, 7, 31. PMID:26924987; PMCID:PMC4757669; DOI:10.3389/fphar.2016.00031.

3. [F] Vyunova et al. (2018). Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein and Peptide Letters, 25(10), 914-923. PMID:30255741; DOI:10.2174/0929866525666180925144642.

4. [D] Kasian et al. (2017). Peptide Selank enhances the effect of diazepam in reducing anxiety in unpredictable chronic mild stress. Behavioural Brain Research. PMID:28280289

5. [D] Kolik et al. (2014). Efficacy of peptide anxiolytic Selank during modeling of withdrawal syndrome in rats with stable alcoholic motivation. Bulletin of Experimental Biology and Medicine, 157(1), 526. PMID:24913576.

6. [D] Pavlov et al. (2005). Effect of new synthetic anxiolytic Selank on gastric wall blood flow and mesenteric lymphatic vessel contractility in anesthetized rats. Rossiiskii Fiziologicheskii Zhurnal imeni I.M. Sechenova, 91(2), 178-183. PMID:15835541.

7. [RouteEvidence] FDA. Certain bulk drug substances for use in compounding that may present significant safety risks.

8. [RouteEvidence] Zozulia et al. Efficacy and possible mechanisms of a new peptide anxiolytic Selank in GAD/neurasthenia. 2008.

• Semaglutide is a synthetic analog of the naturally occurring human Glucagon-Like Peptide-1 (GLP-1) hormone.
• Originally developed by Novo Nordisk, it has 94% structural homology to human GLP-1.
• Modifications include a “spacer” and a fatty acid chain that allow it to bind to albumin, drastically extending its half-life to approximately 7 days.
• It is classified as a long-acting GLP-1 receptor agonist (GLP-1 RA).
• Semaglutide is an approved GLP-1 receptor agonist with distinct injection and oral tablet formulations. Oral semaglutide success is formulation-specific and does not prove that arbitrary oral peptides work.

The Multi-System Metabolic Master Semaglutide operates by activating GLP-1 receptors in three primary areas:

• The Brain (Hypothalamus): It signals the brain to increase feelings of satiety (fullness) and significantly reduce food cravings (“food noise”).
• The Stomach: It slows gastric emptying, keeping food in the stomach longer and extending the sensation of fullness after meals.
• The Pancreas/Liver: It stimulates glucose-dependent insulin secretion (only when blood sugar is high) and suppresses glucagon release, which prevents the liver from dumping excess sugar into the blood.
• It activates GLP-1 receptors to reduce appetite, slow gastric emptying, improve glucose-dependent insulin secretion, and reduce glucagon. Effects are dose-, indication-, and formulation-specific. The mechanism here is a plausibility map, not proof of a clinical outcome.

The “Oral Breakthrough”: On December 22, 2025, the FDA approved the first oral Wegovy pill (semaglutide 25 mg daily) for weight loss, achieving 16.6% mean weight loss with full adherence (13.6% in intention-to-treat analysis). Full US launch began January 2026.

• Wegovy HD (March 2026): FDA approved Wegovy HD (semaglutide 7.2 mg injection) on March 19, 2026, delivering 20.7% mean weight loss, the highest for any semaglutide injection. Available April 2026.
• Orforglipron / Foundayo (April 2026): Eli Lilly received FDA approval for Foundayo (orforglipron), a once-daily oral small-molecule GLP-1, on April 1, 2026. First oral GLP-1 that can be taken any time of day without food or water restrictions. ~12.4% weight loss at highest dose. Cardiovascular &
• Kidney Benefits: 2025 research expanded its use to reducing major adverse cardiovascular events (MACE) and chronic kidney disease (CKD) progression in adults with Type 2 Diabetes.
• MASH Treatment: Clinical trials in late 2025 have validated semaglutide’s efficacy in treating Metabolic Dysfunction-Associated Steatohepatitis (MASH), reducing liver fibrosis in non-cirrhotic patients.
• Weight Regain Data: A 2026 meta-analysis confirms “rapid weight regain” upon cessation of GLP-1 therapy without a comprehensive maintenance plan, reinforcing the drug as a long-term management tool.
• Semaglutide has strong clinical trial and label evidence for diabetes/weight/CV contexts depending on product. This is different from most research peptides in the guide. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.

Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions for you.

• Protocol 1: WEGOVY injectable semaglutide FDA-label escalation [FDA/Approved/Label]; Route: Subcutaneous injection; Dose: WEGOVY injection: 0.25 mg weekly weeks 1-4; 0.5 mg weeks 5-8; 1 mg weeks 9-12; 1.7 mg weeks 13-16; Maintenance week 17 onward per indication.; Frequency: Once weekly; Timing: Same day each week; Abdomen, thigh, or upper arm; Any time of day with or without meals; Duration: Escalation over at least 16 weeks; Chronic maintenance if clinically appropriate; Max: Weight reduction adults: 1.7 or 2.4 mg weekly (2.4 mg recommended); If 2.4 mg tolerated ≥4 weeks and additional reduction is indicated, may increase to 7.2 mg weekly per 2026 label.; Titration/loading: Delay escalation 4 weeks if not tolerated. Pediatric weight maintenance: 2.4 mg recommended or 1.7 mg. MASH: 2.4 mg weekly, decrease to 1.7 if not tolerated.; Status: Yes - FDA-approved label/product protocol for labeled indications only.
• Protocol 2: Oral semaglutide FDA-label protocols: WEGOVY tablets vs RYBELSUS/OZEMPIC tablets [FDA/Approved/Label]; Route: Oral tablet; Dose: WEGOVY tablets: 1.5 mg daily days 1-30 → 4 mg days 31-60 → 9 mg days 61-90 → 25 mg daily day 91 onward. RYBELSUS: 3 mg daily days 1-30 → 7 mg daily days 31-60 → maintain 7 mg or increase to 14 mg daily on day 61+ if needed.; Frequency: Once daily; Timing: Morning, empty stomach, with up to 4 oz water; Wait at least 30 minutes before food, beverage, or other oral medication.; Duration: Daily chronic therapy per labeled indication and response/tolerability; Max: WEGOVY tablets: 25 mg daily. RYBELSUS: 14 mg daily. Any 50 mg oral semaglutide row is research/non-FDA unless tied to a specific approved product label.; Titration/loading: Do not combine the WEGOVY tablet titration and RYBELSUS titration as though they are interchangeable; They are separate labeled products/regimens.; Status: Yes - FDA-approved label/product protocols for their respective labeled indications only.
• Protocol 3: WEGOVY FDA-label escalation to maintenance [FDA/Approved/Label]; Route: Subcutaneous injection; Dose: WEGOVY injection initiation 0.25 mg weekly; Titrate 0.5, 1, 1.7 mg at 4-week intervals toward indication-specific maintenance.; Frequency: Once weekly; Duration: Escalate every 4 weeks per label to maintenance; Max: 2.4 mg weekly recommended maintenance for most weight/CV/MASH contexts; Adult weight-reduction label allows increase to 7.2 mg weekly if 2.4 mg tolerated ≥4 weeks and additional weight reduction is clinically indicated.; Titration/loading: Weeks 1-4: 0.25 mg; Weeks 5-8: 0.5 mg; Weeks 9-12: 1 mg; Weeks 13-16: 1.7 mg; Week 17 onward: 1.7/2.4 mg or 7.2 mg in eligible adult weight-reduction context.; Status: Yes - FDA-approved label/product protocol for labeled indication only.
• Protocol 4: WEGOVY HD 7.2 mg FDA-label adult weight-reduction escalation ceiling [FDA/Approved/Label]; Route: Subcutaneous injection; Dose: 7.2 mg once weekly only after WEGOVY 2.4 mg once weekly has been tolerated for at least 4 weeks and additional weight reduction is clinically indicated.; Frequency: Once weekly; Timing: Same day each week; Abdomen, thigh, or upper arm; Duration: Adult weight-reduction maintenance/escalation context after standard WEGOVY titration; Max: 7.2 mg SC once weekly for eligible adult weight-reduction context under 2026 WEGOVY label; Titration/loading: Standard WEGOVY titration to 2.4 mg first; Tolerate 2.4 mg ≥4 weeks before 7.2 mg escalation.; Status: Yes - FDA-approved label/product protocol for labeled adult weight-reduction context only.
• Label titration and product form control dosing. Compounded or salt-form products are not equivalent to approved branded products without clear legal and quality context. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.

• Half-life basis: Approximately 1 week. This is label-supported for semaglutide products; It also explains why missed-dose and washout windows are long.
• Estimated time until steady state: 4-5 weeks on once-weekly dosing.
• Beginner translation: This estimate uses the standard four-to-five-half-life convention. It describes when plasma exposure would be expected to approach a plateau during repeated dosing, not when the desired outcome is complete.
• Practical interpretation: Semaglutide has an exceptionally long half-life (~165 hours, ~1 week) due to its albumin-binding fatty-acid side chain, enabling once-weekly subcutaneous dosing. The oral form (Rybelsus, Wegovy Pill) uses the SNAC absorption enhancer to overcome low intrinsic GI bioavailability and is dosed daily on an empty stomach. Steady-state plasma concentrations are reached after 4 to 5 weeks of consistent dosing. Feature Semaglutide (Wegovy) Tirzepatide (Zepbound) Retatrutide (Triple) Targets GLP-1 only GLP-1 + GIP GLP-1 + GIP + Glucagon Avg Weight Loss ~15% ~21% ~24% (Phase 2 data) Formulation Injection & Pill Injection Only Injection Only Side Effects Standard GI Lower GI (relative) Higher heart rate risk
• Weekly SC semaglutide and daily oral semaglutide have different exposure logic. Oral tablets rely on SNAC/formulation and strict administration conditions. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.

L-Carnitine: Often co-administered (especially in compounded versions) to assist with fatty acid transport during rapid weight loss.

• BPC-157: Researched as a potential stack to mitigate the “nausea” and GI inflammation side effects common with GLP-1s.
• Metformin: Frequently used alongside semaglutide to provide synergistic blood sugar control and weight loss.
• Stacking with tirzepatide, retatrutide, cagrilintide, or other appetite agents increases overlapping GI and nutrition risks. Combination therapy should be product- and clinician-directed. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.

• Gastrointestinal (Most Common): Nausea (44%), diarrhea (30%), and vomiting. These are usually transient and occur during dose escalation. “Semaglutide Face/Body”: Rapid weight loss can lead to loss of facial volume and muscle mass; Protein-heavy diets and resistance training are recommended.
• Serious Risks: Pancreatitis, gallbladder disease, and acute kidney injury (often due to dehydration from vomiting/diarrhea).
• Boxed Warning: Contraindicated in patients with a personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• Monitor GI intolerance, pancreatitis/gallbladder symptoms, dehydration/renal injury, hypoglycemia with insulin/secretagogues, thyroid C-cell warning context, and malnutrition from overly rapid weight loss. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.

• HgbA1c & Fasting Glucose: Primary markers for metabolic improvement.
• Amylase/Lipase: To monitor for asymptomatic pancreatic stress.
• Cystatin C: Preferred over Creatinine in 2026 for monitoring kidney function during rapid weight loss.
• Gallbladder Ultrasound: Indicated if the patient experiences severe right-side abdominal pain.
• Track weight-loss rate, glucose/A1c, renal function if severe GI symptoms occur, gallbladder symptoms, nutrition/protein, lean mass, and oral medication absorption concerns. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.

• FDA: Approved (Ozempic, Wegovy, Rybelsus). Wegovy approved for MACE risk reduction in obesity (2024). Expanded cardiovascular-risk-reduction label pending (expected 2026).
• EU (EMA): Approved. Added stroke-risk-reduction label September 2025 based on SOUL trial.
• Compounding Status: Novo Nordisk is actively opposing compounded semaglutide; The legal status of compounding remains contested in 2026.
• April 2026 (503B Bulks List): FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound these drugs from bulk substances now that FDA-approved versions are widely available. Commissioner Marty Makary framed the action as protecting patients and preserving drug-approval integrity. If finalized, 503B outsourcing facilities cannot compound these drugs from bulk powder, narrowing compounding lanes left after the 2024-2025 shortage-list removals. 503A pharmacies operate under a separate framework and are not directly addressed by this action.
• WADA: Not on prohibited list.
• Availability: Prescription pharmaceutical; Widely available through standard pharmacies.
• Semaglutide has FDA-approved products, while bulk-compounded and research-market semaglutide raise separate legal and quality issues. FDA has proposed excluding semaglutide from the 503B bulks list. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.

1. [A] Wilding et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. PMID:33567185

2. [A] Marso et al. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine. PMID:27633186

3. [A] Husain et al. (2019). Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine.

4. [A] Lincoff et al. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine. PMID:37952131

5. [A] Deanfield et al. (2025). Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial. The Lancet. 406(10516):2257-2268. PMID:41138739; DOI:10.1016/S0140-6736(25)01375-3

6. [G] FDA. (2025). Wegovy (semaglutide) prescribing information. FDA AccessData.

7. [G] FDA. (2025). Ozempic (semaglutide) prescribing information. FDA AccessData.

8. [RouteEvidence] DailyMed WEGOVY semaglutide injection and tablet label.

9. [RouteEvidence] DailyMed RYBELSUS / OZEMPIC oral semaglutide tablet label.

10. [RouteEvidence] Knop et al. Oral semaglutide 50 mg once daily in adults with overweight or obesity (OASIS 1). Lancet. 2023.

• Semax is a synthetic heptapeptide analog of a fragment of the Adrenocorticotropic Hormone (ACTH 4-10).
• It was developed in the 1980s and 90s by the Institute of Molecular Genetics of the Russian Academy of Sciences.
• Unlike the parent hormone, Semax has no endocrine (hormonal) activity.
• It is classified as a nootropic and neuroprotective agent and has been included on the Russian List of Vital and Essential Drugs since 2001.
• Semax is an ACTH(4-10)-derived heptapeptide analog used intranasally in regional neuro contexts. It is not interchangeable with Adamax or every Semax derivative.

• Semax works through several pathways to enhance brain function and protect neural tissue: BDNF & NGF Induction: It significantly increases the expression of Brain-Derived Neurotrophic Factor (BDNF) and Nerve Growth Factor (NGF) in the hippocampus and cerebral cortex, which are critical for neuroplasticity and neuron survival.
• Melanocortin System Modulation: It acts on melanocortin receptors (specifically MC4 and MC5) in the brain, which helps regulate focus, learning, and neuroinflammation. Dopamine &
• Serotonin Stabilization: It prevents the breakdown of enkephalins and modulates the levels of dopamine and serotonin, leading to improved mood and motivation.
• Transcription Factor Activation: It influences the expression of genes involved in the vascular system and immune response in the brain, particularly during periods of hypoxia (low oxygen).
• Mechanisms include melanocortin-related signaling, BDNF/neurotrophin modulation, neuroprotection, and monoamine/cognitive effects. It is not a stimulant in the classic amphetamine sense. The mechanism here is a plausibility map, not proof of a clinical outcome.

• Stroke Recovery: Widely used clinically to reduce the volume of brain damage after an ischemic stroke and to accelerate the recovery of motor and cognitive functions. ADHD &
• Focus: Research indicates that Semax improves attention span and memory in individuals with ADHD and healthy subjects under high-stress/high-workload environments.
• Neuroprotection: Studies show it protects neurons against oxidative stress, glutamate excitotoxicity, and heavy metal toxicity.
• Optic Nerve Repair: Evidence suggests Semax can be used to treat optic nerve damage (glaucoma or optic neuropathy) by improving retinal cell survival.
• There is regional human literature and growing preclinical work, but not FDA-level proof for cognition or stroke recovery. The best wording is studied but not broadly approved. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.

Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions for you.

• Protocol 1: Clinical/Trial Protocols [Clinical/Human Trial]; Route: Intranasal spray; Dose: 0.1% Solution: 2–3 drops per nostril (2–3× daily); 1.0% Solution: 1–2 drops per nostril (Acute stroke); Frequency: 2 to 3 times daily; Timing: Post-stroke or early morning; Duration: 10 to 14 days; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 2: Common Biohacker Protocols [Community/Biohacker/Anecdotal]; Route: Intranasal spray; Dose: 0.1%: 200 mcg – 600 mcg (per dose); 1.0%: 1 mg – 2 mg (Advanced use); Frequency: 1 to 2 times daily; Timing: Morning or prior to deep work; Duration: 2 to 4 weeks; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 3: Subcutaneous injection note [Community/Biohacker/Anecdotal]; Route: Subcutaneous (SC); Dose: 100 mcg – 500 mcg; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Intranasal use is the main practical route. Spray concentration, total daily volume, and nasal technique determine actual exposure. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.

• Time until steady state: not calculable.
• Half-life basis: Very short systemic exposure is often described, but reliable human PK is limited. Intranasal CNS-effect claims are pharmacodynamic, not a stable plasma concentration target.
• Beginner translation: this is a deliberately conservative read. A missing steady-state number does not mean the compound has no effect; It means the available human PK data are not strong enough to justify a precise accumulation estimate for common use patterns.
• Half-life: Very short systemically (minutes), but its influence on BDNF and gene expression lasts for 20-24 hours.
• Delivery: intranasal is the best Semax-specific route in the guide, but it is potential CNS-relevant nasal delivery rather than guaranteed direct-to-brain targeting. It is stable at room temperature for short periods but is best stored in the refrigerator for long-term use.
• Semax is short-lived, but downstream neurotrophin/gene-expression effects may last longer than plasma exposure. Do not equate half-life with duration of perceived focus. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.

• Selank: Frequently stacked with Selank. Semax provides the “gas” (focus/energy), while Selank provides the “brake” (calm/anxiety reduction), creating a balanced flow state.
• Stimulants: Often used to mitigate the “crash” from caffeine or ADHD medications due to its dopamine-stabilizing properties.
• Cerebrolysin: Combined in Russian hospitals for severe neurological rehabilitation.
• Often paired with Selank, nootropics, cholinergics, or mitochondrial/NAD strategies. Start singly when evaluating attention, anxiety, or sleep effects. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.

• Side Effects: Extremely well-tolerated. Rare reports of mild irritation of the nasal mucosa, transient headaches, or irritability if the dose is too high.
• Hair Loss Concern: A common (though largely anecdotal) concern in the biohacking community is that increased BDNF could potentially accelerate hair thinning in those predisposed to MPB; However, this is not reflected in clinical literature.
• Contraindications: History of seizures (threshold may be lowered) and pregnancy/breastfeeding.
• Possible adverse effects include headache, irritability, insomnia, anxiety shift, nasal irritation, and blood-pressure sensitivity in susceptible users. Long-term data are limited. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.

• Cognitive Tasks: Monitoring “time to completion” and error rates in complex tasks.
• Mood Tracking: Observation of anxiety levels and emotional resilience during high-stress periods.
• Sleep Quality: Ensuring the stimulatory effect does not lead to late-night insomnia.
• Track attention tasks, mood, anxiety, sleep latency, headache, nasal irritation, and timing relative to caffeine/stimulants. Use baseline comparisons. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.

• FDA: Semax was among the 12 peptides HHS removed from Category 2 on April 15, 2026. Scheduled for specific PCAC review on July 24, 2026 for the indications of cerebral ischemia and trigeminal neuralgia (FDA Docket FDA-2025-N-6895). Compounding-pharmacy access remains blocked pending final FDA action.
• Russia: Registered since 1994 for stroke rehabilitation.
• WADA: Not currently prohibited (has been subject to periodic reconsideration).
• Semax is not FDA-approved. PCAC review relates to compounding-list status, not approval as a cognitive drug. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.

1. [C] Gusev et al. (1997). [Effectiveness of Semax in acute period of hemispheric ischemic stroke]. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. PMID:11517472.

2. [E] Miasoedova et al. (1999). [Investigation of mechanisms of neuroprotective effect of Semax in acute ischemic stroke]. Russian-language peer-reviewed journal. PMID:10358912.

3. [C] Gusev et al. (2018). [The efficacy of Semax in the treatment of patients at different stages of ischemic stroke]. Russian-language peer-reviewed journal. PMID:29798983.

4. [D] Dolotov et al. (2003). The heptapeptide Semax stimulates BDNF expression in different areas of the rat brain in vivo. Doklady Biological Sciences. PMID:14556513

5. [D] Shadrina et al. (2010). Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action. Peer-reviewed article. PMID:19662538.

6. [D] Stavchanskii et al. (2011). [The effect of Semax and its C-end peptide PGP on expression of neurotrophins and their receptors in rat brain during incomplete global ischemia]. Russian-language peer-reviewed journal. PMID:22295573.

7. [D] Medvedeva et al. (2014). The peptide Semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis. BMC Genomics, 15, 228. PMID:24661604; PMCID:PMC3987924; DOI:10.1186/1471-2164-15-228.

8. [D] Inozemtseva et al. (2024). Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogs Semax and Melanotan II on male rats in a model of chronic unpredictable stress. European Journal of Pharmacology. 984:177068. PMID:39442746; DOI:10.1016/j.ejphar.2024.177068

9. [RouteEvidence] FDA. Certain bulk drug substances for use in compounding that may present significant safety risks.

10. [RouteEvidence] Lebedeva et al. Effects of Semax on the default mode network of the brain. Bull Exp Biol Med. 2018.

11. [RouteEvidence] Gusev et al. Effectiveness of Semax in acute hemispheric ischemic stroke. PubMed record.

• Sermorelin is not among the peptides affected by the 2023 Category 2 action or the 2026 reclassification.
• It has its own FDA-approval history (1997) for pediatric GH deficiency and has never been on the restricted list, which is a meaningful differentiator for clinicians seeking a regulatorily-settled GHRH analog.
• Sermorelin is a synthetic 29-amino acid peptide that represents the amino-terminal fragment of the naturally occurring human Growth Hormone-Releasing Hormone (GHRH).
• While natural GHRH is 44 amino acids long, researchers in the 1970s discovered that the first 29 amino acids contain the full biological potency.
• It is classified as a Growth Hormone Secretagogue (GHS) and was the first GHRH analog to be FDA-approved (though the brand name Geref was discontinued in 2008 for commercial reasons).
• Sermorelin is GHRH(1-29), a short-acting GHRH analog historically used in GH-axis testing/therapy contexts. It is distinct from CJC-DAC and ghrelin mimetics.

The Pituitary Stimulator Unlike GHRPs (like Ipamorelin) which mimic ghrelin, Sermorelin acts directly on the GHRH receptors:

• Direct Receptor Binding: It binds to the GHRH receptors in the anterior pituitary, stimulating the production and secretion of endogenous Growth Hormone.
• Preservation of Feedback Loops: Because it stimulates the pituitary rather than replacing GH (like synthetic HGH does), the body’s natural somatostatin feedback loop remains intact. This prevents “GH bleed” and reduces the risk of excessive hormone levels.
• Physiological Pulsatility: Sermorelin mimics the natural, pulsatile release of GH, which is essential for maintaining youthful metabolic function and avoiding receptor desensitization.
• Transcription Enhancement: It encourages the pituitary gland to increase the transcription of GH messenger RNA (mRNA), essentially “strengthening” the pituitary’s ability to produce its own hormones over time.
• It stimulates pituitary GHRH receptors, relying on pituitary capacity to release endogenous GH. It does not bypass the axis like exogenous GH. The mechanism here is a plausibility map, not proof of a clinical outcome.

• Muscle Preservation during GLP-1 Therapy: Sermorelin is sometimes used off-label as an ancillary aimed at preserving lean mass during semaglutide/tirzepatide weight loss, but this rests on low-certainty, largely anecdotal evidence rather than controlled trials.
• Sleep Architecture Improvement: 2025 research has solidified its role in increasing the duration of Stage 3/4 Deep Sleep, correlating with faster neuro-recovery and reduced morning brain fog.
• Neuroendocrine Aging: Recent 2026 findings explore Sermorelin’s potential to slow the decline of the pituitary-somatotropic axis, the first hormonal system to deteriorate with age.
• Cognitive Function: Emerging studies suggest that by restoring GH/IGF-1 levels to “young adult” ranges, Sermorelin may improve executive function and memory in the elderly.
• Clinical use history supports GH stimulation, especially diagnostic/deficiency contexts, but anti-aging/body-composition claims are less established. Response is variable with age, obesity, sleep, and baseline GH reserve. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.

Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions for you.

• Protocol 1: Anti-Aging / Wellness [Community/Biohacker/Anecdotal]; Route: Subcutaneous (SC); Nasal/buccal use is popular in some settings, but route efficacy and dose equivalence require product-specific PK/PD; Dose: 200 mcg – 300 mcg; Frequency: 5 days on / 2 days off; Timing: Fasted (Before Bed); Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 2: Performance / Recovery [Community/Biohacker/Anecdotal]; Route: Subcutaneous (SC); Dose: 300 mcg – 500 mcg; Frequency: 5 to 7 days a week; Timing: Fasted (Before Bed); Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Bedtime pulse-style protocols are common; 5-on/2-off is a convention, not proven necessary. Combining with ipamorelin is common, but that is a stack strategy rather than a standalone protocol. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.

• Time until steady state: about 55-60 minutes.
• Half-life basis: About 11-12 minutes after IV or SC administration in drug-reference summaries. The downstream GH pulse lasts longer than the peptide itself; Steady-state peptide concentration is not the desired endpoint.
• Beginner translation: This estimate uses the standard four-to-five-half-life convention. It describes when plasma exposure would be expected to approach a plateau during repeated dosing, not when the desired outcome is complete.
• Practical interpretation: Sermorelin has a very short plasma half-life (around 10 to 20 minutes), but its biological effect persists due to the natural pulsatile GH release it triggers. Subcutaneous administration produces a GH pulse within 15 to 30 minutes, with peak GH levels around 60 minutes. Because it works upstream of the pituitary, the body retains its own negative-feedback safety mechanisms.
• Route note: do not generalize intranasal/oral findings across GH secretagogues. Older GHRP-2 and hexarelin data, animal ipamorelin nasal PK, and community sermorelin/CJC nasal-buccal products are different evidence categories.
• Very short half-life supports pulsatile use. IGF-1 response and symptom outcomes are downstream and slower than the injection exposure. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.

• Ipamorelin: Often combined into a single injection. Ipamorelin inhibits somatostatin (the “brake”) while Sermorelin pushes the GHRH receptor (the “gas”), leading to a synergistic GH pulse.
• CJC-1295 (No DAC): Used for those who want a longer duration of GH release than Sermorelin alone can provide.
• TRT (Testosterone): Stacking with testosterone can improve the “anabolic environment,” as GH increases the sensitivity of androgen receptors.
• Stacking with ipamorelin or other GHRPs combines GHRH and GHS-R signals. Avoid layering with CJC-DAC or GH without a clear endocrine reason. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.

• Injection Site Reactions: Redness, itching, or swelling is the most common complaint (over 15% of users).
• Flushing: A temporary “warmth” or redness in the face/neck shortly after injection.
• Headache/Dizziness: Usually temporary as the body adjusts to increased GH levels.
• Thyroid Interaction: An underactive thyroid can interfere with Sermorelin’s efficacy; Clinicians often check TSH levels before starting therapy.
• Cancer Warning: Should not be used by individuals with active malignancies, as GH can stimulate the growth of existing tumors.
• Watch injection reactions, flushing, headache, edema, tingling, glucose changes, and high IGF-1. Cancer history, sleep apnea, and uncontrolled diabetes are caution contexts. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.

• Serum IGF-1: The most reliable way to monitor if the pituitary is responding to the Sermorelin signal.
• Fasting Insulin: To ensure the increased GH isn’t negatively impacting blood sugar regulation.
• Physical Assessments: Tracking changes in skin elasticity, waist-to-hip ratio, and recovery speed.
• Track IGF-1, fasting glucose/A1c, sleep, edema, blood pressure, weight/waist, and clinical symptoms. Lab timing should be consistent. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.

• FDA: Sermorelin was FDA-approved but the original brand (Geref) was withdrawn. In 2026, it is widely used offlabel and available through specialized compounding pharmacies.
• WADA: Strictly Banned in all competitive sports (S2 category) as it is a Growth Hormone Secretagogue.
• Compounding Status: While some peptides have faced 2023-2025 compounding bans, Sermorelin remains a staple in “Age Management” clinics due to its extensive history of safety data.
• Sermorelin's U.S. commercial history and current availability are not the same as broad FDA-approved anti-aging use. Clarify product and prescribing context. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.

1. [F] Prakash & Goa. (1999). Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. PMID:18031173

2. [C] Thorner et al. (1996). Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. Journal of Clinical Endocrinology & Metabolism, 81(3), 1189-1196. PMID:8772599; DOI:10.1210/jcem.81.3.8772599.

3. [C] Wilton et al. (1993). The growth hormone-releasing hormone analogue GHRH(1-29)-NH2 by intravenous and intranasal routes in healthy men. Acta Paediatrica, 82, 983-986. PMID:8329825.

4. [C] Spoudeas, Winrow, Hindmarsh, & Brook (1994). Low-dose growth hormone-releasing hormone tests: a dose-response study. European Journal of Endocrinology, 131(3), 238-245. PMID:7921207; DOI:10.1530/eje.0.1310238.

5. [C] Barron et al. (1985). Growth hormone responses to growth hormone-releasing hormone (1-29)-NH2 and a D-Ala2 analog in normal men. Peptides, 6, 575-577. PMID:2866496.

6. [C] Khorram et al. (1997). Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. Journal of Clinical Endocrinology & Metabolism, 82(5), 1472-1479. PMID:9141536; DOI:10.1210/jcem.82.5.3943.

7. [F] Walker. (2006). Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?. Clinical Interventions in Aging.

8. [G] WADA. (2026). International Standard: Prohibited List. World Anti-Doping Agency.

9. [RouteEvidence] Lewis et al. Intranasal human growth hormone induces IGF-1 comparable with SC injection with lower systemic exposure. 2015.

10. [RouteEvidence] Pihoker et al. Intranasal GHRP-2 in children of short stature. PubMed record.

11. [RouteEvidence] Johansen et al. Pharmacokinetic evaluation of ipamorelin and other peptidyl GH secretagogues with emphasis on nasal absorption. PubMed record.

• SS-31, also known as elamipretide, is a mitochondria-targeted tetrapeptide.
• The approved commercial product is FORZINITY for Barth syndrome; Research-grade SS-31 is not automatically interchangeable with the approved drug product.
• SS-31/elamipretide is a mitochondria-targeted tetrapeptide that binds cardiolipin-associated mitochondrial membranes. Approved Forzinity is a specific elamipretide product for Barth syndrome, not a general mitochondrial wellness peptide.

• Elamipretide binds cardiolipin and is intended to stabilize inner mitochondrial membrane function, support electron-transport efficiency, and reduce mitochondrial oxidative stress in the disease context studied.
• The mechanism centers on mitochondrial inner-membrane/cardiolipin stabilization and improved electron transport efficiency under stress. It does not simply increase energy for everyone. The mechanism here is a plausibility map, not proof of a clinical outcome.

• The approved Barth syndrome indication is based on an intermediate endpoint involving muscle strength and remains subject to confirmatory-trial requirements.
• Other disease programs and wellness uses are separate and do not generalize.
• Elamipretide has disease-specific trial and regulatory evidence, culminating in accelerated approval for Barth syndrome. Evidence for broad fatigue, aging, or athletic use remains separate and unproven. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.

Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions for you.

• Protocol 1: Clinical (FDA/Barth) Protocol [FDA/Approved/Label]; Route: Subcutaneous (SC); Dose: 40 mg (Fixed SC dose); Frequency: Once daily; Duration: Chronic (for Barth Syndrome); Status: Yes - FDA-approved label/product protocol for the labeled indication only.
• Protocol 2: Common Research/Biohacker [Community/Biohacker/Anecdotal]; Route: Subcutaneous (SC) or IV Infusion; Dose: 10 mg – 40 mg; Frequency: Once daily; Duration: 4 to 8 weeks; Max: IV Dose: 0.05 mg/kg/h (Slow infusion); Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 3: FORZINITY FDA-label Barth syndrome protocol [FDA/Approved/Label]; Route: Subcutaneous injection; Dose: 40 mg; Frequency: Once daily; Timing: Same time each day; Duration: Chronic labeled use; Accelerated approval context; Status: Yes - FDA-approved label/product protocol for Barth syndrome in patients weighing at least 30 kg only.
• Forzinity label dosing is separate from research-market SS-31 dosing reports. Approved product instructions, missed-dose rules, and no-mix instructions override general peptide logic. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.

• Time until steady state: Per label language – minimal accumulation with daily dosing.
• Half-life basis: the FORZINITY label gives daily subcutaneous PK with minimal accumulation but does not present a simple half-life-based steady-state estimate suitable for general extrapolation.
• Beginner translation: If you're new, this means do not force a generic half-life rule when the label frames the product differently.
• Practical interpretation: For approved Barth syndrome use, follow the label and specialist care. Do not extrapolate PK to general mitochondrial optimization.
• Daily SC product context is relevant for Forzinity, but research formulations may not match. Mitochondrial targeting and tissue disease context matter more than a generic half-life. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.

• MOTS-c, NAD+, coenzyme Q10, exercise, or photobiomodulation pairings are mechanistic or anecdotal unless tested for the same indication. Mitochondrial stacks should not be portrayed as label-supported.
• Often discussed with MOTS-c, Humanin, NAD, CoQ10, or exercise/mitochondrial stacks. Avoid same-syringe mixing because the approved label specifically says not to mix Forzinity with other medicines in the same syringe. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.

• Use the current FORZINITY label for adverse reactions, warnings, and monitoring in approved use.
• Research-grade SS-31 has separate quality, sterility, and regulatory risks.
• Injection reactions, hypersensitivity, disease-specific monitoring, and unknown off-label long-term use are key. Approved status for Barth syndrome does not generalize safety to healthy users. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.

• In approved disease use, monitoring is disease-specific and clinician-directed.
• General ATP tests or wellness mitochondrial panels are not validated endpoints for broad use.
• Track functional capacity, fatigue, muscle symptoms, injection reactions, and disease-specific markers when used clinically. In research contexts, objective exercise tolerance measures are more useful than vague energy ratings. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.

• FDA: accelerated approval for FORZINITY in Barth syndrome patients weighing at least 30 kg.
• Not approved for general mitochondrial optimization.
• Other jurisdictions require current-status verification.
• Forzinity/elamipretide is FDA accelerated-approved for Barth syndrome in patients weighing at least 30 kg. SS-31 research products are not automatically equivalent to the approved drug. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.

1. [G] FDA. (2025). Forzinity (elamipretide) prescribing information. FDA AccessData.

2. [G] FDA. (2025). Forzinity (elamipretide) integrated review. FDA.

3. [B] Karaa et al. (2018). Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology. PMID:29500292

4. [B] Karaa et al. (2020). A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy. Neurology. PMID:32096613

5. [A] Karaa et al. (2023). MMPOWER-3: randomized trial of elamipretide in primary mitochondrial myopathy. Annals of Neurology. PMID:37268435

6. [B] Reid Thompson et al. (2021). A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. Genetics in Medicine, 23(3), 471-478. PMID:33077895; PMCID:PMC7935714; DOI:10.1038/s41436-020-01006-8.

7. [C] Thompson et al. (2024). Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER. Genetics in Medicine, 26(7), 101138. PMID:38602181; DOI:10.1016/j.gim.2024.101138.

8. [E] Mitchell et al. (2020). The mitochondria-targeted peptide SS-31 binds lipid bilayers and modulates surface electrostatics as a key component of its mechanism of action. Journal of Biological Chemistry, 295(21), 7452-7469. PMID:32273339; PMCID:PMC7247319; DOI:10.1074/jbc.RA119.012094.

9. [F] Tung et al. (2025). Elamipretide: a review of its structure, mechanism of action, and therapeutic potential. International Journal of Molecular Sciences, 26(3), 944. PMID:39940712; PMCID:PMC11816484; DOI:10.3390/ijms26030944.

10. [F] Shirley (2025). Elamipretide: First Approval. Drugs. PMID:41335372.

The first classification step is identity control. TB-500 and full-length thymosin beta-4/Tβ4 should not be used as interchangeable names unless the product documentation proves it.

• FDA-described TB-500 is thymosin beta-4 fragment LKKTETQ, a heptapeptide fragment.
• Full-length thymosin beta-4/Tβ4/timbetasin is a naturally occurring 43-amino-acid actin-sequestering peptide found in many tissues and wound contexts.
• Vendor-labeled TB-500 may refer to LKKTETQ fragment, N-acetylated fragment, full-length Tβ4, salt forms, a blend component, or inaccurately labeled material.
• The key identity issue is sequence: LKKTETQ and full-length Tβ4 have different residue profiles, likely different PK, and different evidence boundaries.
• COA review to distinguish exact makeup should include full HPLC/UPLC purity, high-resolution mass-spec identity, expected molecular mass, sequence confirmation when possible, endotoxin testing, sterility testing, and blend-specific content where applicable.
• FDA-described TB-500/LKKTETQ fragment, full-length thymosin beta-4, and unresolved vendor-labeled TB-500 are three different things. These are not interchangeable for sequence, mechanism, route evidence, or oxidation assumptions.

The repair rationale for thymosin beta-4-family products centers on actin/cell-migration biology, but the strength and meaning of that claim depends on the exact identity.

• Full-length Tβ4: sequesters G-actin and helps regulate cytoskeletal organization; This is central to cell movement and repair-cell migration.
• TB-500/LKKTETQ: an active-region fragment associated with the actin-binding region; Do not assume it reproduces full-length Tβ4 distribution, half-life, or all biological functions.
• Cell migration: epithelial cells, endothelial cells, keratinocytes, and other repair cells must migrate across damaged tissue; Tβ4-family biology is repeatedly linked to this process.
• Angiogenesis: repair requires blood-vessel support; This may help explain wound-healing signals but also raises cancer and abnormal-angiogenesis caution.
• Anti-inflammatory/anti-fibrotic effects: strongest as full-length Tβ4-family research context, not as proof for every TB-500-labeled product.
• Product-specific uncertainty: fragment, full-length, recombinant, salt, and blend products can differ in receptor/signaling context, immunogenicity, stability, and PK.
• Full-length Tβ4 biology includes actin-binding, cell migration, angiogenesis, and wound-repair signaling. The LKKTETQ fragment may capture only part of this biology, so mechanism claims hold only when they match identity. The mechanism here is a plausibility map, not proof of a clinical outcome.

• Identity distinction: FDA identifies TB-500 as thymosin beta-4 fragment LKKTETQ in its compounding safety-risk discussion; That is not the same as full-length 43-amino-acid Tβ4.
• Full-length Tβ4 research: corneal epithelial healing, dry eye, neurotrophic keratopathy, wound repair, inflammatory modulation, and cardiac contexts are mostly Tβ4-family/full-length evidence, not generic TB-500 validation.
• Human safety/PK research: human Phase 1 work with recombinant human thymosin beta-4 reported tolerability and collected pharmacokinetic and anti-drug-antibody data; This supports continued research but does not validate unregulated TB-500 products.
• Fragment/TB-500 gap: FDA states it has not identified human exposure data for drug products containing thymosin beta-4 fragment LKKTETQ/TB-500 in the compounding safety-risk context.
• Sports-medicine translation: animal, equine, and anti-doping detection literature contribute to TB-500’s reputation in injury recovery; These data do not establish an approved human injury-repair regimen.
• Full-length Tβ4 has more topical/ophthalmic and wound-related investigational literature than the short TB-500 fragment. Community injury-repair reports do not establish efficacy for either product class. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.

Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions for you.

• Protocol 1: Intensive Repair Protocol [Community/Biohacker/Anecdotal]; Route: Subcutaneous (SC) or Intramuscular (IM); Dose: Weekly Dose: 5.0 mg – 10.0 mg; Frequency: Split into 2 or 3 injections; Duration: 4 to 6 weeks; Max: 15.0 mg (per week, acute); Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written; Identity note: rows do not establish equivalence between TB-500 fragment, full-length Tβ4, and unresolved vendor products.
• Protocol 2: Maintenance / Chronic Use [Community/Biohacker/Anecdotal]; Route: Subcutaneous (SC) or Intramuscular (IM); Dose: Weekly Dose: 2.0 mg – 5.0 mg; Frequency: Once weekly; Duration: 8 to 12 weeks; Max: 5.0 mg (per week); Titration/loading: Biohacker loading: 5 mg/week (e.g., 2.5 mg Monday/Thursday) for first 4 weeks, then 2 mg/week for another 4 weeks.; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written; Identity note: rows do not establish equivalence between TB-500 fragment, full-length Tβ4, and unresolved vendor products.
• Community protocols often use loading/maintenance-style cycles, but those are not trial-validated. The exact sequence and vial identity matter before comparing doses. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.

• Time until steady state: not calculable for generic TB-500 because product identity varies. Full-length Tβ4 pharmacokinetic data does not apply to the LKKTETQ fragment unless product, route, and formulation match.
• Half-life basis: no single validated human half-life applies to TB-500-family products. Full-length Tβ4, recombinant Tβ4, LKKTETQ fragment, N-acetylated fragments, and blends are different pharmacokinetic questions.
• Calculator rule: exclude generic TB-500/Tβ4-family products from steady-state, missed-dose, and loading-dose calculators unless exact human PK inputs are available for that specific product and route.
• Why this matters: weekly dosing patterns used online are driven more by community convention than by a validated plasma steady-state target.
• Different Tβ4-family identities can have different degradation, tissue distribution, and assay behavior. The calculator cannot assume one half-life or oxidation profile for all TB-500-labeled products. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.

• BPC-157: common Wolverine pairing. Mechanistic framing is BPC-157 as vascular/fibroblast/gut-repair signal plus TB-500-family product as actin/cell-migration signal. The combination is popular but not proven superior in controlled human trials.
• GHK-Cu: common Glow add-on for skin, collagen, scar, and matrix remodeling. GHK-Cu does not automatically destroy TB-500/LKKTETQ, but stability is exact-formulation-specific.
• GLOW stack: BPC-157 + GHK-Cu + TB-500-family product. Always specify whether the third component is LKKTETQ fragment or full-length Tβ4.
• KPV: common Klow add-on when the target is gut, skin inflammation, autoimmune-type irritation, or mucosal inflammation.
• KLOW stack: GHK-Cu + BPC-157 + KPV + TB-500-family product. This is a market/community stack, not a standardized clinical product.
• Stacking caution: repair, angiogenesis, and product-identity uncertainty can increase theoretical cancer/angiogenesis concern and makes benefit/harm attribution difficult.
• Common stacks include BPC-157, GHK-Cu, KPV, and rehab protocols. Same-vial blend claims depend on whether the product is LKKTETQ fragment or full-length Tβ4 and on exact stability data. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.

• Product-identity risk: the biggest TB-500-specific safety issue is uncertainty about what is actually in the vial. A TB-500 label does not prove LKKTETQ fragment, full-length Tβ4, purity, sterility, endotoxin safety, dose accuracy, or stability.
• Residue/oxidation risk: TB-500/LKKTETQ lacks methionine/cysteine/tryptophan; Full-length Tβ4 contains methionine and behaves differently in copper/oxidation assessments.
• Immunogenicity and impurity risk: FDA highlights immunogenicity, aggregation, peptide-related impurities, API characterization, and lack of human exposure data for thymosin beta-4 fragment products.
• Reported side effects: community reports include lethargy, head pressure, transient flu-like sensations, injection-site reactions, water retention, unusual swelling, and sleep changes. True incidence is unknown.
• Contraindications/cautions: active malignancy, suspicious lesions, recent cancer treatment, proliferative retinopathy, severe cardiovascular disease, pregnancy, breastfeeding, active infection, and athlete testing status.
• Concerns include product misidentity, angiogenesis/fibrosis theoretical issues, immune response, injection risk, and lack of robust human safety data. Full-length and fragment risks do not merge blindly. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.

• Injury tracking: Range of motion, pain score, strength testing, standardized photos for wounds, ultrasound/MRI for structural injuries, and return-to-training milestones.
• Safety tracking: Injection-site log, temperature/fever log, CBC/CMP when cycles are prolonged, and clinical evaluation for any unexplained swelling, shortness of breath, chest pain, severe headache, or signs of infection.
• Quality tracking: Record vendor, lot number, COA date, mass-spec result, purity, endotoxin value, reconstitution date, and storage conditions.
• Identity tracking: record whether the product is TB-500/LKKTETQ, full-length Tβ4, N-acetylated fragment, salt form, blend, or unknown; Record expected molecular mass and mass-spec result.
• Track injury diagnosis, pain/function, swelling, range of motion, rehab load, and adverse reactions. Avoid returning to training solely because pain improves. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.

• FDA/compounding: FDA’s safety-risk page identifies thymosin beta-4 fragment LKKTETQ, also known as TB-500, and flags lack of human exposure data plus immunogenicity/aggregation/peptide-impurity concerns. FDA review does not equal approval.
• Full-length Tβ4 distinction: full-length thymosin beta-4/Tβ4 is a separate molecule from LKKTETQ TB-500 and is named separately in regulatory and evidence discussions.
• Anti-doping: WADA lists thymosin beta-4 and derivatives such as TB-500 as prohibited. Athletes should treat TB-500-family products as banned unless a qualified anti-doping professional confirms otherwise.
• Availability: mostly research-use-only vendors and nonstandard wellness channels. Product identity and sequence verification are critical.
• FDA describes TB-500 as thymosin beta-4 fragment LKKTETQ in safety-risk materials and has raised safety/characterization concerns. Full-length Tβ4 evidence does not confer approval on TB-500 products. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.

1. [D] Sosne et al. (2002). Thymosin beta 4 promotes corneal wound healing. Investigative Ophthalmology & Visual Science. PMID:11950239

2. [D] Sosne et al. (2007). Thymosin beta 4 suppression of corneal NF-kappaB: a potential antiinflammatory pathway. Experimental Eye Research. PMID:17254567.

3. [F] Sosne et al. (2009). Thymosin beta 4: a novel corneal wound healing and anti-inflammatory agent. Clinical Ophthalmology. PMID:19668473

4. [F] Sosne et al. (2010). Thymosin beta 4 and corneal wound healing. Annals of the New York Academy of Sciences. PMID:20536468

5. [F] Shrivastava et al. (2010). Thymosin beta 4 and cardiac repair. Annals of the New York Academy of Sciences. PMID:20536454

6. [F] Bollini et al. (2015). Thymosin beta 4: multiple functions in protection, repair and regeneration. Expert Opinion on Biological Therapy. PMID:26094634

7. [C] Zhang et al. (2025). Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion. Cardiovascular Research, 121(17). PMID:41229390; DOI:10.1093/cvr/cvaf223.

8. [G] WADA. (2026). International Standard: Prohibited List. World Anti-Doping Agency.

9. [G] U.S. Food and Drug Administration. July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee.

10. [G] U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding May Present Significant Safety Risks.

11. [G] World Anti-Doping Agency. The Prohibited List.

12. [D] Xing Y, et al. Progress on the Function and Application of Thymosin beta-4.

13. [C] Sosne G, et al. Thymosin beta-4 ophthalmic solution for dry eye and related corneal research.

14. [G] IVs in the Keys. Glow (BPC-157/TB-500/GHK-Cu).

15. [G] Bio Longevity Labs. KLOW Blend (GHK-Cu, BPC-157, TB-500, KPV).

16. [G] U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding May Present Significant Safety Risks. TB-500 described as thymosin beta-4 fragment LKKTETQ; safety-risk concerns include immunogenicity, aggregation, peptide impurities, and lack of human exposure data.

17. [D] Xing Y, et al. Progress on the Function and Application of Thymosin beta-4. Review context for full-length Tβ4 biology and 43-amino-acid peptide framing.

18. [D] Sosne G, et al. Biological activities of thymosin beta4 defined by active sites in short peptide sequences. PubMed PMID: 20179146. LKKTETQ active-region context.

19. [RouteEvidence] FDA. Certain bulk drug substances for use in compounding that may present significant safety risks.

20. [RouteEvidence] Sosne et al. Thymosin beta 4 ophthalmic solution for dry eye: randomized Phase II trial. PubMed.

21. [RouteEvidence] Treadwell et al. Thymosin beta 4 accelerates dermal healing in preclinical models and patients. PubMed.

• Tesamorelin is a synthetic analog of human growth-hormone-releasing hormone (GHRH) developed by Theratechnologies.
• It stimulates endogenous production and release of growth hormone from the pituitary.
• It is the only FDA-approved GHRF peptide and the only FDA-approved medication for reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy.
• New formulation, EGRIFTA WR (tesamorelin F8), FDA-approved March 25, 2025 Theratechnologies received FDA approval for a concentrated F8 formulation of tesamorelin under the trade name EGRIFTA WR.
• EGRIFTA WR is formulation-specific. Bioequivalence-style wording is not a practical interchangeability statement: EGRIFTA WR and EGRIFTA SV are not substitutable and have different doses, vial preparation, reconstitution, storage, and label PK values.
• EGRIFTA WR is replacing EGRIFTA SV in the U.S. market; The two formulations are not substitutable, dosing, vial count per dose, reconstitution protocol, and storage requirements all differ.
• Tesamorelin is a GHRH analog with an FDA-approved product context for HIV-associated lipodystrophy/visceral adipose tissue reduction. It does not belong with generic GH secretagogue wellness protocols.

Tesamorelin acts as a highly specific secretagogue for the pituitary gland:

• GHRH Receptor Agonism: It binds to GHRH receptors on pituitary somatotrophs, stimulating the natural, pulsatile release of endogenous Growth Hormone (GH).
• Lipolysis (Visceral Fat Targeting): Elevated GH acts directly on adipocytes and stimulates the production of IGF-1 in the liver. Clinical data in the approved HIV-lipodystrophy context show reduction of excess visceral adipose tissue (VAT). This is GH/IGF-1-mediated VAT reduction in a specific indication, not a literal “unique affinity” or direct fat-melting effect. Mitochondrial &
• Cognitive Support: Recent research suggests it improves mitochondrial oxidative phosphorylation in muscles and may have neuroprotective effects by reducing brain pro-inflammatory markers.
• It stimulates endogenous GH and IGF-1 through GHRH receptor signaling, leading to VAT reduction in the approved context. It does not directly melt fat independent of the GH/IGF-1 axis. The mechanism here is a plausibility map, not proof of a clinical outcome.

• Visceral Fat Reduction: Phase III clinical trials consistently demonstrate a 15-20% reduction in VAT over 26 weeks.
• Lipid Profile Improvement: Significant reductions in triglycerides and non-HDL cholesterol have been observed, contributing to better cardiovascular health.
• Cognitive Impact: Studies in both HIV-positive and healthy elderly populations suggest improvements in executive function and memory, potentially linked to increased IGF-1 in the brain.
• Liver Health: It has been shown to reduce liver fat (intrahepatic triglycerides) by nearly 40% in patients with Non-Alcoholic Fatty Liver Disease (NAFLD).
• Clinical evidence is disease-specific and stronger than most GH-axis peptides in the guide. Benefits and risks are tied to the studied HIV-lipodystrophy population and label endpoints. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.

Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions for you.

• Protocol 1: EGRIFTA SV (legacy F4, 2 mg/vial) [FDA/Approved/Label]; Route: Subcutaneous abdomen injection; Dose: Daily dose: 1.4 mg (0.35 mL) SC; Frequency: Daily; Status: Yes - FDA-approved label/product protocol for the labeled indication only.
• Protocol 2: EGRIFTA WR (new F8, 11.6 mg/vial) [FDA/Approved/Label]; Route: Subcutaneous abdomen injection; Dose: Daily dose: 1.28 mg (0.16 mL) SC; Frequency: Daily dosing from weekly-reconstituted vial; Status: Yes - FDA-approved label/product protocol for the labeled indication only.
• Protocol 3: EGRIFTA WR FDA-label formulation and dose protocol [FDA/Approved/Label]; Route: Subcutaneous (abdomen); Dose: 1.28 mg (0.16 mL) once daily; Frequency: Once daily; Timing: Administer as directed in product instructions; Rotate abdominal injection sites; Duration: Chronic use only for the labeled HIV-associated lipodystrophy indication while clinically appropriate; Max: 1.28 mg once daily per EGRIFTA WR IFU/label context; Titration/loading: No biohacker titration inserted; Product-specific labeled instructions apply; Status: Yes - FDA-approved label/product protocol for HIV-associated lipodystrophy indication only.
• EGRIFTA WR and SV are not substitutable, and label dosing is once daily SC. Community 5-on/2-off logic does not replace label instructions. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.

• Simple plasma time until steady state: roughly 40–55 minutes by the 5-half-life rule using current label half-lives; Clinical response is not judged by maintaining tesamorelin plasma levels.
• Half-life basis: current labels report mean t½ of about 11 minutes for EGRIFTA WR after 1.28 mg SC and about 8 minutes for EGRIFTA SV after 1.4 mg SC.
• Beginner translation: plasma exposure is very short, but downstream GH/IGF-1 effects are monitored over time; Use IGF-1, glucose/A1c, adverse effects, and label response measures rather than constant peptide levels.
• Bioavailability: low absolute SC bioavailability; Label/context values do not mix across formulations.
• Delivery: subcutaneous injection into the abdomen under product-specific label instructions; EGRIFTA WR and EGRIFTA SV are not interchangeable.
• Plasma half-life is short, but IGF-1 and VAT outcomes are downstream. The label half-life and formulation distinctions apply here, not generic GHRH assumptions. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.

• Ipamorelin: Often stacked to maximize the GH pulse. While Tesamorelin provides the GHRH signal, Ipamorelin acts on the Ghrelin receptor for a multi-pathway release.
• AOD-9604: Combined as a “belly fat shredder” stack, where AOD handles subcutaneous fat mobilization and Tesamorelin targets visceral fat.
• MOTS-c: Used together to maximize mitochondrial efficiency and metabolic resilience.
• Stacking with other GH secretagogues, GH, or IGF-1 analogs risks excessive IGF-1 and glucose effects. Combining with GLP-1s may complicate body-composition interpretation. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.

• Side Effects: Common reactions include injection site redness (erythema), joint pain (arthralgia), and mild peripheral edema (water retention).
• Glycemic Control: It can increase blood glucose levels; Diabetic or pre-diabetic users must monitor HbA1c closely.
• Contraindications: Active malignancy (cancer), pregnancy (Category X), and disruption of the hypothalamic-pituitary axis (e.g., history of pituitary tumors).
• Watch IGF-1 elevation, glucose intolerance/diabetes, edema, arthralgia, injection reactions, and malignancy contraindication/caution contexts. It is an endocrine drug, not merely a peptide supplement. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.

• IGF-1 Levels: Monitored to ensure they stay within a physiological range (typically aiming for the upper quartile of the age-matched range).
• Fasting Glucose: To screen for the development of insulin resistance.
• Waist-to-Hip Ratio: A primary physical marker for the reduction of visceral adiposity.
• Track IGF-1, glucose/A1c, waist/VAT endpoints, edema, joint symptoms, and contraindications such as active malignancy or pregnancy per label context. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.

• FDA: Original Egrifta approved 2010 for HIV-associated lipodystrophy. EGRIFTA WR (tesamorelin F8) approved March 25, 2025 for the same indication. EGRIFTA SV is being phased out during a transitional supply period. Not approved for weight loss in any population, this remains a critical off-label caveat for non-HIV users.
• WADA: Prohibited (S2).
• Availability: Specialty-pharmacy distribution. The only FDA-approved growth-hormone-releasing-factor peptide.
• Tesamorelin has FDA-approved formulations with specific dosing and reconstitution instructions. Approved-product status does not generalize to compounded substitutes. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.

1. [A] Falutz et al. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine.

2. [B] Falutz et al. (2005). Placebo-controlled dose-ranging study of TH9507 in HIV lipodystrophy. AIDS. PMID:16052083

3. [A] Falutz et al. (2010). Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: two phase 3 trials. Journal of Clinical Endocrinology & Metabolism. PMID:20101189

4. [B] Stanley et al. (2014). Effects of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal obesity. JAMA. PMID:25038357

5. [B] Stanley et al. (2019). Effects of tesamorelin on liver fat and histology in HIV-associated NAFLD. Lancet HIV. PMID:31611038

6. [E] Fourman et al. (2020). Tesamorelin and hepatic transcriptomic signatures/fibrosis pathways in HIV-associated NAFLD. JCI Insight.

7. [G] FDA / Theratechnologies. (2025). Egrifta WR (tesamorelin F8) prescribing information. FDA AccessData.

8. [C] Adrian et al. (2019). The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV. Journal of Frailty and Aging, 8(3), 154-159. PMID:31237318; PMCID:PMC6766405; DOI:10.14283/jfa.2018.45.

• A 28-amino-acid acetylated peptide (about 3,108 Da) cleaved from the N-terminus of prothymosin alpha by the enzyme legumain.
• First isolated from calf thymus by Allan Goldstein in 1972 and fully synthesized by 1977.
• The synthetic form, thymalfasin, is sold as Zadaxin by SciClone and is approved in 35+ countries (including China, Italy, and much of Asia) for chronic hepatitis B, chronic hepatitis C, and as an immune adjuvant.
• Not FDA-approved in the United States, though it has held Orphan Drug Designation for hepatocellular carcinoma, chronic hepatitis B, and DiGeorge syndrome.
• Thymosin alpha-1 is an immune-modulating 28-amino-acid peptide used in some countries as thymalfasin/Zadaxin. It is not U.S. FDA-approved.

A bidirectional immune modulator: it amplifies deficient responses and dampens overactive ones, rather than simply boosting immunity.

• Toll-like receptor agonism: binds TLR2, 3, 4, 7, and 9 on dendritic cells (TLR9 is the signature action), activating MyD88, IRF3, and NF-κB signaling.
• Dendritic-cell maturation: primes a Th1-biased response, shifting adaptive immunity toward the cell-mediated arm that handles intracellular viruses and tumors.
• T-cell reconstitution: drives maturation of CD4+ helper and CD8+ cytotoxic T-cells and opposes cortisol-induced thymocyte apoptosis, the basis for its use in lymphopenic states.
• NK-cell activation and cytokine rebalancing: raises IL-2, IFN-γ, and IL-12 while suppressing excess IL-6, TNF-α, and IL-1β during cytokine storms.
• Zinc dependency: it needs zinc to fold into its active shape, so subclinical zinc deficiency blunts the response.
• Mechanisms include T-cell, dendritic-cell, NK-cell, Toll-like receptor, and antiviral immune modulation. It is immune-regulatory, not simply immune-boosting. The mechanism here is a plausibility map, not proof of a clinical outcome.

• Chronic hepatitis B: multiple RCTs and a 2001 meta-analysis (Chan et al.) showed improved HBeAg seroconversion at 1.6 mg twice weekly for 6 months, comparable-to-superior to interferon-α. This is its core approved indication.
• Chronic hepatitis C: pegylated-interferon plus Tα1 helped prior non-responders (Rustgi et al.), now largely replaced by direct-acting antivirals.
• Sepsis, ETASS to TESTS: the 2013 ETASS trial (361 patients) showed a 9% absolute mortality reduction (26.0% vs 35.0%), but the definitive 2025 TESTS trial (1,106 patients, BMJ) was negative (23.4% vs 24.1%). Benefit in unselected sepsis is now uncertain, though severely immunosuppressed subgroups may still gain.
• Cancer: as an adjuvant after curative resection of HBV-related hepatocellular carcinoma, a 2022 analysis (Linye et al.) found improved recurrence-free survival.
• COVID-19: a 2020 retrospective of 76 severe cases (Liu et al.) reported lower mortality and restored CD4+/CD8+ counts. Disease context and study design matter; These results do not generalize to broad immune support.
• Clinical literature exists in hepatitis, cancer-adjunct, sepsis, and immune contexts, but study quality and regional use vary. Do not generalize all immunology findings to wellness immunity. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.

Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions for you.

• Protocol 1: Approved (Zadaxin / HBV) [Ex-US Approved/Label (Not FDA-approved in U.S.)]; Route: Subcutaneous; Dose: 1.6 mg; Frequency: Twice weekly; Duration: 6 to 12 months; Status: No - thymalfasin/Zadaxin protocol is not FDA-approved in the United States.
• Protocol 2: General Immune Support [Community/Biohacker/Anecdotal]; Route: Subcutaneous; Dose: 0.8 mg – 1.6 mg; Frequency: 1 to 2 times weekly; Duration: 4 to 8 weeks (cycled); Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 3: Acute Loading (Viral / Sepsis) [Clinical/Human Trial]; Route: Subcutaneous; Dose: 1.6 mg; Frequency: Daily; Duration: 5 to 7 days, then taper; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 4: Community loading-to-maintenance pattern [Community/Biohacker/Anecdotal]; Route: Subcutaneous; Dose: 1.6 mg daily for first 5 to 7 days; Then 1.6 mg twice weekly; Duration: 4 to 8 weeks after step-down; Subsequent cycles 1.6 mg twice weekly for 4 weeks, 2 to 3 times per year; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Ex-U.S. product dosing, trial dosing, and community dosing are separate. Immune context and indication matter more than generic cycle numbers. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.

• Time until steady state: roughly 8 to 10 hours by half-life math, but daily dosing does not necessarily produce clinically meaningful accumulation.
• Half-life basis: FDA compounding-review material cites a subcutaneous half-life around 2 hours and no accumulation after daily dosing for 5 days.
• Beginner translation: The immune effect is not simply the blood level. Immune-cell signaling may change after the peptide itself has cleared.
• Practical interpretation: Match any claim to the studied indication. Monitor clinical context and immune/inflammatory markers rather than assuming a generic steady-state benefit.
• Human PK has been characterized in product contexts, but immune effects are downstream. Half-life alone does not predict immune response. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.

• Zinc (essential cofactor): Tα1 needs zinc to fold correctly, so checking RBC zinc and, if low, supplementing 15 to 30 mg zinc glycinate daily is standard in integrative protocols.
• Thymosin Beta-4 (TB-500): complementary, not redundant. Tα1 modulates T-cell and innate immunity while T-beta-4 drives tissue repair.
• Vitamin D, BPC-157, probiotics, glutathione, NAC: complementary immune or gut-recovery support with no known interactions.
• Interferon-α (clinical): historically stacked for chronic HBV and HCV; Augments antiviral response but adds interferon's flu-like effects.
• Oncology adjuncts: added to chemotherapy in HCC, NSCLC, and melanoma (Garaci et al.) to offset immunosuppression; Early 2025 interest pairs it with PD-1/PD-L1 checkpoint inhibitors to restore dendritic-cell function.
• Often paired with vaccines, antivirals, cancer adjuncts, or immune stacks in discussion. Combining immune modulators can obscure benefit and risk, especially in autoimmune disease. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.

One of the strongest safety records of any peptide here: across 3,000+ patients and 70+ studies, toxicity has been close to placebo.

• Common: mild injection-site redness, itching, or discomfort (low single-digit incidence).
• Uncommon: transient fatigue, mild flu-like symptoms, or headache in the first days; Transient mild ALT elevation in some HCV trials.
• No immune-overactivation pattern: unlike interferon-α or IL-2, it does not cause high fever, rigors, cytopenia, or CNS toxicity at standard doses.
• Absolute contraindication: deliberate immunosuppression (transplant recipients on tacrolimus or cyclosporine, high-dose corticosteroids), where immune stimulation could precipitate graft rejection.
• Use caution in active autoimmune flare (MS, SLE, RA), known hypersensitivity to the peptide or excipients (mannitol, sodium phosphate), pregnancy or breastfeeding, and severe liver failure (monitor ALT).
• Usually described as well tolerated in studied contexts, but autoimmune disease, transplant immunosuppression, cancer therapy, and pregnancy require caution. Product purity matters for injectable use. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.

Because it is an immunomodulator, the useful markers are immune readouts, not organ-toxicity panels.

• Baseline: CBC with differential, CD4+ and CD8+ counts with the CD4/CD8 ratio, NK count and activity where available, serum or RBC zinc, ALT/AST, hs-CRP, and disease-specific markers (HBV DNA, HCV RNA, tumor markers, autoimmune panels).
• During therapy (every 4 to 8 weeks): CD4/CD8 counts and ratio (changes usually visible by 4 to 6 weeks), hs-CRP, ALT/AST, the relevant disease markers, plus infection frequency and recovery speed.
• Longer-term research markers: monocyte HLA-DR expression (the key restoration marker in the ETASS sepsis trial), sjTREC for fresh thymic output, and serum Tα1 by ELISA (baseline levels run low in chronic autoimmune disease).
• Track infection frequency/severity, CBC with differential when clinically relevant, inflammatory/autoimmune symptoms, liver markers in hepatitis contexts, and adverse reactions. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.

• FDA (US): not approved. Placed in Category 2 (do-not-compound) in late 2023; The nominators withdrew in 2024, which removed it from Category 2 without a Category 1 determination, the same path as CJC-1295 and Ipamorelin.
• Under review: expected to be referred to a future Pharmacy Compounding Advisory Committee meeting. It was not among the 12 peptides in the April 15, 2026 HHS action, and interim compounding access is contested.
• Zadaxin (thymalfasin): approved in 35+ countries for chronic HBV, chronic HCV, and immune-adjuvant use, with FDA Orphan Drug Designation for HCC, chronic HBV, and DiGeorge syndrome.
• WADA: not prohibited. It is treated as an immunomodulator with no anabolic or growth-factor activity, unlike thymosin beta-4, which is banned under S2.
• FDA materials state Ta1 is not approved in the United States and no FDA-approved drug products contain Ta1. Ex-U.S. approval stands separately. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.

1. [B] Mutchnick et al. (1999). Thymosin alpha-1 treatment of chronic hepatitis B: multicenter randomized placebo-controlled double-blind study. Annals of the New York Academy of Sciences. PMID:10607256

2. [C] Chien et al. (1998). Efficacy of thymosin alpha-1 in chronic hepatitis B. Hepatology. PMID:9581695

3. [F] Chien et al. (2004). Thymalfasin for the treatment of chronic hepatitis B. Expert Review of Antiinfective Therapy. 2(1):9-16. PMID:15482167; DOI:10.1586/14787210.2.1.9

4. [A] Iino et al. (2005). The efficacy and safety of thymosin alpha-1 in Japanese patients with chronic hepatitis B; results from a randomized clinical trial. Journal of Viral Hepatitis. 12(3):300-306. PMID:15850471; DOI:10.1111/j.1365-2893.2005.00633.x

5. [F] Wu et al. (2015). Thymosin alpha-1 treatment in chronic hepatitis B. Expert Opinion on Biological Therapy. PMID:25640173.

6. [F] Dominari et al. (2020). Thymosin alpha 1: a comprehensive review of the literature. World Journal of Virology, 9(5), 67-78. PMID:33362999; PMCID:PMC7747025; DOI:10.5501/wjv.v9.i5.67.

7. [A] Wu et al. (2025). The efficacy and safety of thymosin alpha1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. BMJ, 388, e082583. PMID:39814420.

8. [F] Gu et al. (2025). Efficacy of thymosin alpha1 for sepsis: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Cellular and Infection Microbiology, 15, 1673959. PMID:40969554; PMCID:PMC12440967; DOI:10.3389/fcimb.2025.1673959.

9. [F] Wei et al. (2023). Thymosin alpha-1 in cancer therapy: Immunoregulation and potential applications. International Immunopharmacology, 117, 109744. PMID:36812669; DOI:10.1016/j.intimp.2023.109744.

• Tirzepatide (Zepbound) received FDA approval for obstructive sleep apnea in December 2024, the first medication ever approved for OSA.
• 2025 real-world MASLD/MASH data (ACG 2025) show favorable CV and renal outcomes vs semaglutide in liver-disease populations.
• Tirzepatide is a synthetic 39-amino acid peptide developed by Eli Lilly.
• It is a first-in-class “twincretin,” acting as a dual agonist for both GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-Dependent Insulinotropic Polypeptide) receptors.
• It was FDA-approved in 2022 for Type 2 Diabetes and in 2023 for chronic weight management.
• Tirzepatide is an approved dual GIP/GLP-1 receptor agonist, not just a GLP-1. Product identity, salt/form, device, and indication determine appropriate interpretation.

Tirzepatide is unique because it mimics two endogenous metabolic hormones, creating a synergistic effect on weight and glucose:

• GIP Receptor Agonism: This is the distinguishing arm of Tirzepatide. GIP improves insulin sensitivity and, crucially, acts on the brain to buffer the nausea often caused by GLP-1. It also promotes healthier lipid metabolism in adipose tissue.
• GLP-1 Receptor Agonism: It slows gastric emptying (the “fullness” effect) and signals the brain’s satiety centers to reduce food cravings and “food noise.” Pancreatic Regulation: It stimulates insulin secretion only when blood glucose is high and suppresses glucagon secretion, leading to stabilized blood sugar levels.
• Neuro-Metabolic Signaling: It re-sensitizes the body to its own metabolic signals, making it easier for the body to utilize stored fat for energy.
• It combines GIP and GLP-1 receptor activity to improve glucose regulation, satiety, and weight loss. Delayed gastric emptying is clinically relevant, especially during initiation and escalation. The mechanism here is a plausibility map, not proof of a clinical outcome.

• Weight Loss Superiority: In the SURMOUNT-1 clinical trials, participants without diabetes lost an average of 20.9% (approx. 52 lbs) of their body weight over 72 weeks on the 15 mg dose.
• Cardiovascular Benefits: Research indicates significant improvements in blood pressure, triglycerides, and cholesterol. 2025 data suggests a marked reduction in the risk of heart failure and stroke.
• A1c Normalization: In the SURPASS trials, nearly 90% of Type 2 Diabetic patients achieved an A1c of less than 7% (the standard for controlled diabetes).
• Sleep Apnea: 2024-2025 studies have shown that Tirzepatide significantly reduces the severity of Obstructive Sleep Apnea (OSA) by reducing neck circumference and systemic inflammation. 2024-2026 clinical developments First FDA approval for OSA (December 2024). Tirzepatide (Zepbound) became the first medication approved by the FDA for moderate-to-severe obstructive sleep apnea in adults with obesity, based on the SURMOUNT-OSA trials. MASLD/MASH data (ACG 2025). Real-world retrospective cohort of ~43,000 patients (Jalamneh et al., ACG 2025) found tirzepatide associated with favorable cardiovascular outcomes and lower acute kidney injury risk (HR 0.88) vs semaglutide in MASLD + T2D populations. Propensity-matched, ~6-month follow-up. SURMOUNT-MMO. Cardiovascular-outcomes trial in obesity, enrolling ~15,000 patients. Readout expected 2027. Dysesthesia context. The new dysesthesia safety signal observed with retatrutide at 12 mg (20.9%) has not been observed at this rate with tirzepatide across the SURMOUNT program, a potentially meaningful tolerability differentiator as retatrutide approaches market.
• Tirzepatide has strong clinical trial and label evidence for diabetes, chronic weight management, and OSA/obesity contexts depending on product. That evidence applies to approved products, not arbitrary compounded or RUO material. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.

Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions for you.

• Protocol 1: Clinical Titration Schedule [FDA/Approved/Label]; Route: Subcutaneous (SC); Dose: Start 2.5 mg SC once weekly for 4 weeks; Increase to 5 mg once weekly; May increase by 2.5 mg increments after at least 4 weeks on current dose.; Frequency: Once weekly; Timing: Same day each week; Administer SC in abdomen, thigh, or upper arm per product label; Duration: Dose escalation at ≥4-week intervals; Chronic maintenance per labeled indication; Max: 15 mg SC once weekly; Titration/loading: 2.5 mg weekly x4 weeks → 5 mg weekly; Optional +2.5 mg increments after ≥4 weeks. Weight maintenance: 5, 10, or 15 mg weekly. OSA: 10 or 15 mg weekly.; Status: Yes - FDA-approved label/product protocol for labeled indications only.
• Protocol 2: Community Slow Protocol [Community/Biohacker/Anecdotal]; Route: Subcutaneous (SC); Dose: Community slow protocol: 2.5 mg weekly starting dose; Many hold at 2.5 mg or 5 mg if weight loss continues and side effects are tolerable.; Frequency: Once weekly; Some community users split doses off-label; Max: 15 mg weekly ceiling in label; Community maintenance often 2.5-5 mg weekly or every 10-14 days after target weight; Titration/loading: Month 1: 2.5 mg weekly; Month 2: 2.5 mg or 5 mg if no side effects; Month 3: often hold at 5 mg if losing weight; Escalate only if needed.; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 3: Micro-Dosing / Splitting [Community/Biohacker/Anecdotal]; Route: Subcutaneous (SC); Dose: Example: 2.5 mg every 3.5 days; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 4: Maintenance [Community/Biohacker/Anecdotal]; Route: Subcutaneous (SC); Dose: 2.5 mg or 5.0 mg every 10-14 days; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 5: ZEPBOUND FDA-label escalation to maintenance [FDA/Approved/Label]; Route: Subcutaneous injection; Dose: 2.5 mg initiation; Increase to 5 mg after 4 weeks; Then 2.5 mg increments as needed/tolerated; Frequency: Once weekly; Duration: Escalate after at least 4 weeks on current dose; Max: 15 mg once weekly in label context; Titration/loading: 2.5 mg is for initiation and not approved as a maintenance dose.; Status: Yes - FDA-approved label/product protocol for labeled indication only.
• Label titration uses 2.5 mg initiation and stepwise escalation. Oral or non-injection tirzepatide claims are unsupported unless an exact validated formulation exists. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.

• Half-life: Approximately 5 days. This long half-life allows for convenient once-weekly administration.
• Steady State: It takes approximately 4 weeks of consistent dosing at the same level to reach “steady state” concentrations in the blood.
• Delivery: Exclusively Subcutaneous (SC) injection into the abdomen, thigh, or upper arm.
• Half-life basis: Approximately 5-6 days. This is label-supported and relevant to titration, oral-contraceptive counseling, and adverse-effect persistence.
• Beginner translation: This estimate uses the standard four-to-five-half-life convention. It describes when plasma exposure would be expected to approach a plateau during repeated dosing, not when the desired outcome is complete.
• Weekly dosing reflects long-acting design. Tolerability and gastric-emptying effects can change after dose escalation, so steady-state math is only part of practical use. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.

• BPC-157: Frequently used to manage “GLP-1 stomach” (nausea or slow digestion) due to BPC’s gut-healing properties.
• Tesamorelin: Stacked by those looking to specifically target visceral (belly) fat while Tirzepatide manages overall caloric intake. L-Carnitine: Often co-administered to support mitochondrial fat oxidation during the weight loss phase.
• Avoid stacking with other GLP-1/GIP/amylin agents unless clinician-directed. Oral contraceptive absorption warning is product-specific and stronger for tirzepatide than for semaglutide. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.

• Gastrointestinal Effects: Nausea, vomiting, diarrhea, and constipation are common during dose escalations.
• Lean-mass loss: rapid weight loss can reduce lean mass as well as fat mass. Adequate protein intake and resistance training are common risk-reduction strategies, but they are not product-label requirements and should be individualized to medical status, kidney function, ability, and clinician guidance.
• Pancreatitis: Rare but serious risk. Users with a history of pancreatitis should avoid this peptide.
• Contraindications: Personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• Monitor GI effects, dehydration/renal injury, gallbladder disease, pancreatitis symptoms, hypoglycemia with insulin/secretagogues, thyroid C-cell warning context, and nutrition/lean mass. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.

• Hgb A1c & Fasting Insulin: To monitor improvements in metabolic health.
• Body Composition (DEXA): To ensure weight loss is coming from fat, not lean muscle mass.
• Gallbladder Ultrasound: Rapid weight loss increases the risk of gallstones.
• Track A1c/glucose, weight-loss rate, GI tolerance, renal function if vomiting/diarrhea occurs, gallbladder symptoms, nutrition/protein intake, and contraception counseling when relevant. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.

• FDA: Approved for T2D (Mounjaro, 2022) and chronic weight management (Zepbound, 2023). Added OSA indication December 2024, first FDA-approved medication for OSA.
• April 2026 (503B Bulks List): FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound these drugs from bulk substances now that FDA-approved versions are widely available. Commissioner Marty Makary framed the action as protecting patients and preserving drug-approval integrity. If finalized, 503B outsourcing facilities cannot compound these drugs from bulk powder, narrowing compounding lanes left after the 2024-2025 shortage-list removals. 503A pharmacies operate under a separate framework and are not directly addressed by this action.
• WADA: Not on prohibited list.
• Availability: Prescription pharmaceutical; Widely available through standard pharmacies.
• Tirzepatide has FDA-approved products, while bulk compounding is subject to evolving FDA policy. FDA has proposed excluding tirzepatide from the 503B bulks list. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.

1. [A] Jastreboff et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. PMID:35658024

2. [A] Jastreboff et al. (2025). Tirzepatide for obesity treatment and diabetes prevention. New England Journal of Medicine. PMID:39536238

3. [A] Aronne et al. (2024). Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: SURMOUNT-4. JAMA. PMID:38078870

4. [A] Frias et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine. PMID:34170647

5. [A] Malhotra et al. (2024). Tirzepatide for the treatment of obstructive sleep apnea and obesity. New England Journal of Medicine. PMID:38912654

6. [A] Aronne et al. (2025). Tirzepatide as compared with semaglutide for the treatment of obesity. New England Journal of Medicine. PMID:40353578.

7. [G] FDA. (2026). Zepbound (tirzepatide) prescribing information. FDA AccessData.

8. [G] FDA. (2026). Mounjaro (tirzepatide) prescribing information. FDA AccessData.

• Vilon is L-lysyl-L-glutamic acid, a synthetic dipeptide usually written as Lys-Glu or KE.
• PubChem lists lysylglutamic acid with formula C11H21N3O5 and molecular weight about 275.30 g/mol.
• Some databases also list lysylglutamic acid dihydrate under names such as Lys-Glu dihydrate, lysine glutamate dihydrate, and Vilon dihydrate.
• Vilon is part of the short-peptide or Khavinson bioregulator family, a group of ultrashort peptides studied mainly for tissue-specific regulation, gene expression, chromatin organization, immune signaling, and aging-related models.
• Vilon is generally framed as thymic or immunomodulatory, while Epithalon is pineal/telomere-oriented, Thymogen is Glu-Trp, and Thymalin is a broader thymic peptide complex rather than a single dipeptide. Because Vilon contains only two amino acids, it does not behave like a large protein hormone.
• Its proposed biology is less about receptor saturation and more about short-peptide signaling, gene-expression effects, or cellular regulatory models. Those mechanisms remain incompletely validated by modern human pharmacology.
• Vilon is a short dipeptide bioregulator associated with immune and aging claims in regional literature. It is not a proven geroprotective drug.

• The central Vilon hypothesis is immunomodulation.
• Older and newer studies describe effects on thymus-cell culture, splenocytes, interleukin-2 expression, T-cell-related activity, macrophage/monocyte behavior, cytokine signaling, and inflammatory adhesion pathways.
• The common claim is not blanket immune stimulation; It is immune normalization or modulation.
• A second hypothesis is gene-expression and chromatin regulation.
• Some short-peptide literature reports changes in chromatin decondensation, ribosomal-gene activity, DNA-microarray expression patterns, and other epigenetic-like effects.
• These findings are interesting but warrant careful interpretation, because many studies are small, model-specific, and not independently replicated at modern drug-development standards.
• Vilon is not a direct cytokine drug, antiviral, vaccine substitute, or immune-booster supplement.
• The more careful statement is that Lys-Glu has been studied as an ultrashort bioregulator that may influence immune-cell signaling and gene-expression patterns in experimental systems.
• Proposed mechanisms include gene-expression modulation and thymic/immune bioregulation. These are broad hypotheses or regional research findings, not settled conclusions. The mechanism here is a plausibility map, not proof of a clinical outcome.

• Human and animal thymus-cell culture: A 2013 Bulletin of Experimental Biology and Medicine paper reported immunomodulating effects of Vilon and an analog in cultures of human and animal thymus cells. This supports a thymic-immune research rationale, but culture response is not the same as clinical immune restoration.
• Inflammation and monocyte/macrophage models: A 2022 in-vitro THP-1 study evaluated several Khavinson peptides including Vilon. The study reported modulation of proliferative and inflammatory pathways, including effects on TNF, IL-6, STAT signaling, extracellular vesicles, and immune-cell adhesion in the model. This is mechanistic evidence, not human therapeutic proof.
• Gene expression and chromatin: DNA-microarray and chromatin-reactivation papers reported that Vilon and related short peptides can alter gene-expression patterns or chromatin organization in experimental cells. These findings help explain why Vilon is discussed as an epigenetic bioregulator, but they do not establish a measurable anti-aging outcome in humans.
• Animal aging and tumor models: Mouse studies reported effects on biological age, lifespan, spontaneous tumor growth, and bladder carcinogenesis models. One rat bladder-carcinogenesis study reported tumor development in 56% of Vilon-treated animals compared with 75.5% of controls. These data justify research interest but are not proof that Vilon prevents cancer in humans.
• GI and renal animal models: Vilon and Epithalon have been studied in aged-rat intestinal transport/enzyme models, and Vilon has been studied in chronic renal failure rat models with effects on transforming growth factor-beta and microvessel permeability. These are animal physiology findings, not renal or gut treatment protocols.
• Evidence is mainly Eastern European/Russian bioregulator literature, preclinical reports, and small human-context claims. It is low confidence compared with approved peptides. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.

Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions for you.

• Protocol 1: Preclinical Vilon/Lys-Glu tumor/lifespan context [Animal/Preclinical]; Route: Animal/preclinical administration; Exact regimen not standardized from abstract; Dose: Dose details not fully extractable from abstract/snippet; Frequency: Preclinical study-specific; Duration: Preclinical study context; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 2: Community standard 10 mg cycle [Community/Biohacker/Anecdotal]; Route: Subcutaneous; Dose: 10 mg; Frequency: Once daily; Duration: 5–10 days; Repeat every 3–6 months; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 3: Community gradual dose protocol [Community/Biohacker/Anecdotal]; Route: Subcutaneous; Dose: 67 mcg – 333 mcg in first cycle; 333 mcg – 667 mcg in later cycles; Frequency: Once daily during dosing days; Duration: 5 days, then rest for remainder of 4-week cycle; Repeat monthly; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 4: Biohacker 10 mg monthly/biannual cycle [Community/Biohacker/Anecdotal]; Route: Subcutaneous or intramuscular; Dose: 10 mg; Frequency: Once daily; Duration: 5–10 days per month, or 10 days twice yearly; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Community and regional cycles are empirical. Route and product matter in any protocol, because small peptides may be used orally, injectable, or in other formats with different assumptions. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.

• Time until steady state: not calculable from available human data.
• Half-life basis: no validated human route-specific half-life was identified. Because Vilon is a dipeptide, enzymatic hydrolysis and transporter effects are plausible, but a reliable steady-state number cannot be assigned.
• Beginner translation: Small does not automatically mean predictable. A two-amino-acid molecule may be degraded quickly, transported, or metabolized differently depending on route.
• Practical interpretation: Do not borrow half-lives from Epithalon, Thymogen, dietary dipeptides, or vendor claims. Without a validated Vilon-specific half-life, any steady-state language stays qualitative. The practical PK unknowns are absorption, first-pass degradation, tissue distribution, intracellular access, renal clearance, and whether any observed cell-culture effect requires concentrations that are achievable in humans. Those questions have to be answered before meaningful accumulation or washout timing can be stated.
• As a dipeptide, systemic persistence may be short, and proposed effects are downstream. Half-life calculators are not a useful efficacy model. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.

• Vilon is commonly grouped with Epithalon, Thymalin, Thymogen, Pinealon, and other short bioregulators. The logic is usually “organ-system signaling” or immune-aging support, which is not the same as controlled evidence that combining them improves outcomes.
• Vilon is separate from Thymosin Alpha-1. Thymosin Alpha-1 has a more recognizable clinical immunology literature and regulatory history in some countries.
• Vilon is an ultrashort dipeptide with a much less established human evidence base.
• Stacking the two can make immune-marker interpretation unclear.
• Use caution around immunosuppressants, autoimmune disease, transplant medicine, active infection, active cancer treatment, and vaccine-response questions.
• In those contexts, immune modulation is not automatically beneficial, and a clinician should direct care.
• Stacking with the aforementioned peptides can create a story of rejuvenation without measurable endpoints. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.

• Modern, large human safety datasets are lacking.
• Potential risks include allergic or injection-site reactions, product contamination, endotoxin exposure, and unpredictable immune effects in susceptible people.
• Oral products may have different risks than injectable products, but lower route risk does not prove efficacy.
• Avoid casual use in pregnancy, breastfeeding, children, active cancer, unexplained weight loss, autoimmune flare, transplant recipients, severe immunodeficiency, or concurrent chemotherapy/immunotherapy unless part of formal clinical care.
• These cautions reflect the uncertainty around immune and cell-survival signaling, not a proven specific toxicity.
• Cancer-prevention claims deserve special caution.
• Animal tumor findings are not an invitation to use Vilon for human cancer prevention or treatment.
• Anyone with cancer risk, cancer history, or abnormal screening results needs standard medical evaluation, not peptide substitution.
• Short sequence does not equal proven safety. Immune modulation, unknown long-term effects, and product authenticity are the main concerns. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.

• For immune/inflammation research framing, useful markers may include CBC with differential, hs-CRP, ESR, infection frequency, vaccine-response history when medically indicated, immunoglobulins in suspected immune deficiency, and clinician-selected lymphocyte subsets.
• Cytokine panels can be noisy, so one reading does not support strong conclusions.
• For aging or recovery claims, use objective endpoints rather than vague “immune boost” language: illness frequency, recovery time, sleep, training load, medication changes, body weight, and inflammatory markers.
• For oncology-adjacent claims, standard screening and oncology follow-up are the monitoring plan; Vilon-specific self-monitoring is not enough.
• For safety, document route, lot number, COA, endotoxin result if injectable, start/stop dates, new symptoms, rash, fever, lymph-node swelling, infection pattern, and any changes in autoimmune symptoms.
• Track infection patterns, CBC if immune goals are claimed, sleep/energy, and general health markers. Do not rely on vague anti-aging impressions. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.

• Vilon is not an FDA-approved drug with a labeled therapeutic indication.
• It may appear as a research peptide, a bioregulator supplement, or a gray-market product depending on jurisdiction.
• Those categories do not provide the same assurance as an approved medicine.
• Anti-doping: Vilon is not treated here as athlete-safe.
• Even when not specifically named, a non-approved biologically active peptide may fall under S0 non-approved-substance risk.
• Competitive athletes should verify current status with WADA/USADA or their sport’s anti-doping authority.
• Vilon is not FDA-approved. Regional bioregulator use is not U.S. therapeutic validation. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.

1. [G] National Center for Biotechnology Information. PubChem Compound Summary: Lysylglutamic acid. Use: Vilon/Lys-Glu synonyms, formula C11H21N3O5, and molecular weight about 275.30 g/mol.

2. [G] NCATS Inxight Drugs. LYSYLGLUTAMIC ACID DIHYDRATE. Use: Vilon dihydrate/Lys-Glu dihydrate synonym context.

3. [D] Avolio F, et al. (2022). Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line. International Journal of Molecular Sciences, 23(7), 3607. PMID: 35408963; PMCID: PMC8999041; DOI: 10.3390/ijms23073607. Use: Vilon as Lys-Glu in a short-peptide panel; monocyte/macrophage inflammatory-pathway context.

4. [D] Sevostianova NN, Linkova NS, Polyakova VO, et al. (2013). Immunomodulating effects of Vilon and its analogue in the culture of human and animal thymus cells. Bulletin of Experimental Biology and Medicine, 154(4), 562-565. PMID: 23486604; DOI: 10.1007/s10517-013-2000-0. Use: Thymus-cell culture immunomodulation.

5. [D] Khavinson VK, Anisimov VN, Zavarzina NY, et al. (2000). Effect of vilon on biological age and lifespan in mice. Bulletin of Experimental Biology and Medicine, 130(7), 687-690. PMID: 11140587; DOI: 10.1007/BF02682106. Use: Mouse biological-age/lifespan context; not human longevity proof.

6. [D] Pliss GB, et al. (2001). Inhibitory effect of peptide Vilon on the development of induced tumors in rats. PMID: 11586406. Use: Rat bladder-carcinogenesis findings and cancer-claim caution.

7. [D] Anisimov SV, Bokheler KR, Khavinson VKh, Anisimov VN. (2002). Studies of the effects of Vilon and Epithalon on gene expression in mouse heart using DNA-microarray technology. Bulletin of Experimental Biology and Medicine, 133(3), 293-299. PMID: 12360356; DOI: 10.1023/A:1015859322630. Use: Gene-expression context for Vilon/Epithalon; exploratory and preclinical.

8. [D] Lezhava T, Monaselidze J, Kadotani T, Dvalishvili N, Buadze T. (2006). Anti-aging peptide bioregulators induce reactivation of chromatin. Georgian Medical News, 133, 111-115. PMID: 16705247. Use: Chromatin-reactivation context for short bioregulators; low-certainty translational relevance.

9. [G] World Anti-Doping Agency. (2025). International Standard: Prohibited List 2026. Use: S0 non-approved-substance and S2 peptide-hormone/growth-factor category caution for athletes using non-approved biologically active peptides.

10. [RouteEvidence] Tyagi et al. Oral peptide delivery: translational challenges due to physiological effects. J Control Release. 2018.

• 5-Amino-1MQ is investigated for NNMT inhibition and metabolic effects.
• It is not FDA-approved as a drug.
• 5-Amino-1MQ is a small-molecule NNMT inhibitor, not a peptide.

• Proposed effects involve NNMT inhibition, NAD-related metabolism, adipose tissue biology, and energy expenditure.
• Its proposed mechanism is NNMT inhibition, affecting NAD/methylation metabolism and adipocyte energy handling. This is pharmacology, not peptide-receptor signaling. The mechanism here is a plausibility map, not proof of a clinical outcome.

• Human efficacy is not established. Evidence is mostly animal/preclinical and community/body-composition discussion. Human efficacy and safety are not established for weight loss. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.

Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions for you.

• Protocol 1: Standard Research Protocol [Research/Experimental]; Route: Oral capsule; Dose: Daily Dose: 50 mg – 100 mg; Frequency: Once daily (Morning); Timing: With or without food; Duration: 2 to 3 months; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 2: Advanced/Performance Protocol [Community/Biohacker/Anecdotal]; Route: Oral capsule; Dose: 150 mg (Split doses); Frequency: 50 mg (3 times daily); Timing: 30 mins before meals/workout; Duration: 1 to 2 months; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Community oral use is reported, but dose claims are not clinical dosing. Interactions with methylation status and NAD pathways matter conceptually. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.

• Time until steady state: not calculable.
• Half-life basis: Not a peptide; Routine human PK not established. This is an investigational small molecule, not a peptide.
• Beginner translation: this is a deliberately conservative read. A missing steady-state number does not mean the compound has no effect; It means the available human PK data are not strong enough to justify a precise accumulation estimate for common use patterns.
• Practical interpretation: Human pharmacokinetic data are limited or not established for routine therapeutic use.
• Peptide PK calculators do not apply. Oral absorption and small-molecule metabolism are the relevant concepts. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.

• Stacks with GLP-1 drugs, NAD+, or fat-loss peptides are anecdotal and not validated.
• Often paired with NAD precursors, GLP-1s, exercise, or fat-loss stacks. Because it may intersect NAD/methylation pathways, avoid overloading with many metabolic modulators. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.

• Unknown long-term safety, hepatic metabolism, drug interactions, pregnancy risk, and metabolic consequences are the default assumption until studied.
• Unknown human safety, liver/metabolic effects, methylation disturbance, and product quality are practical concerns. Do not imply safety from supplement-like oral format. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.

• Weight, waist circumference, glucose, lipids, liver enzymes, renal function, and symptoms may be tracked in research contexts.
• Track weight/waist, glucose/lipids, liver enzymes, sleep/anxiety, and methylation-related symptoms if high-dose NAD/methyl donors are used concurrently. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.

• Not FDA-approved.
• Not a peptide.
• Athletes should treat non-approved metabolic agents as high-risk under S0 unless verified otherwise.
• 5-Amino-1MQ is not an FDA-approved weight-loss drug. It remains labeled non-peptide/RUO in the guide. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.

1. [D] Neelakantan et al. (2018). Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse diet-induced obesity. Cell Chemical Biology. PMID:29155147

2. [D] Neelakantan et al. (2019). Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle. Biochemical Pharmacology. PMID:30753815

3. [D] Dimet-Wiley et al. (2022). Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice. Scientific Reports. PMID:35013352; PMCID:PMC8748953.

4. [D] Dimet-Wiley et al. (2024). Nicotinamide N-methyltransferase inhibition mimics and boosts exercise-mediated improvements in muscle function in aged mice. Scientific Reports. PMID:38969654

5. [D] Babula et al. (2024). Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction. Diabetes, Obesity and Metabolism. PMID:39161060; PMCID:PMC11622326; DOI:10.1111/dom.15879.

6. [F] Liu et al. (2021). Roles of Nicotinamide N-Methyltransferase in Obesity and Type 2 Diabetes. BioMed Research International, 2021, 9924314. PMID:34368359; PMCID:PMC8337113; DOI:10.1155/2021/9924314.

• Bacteriostatic water is sterile water for injection containing a bacteriostatic preservative, commonly benzyl alcohol.
• It is included because reconstitution is a major source of peptide-use errors.
• Bacteriostatic water is a sterile diluent with benzyl alcohol, not a peptide and not a preservative guarantee for every reconstituted product. It belongs in the guide because reconstitution errors are common.

• The 0.9% benzyl alcohol preservative inhibits growth of most common Gram-positive and Gram-negative organisms introduced by repeated needle entries through the vial septum.
• It does not necessarily kill existing bacteria, but suppressing replication is what makes a vial suitable for multi-dose use over roughly a 28-day window.
• It does not sterilize contaminated technique and does not make an unsafe vial safe.
• Its role is dilution and antimicrobial preservation in a multi-dose container. It does not stabilize every peptide chemically or make nonsterile powder safe. The mechanism here is a plausibility map, not proof of a clinical outcome.

• The practical evidence is pharmaceutical-use logic: multi-dose diluents reduce bacterial proliferation risk compared with preservative-free sterile water after repeated punctures.
• Product labels and compatibility instructions remain the controlling source.
• The key evidence is product labeling and sterile-preparation principles, not efficacy trials. Multi-dose antimicrobial preservation is different from peptide stability or endotoxin control. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.

Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions for you.

• Protocol 1: Reconstitution method [Reconstitution/Administration]; Route: Diluent / solvent; Dose: Draw BAC water into sterile syringe; Slowly inject down side of lyophilized peptide vial; Status: Not applicable - FDA-labeled diluent/handling support, not therapeutic protocol.
• Protocol 2: DailyMed/FDA-label diluent-only use [Reconstitution/Administration]; Route: Diluent for IV/IM/SC injectable drugs according to manufacturer instructions; Dose: No therapeutic dose; Used only to dilute or dissolve another drug; Frequency: Multiple-dose container withdrawals according to labeling and drug instructions; Status: Not applicable - FDA-labeled diluent/handling support, not therapeutic protocol.
• Reconstitution math must separate mg, mcg, mL, and syringe units. Syringe units are volume, not peptide mass, and concentration changes with diluent volume. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.

• Time until steady state: not applicable.
• Half-life basis: BAC water is a diluent, not a peptide therapy; Steady-state drug accumulation does not apply.
• Beginner translation: If you're new, BAC water affects concentration and contamination risk, not therapeutic steady state.
• Practical interpretation: The relevant clock is beyond-use dating and sterility after puncture, not plasma half-life.
• PK does not apply to the diluent itself in peptide calculators. The diluent can affect injection volume, irritation, and reconstitution handling, but not a peptide's intrinsic half-life. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.

• Compatibility matters.
• Some products require specific diluents or pH conditions and should not be reconstituted with BAC water unless the product instructions allow it.
• Do not pre-mix multiple peptides into a stock solution.
• Do not use bacteriostatic water as a justification for same-vial blends. Multi-dose preservation does not solve pH, precipitation, oxidation, peptide compatibility, or sterility of starting material. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.

• Benzyl alcohol can cause reactions and is not appropriate for certain neonatal/infant uses.
• Contamination, wrong diluent, expired vial use, and nonsterile technique are major risks.
• Benzyl alcohol sensitivity, neonatal contraindication contexts, contamination from poor technique, wrong diluent, and particulate/cloudiness are practical risks. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.

• Monitor vial clarity, particles, color change, puncture date, storage temperature, and injection-site or systemic reactions.
• Discard cloudy, colored, particulate, expired, or questionable vials.
• Inspect solution clarity, color, particles, vial integrity, expiration/BUD, storage conditions, and injection-site reactions. Discard questionable vials rather than trying to rescue them. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.

• FDA: Bacteriostatic Water for Injection USP is an FDA-approved sterile diluent (multiple manufacturers). It is a US prescription product but is widely accessible through compounding pharmacies and research-supply channels.
• Standards: storage and labeling fall under USP <797> sterile-compounding rules in the dispensing setting.
• WADA: not applicable, since it is an inert vehicle.
• Not interchangeable with tap, distilled, or preservative-free water unless the product instructions specify.
• Use labeled sterile diluent instructions when available. Research-market peptide reconstitution practices are not a substitute for sterile compounding standards. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.

1. [G] DailyMed. (2025). Bacteriostatic Water for Injection, USP label. DailyMed / National Library of Medicine.

2. [G] Pfizer. (2025). Bacteriostatic Water for Injection prescribing information. Pfizer labeling.

3. [G] Pfizer. (2025). Sterile Water for Injection prescribing information. Pfizer labeling.

4. [G] USP. (2025). USP General Chapter <797> sterile compounding updates. United States Pharmacopeia.

5. [G] The Joint Commission. (2025). Managing multi-dose vials. The Joint Commission FAQ.

6. [H] Pfizer. (2025). Bacteriostatic Water for Injection safety data sheet. Pfizer SDS.